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ABSTRACT 
 
 
 
INTRODUCTION: Osteolysis is the most common cause for failure of total hip replacements (THR) and 1 in 10 of 
the 61,000 joint replacements performed each year will require revision surgery. The pathway of osteolysis is 
well studied in tissue and animal models, but there is little work examining differing responses between 
patients.  Lack of effective diagnosis and a poor understanding of the epidemiological risk factors for osteolytic 
change compounds the problem. 
 
METHODOLOGY: Samples of tissue from osteoarthritic hips, osteolytic prosthesis and well-fixed prosthesis 
collected intra-operatively. RNA was extracted from the tissue, and expression levels measured with a 
quantitative real time PCR technique. Expression of 96 genes was measured utilising specific primer and probe 
sets for 96 genes. 
  
At twelve year follow-up a cohort of patients were identified and their risk for interval revision surgery based 
on potential co-morbid risk factors assessed. In addition studies evaluating the value of radiographs and 
patient reported outcome measures in the diagnosis of osteolysis were undertaken. 
 
RESULTS: Significant changes were seen in many genes in study group as compared to the two control groups. 
In addition seven genes (BMP4, FRZB, FGF18, IL8, IRAK 3, OPG and PTGS2) were found to be significantly 
(p<0.05) predictive (AUC>0.77) of osteolytic change when compared to the well fixed prosthesis.  Addtionally 
nine genes (VEGFB, SFRP, TLR3, TLR5, TP53, IGF1, CTSK, CHIT 1, CCL 18) were found to be predictive of 
osteolytic change (AU>0.77) but did not reach significance. 
 
Patient co-morbidities were found to be predictive of eventual failure of THR, and improved sensitivity and 
specificities were demonstrated with iliac-oblique radiographs  and the Harris Hip Score when compared to 
other outcome measures. 
 
CONCLUSIONS:  This study presents the first comprehensive expression profiling of osteolytic hips, and 
comparison to the two control groups allows conclusions to be drawn about those genes involved in 
osteolysis, and how patient responses may differ between individuals. In addition improvements in diagnosis 
and epidemiological risk factors have been identified that enable identification of individuals at risk of 
loosening, and improved follow up regimes. 
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SECTION 1 : BACKGROUND 
Total hip replacement (THR) is one of the commonest procedures performed in the world. Over 61,000 were 
performed in the UK in 20071 (NJR 2007), and the year on year incidence is increasing. THR is a successful 
intervention and marked increases in quality of life can be expected with an improvement in pain and 
function2-4. This makes THR one of the most successful orthopaedic interventions5. Total joint arthroplasty is 
the single intervention performed for diseased hip joints irrespective of the primary diagnosis. 
 
THR has been found to be successful for periods in excess of 30 years in patients with primary osteoarthritis6. 
The same prosthetic joints have been found to be equally successful in secondary arthritidies :  
 Inflammatory arthropathies (rheumatoid arthritis (RA)7-9, ankylosing spondylitis10;11 and other 
autoimmune conditions) 
 Avascular necrosis12-14 
 Previous septic arthritis15-17 
 Haemophiliac arthropathy18 
 Developmental dysplasia of the hip (DDH)19-21 
 Fracture22-24 
However the rate of survival is not uniform across these groups (Fig 1.1) with significantly higher failure rates 
in some groups such as rheumatoid arthritis (RA) and avascular necrosis (AVN) when compared to 
osteoarthritis (OA). The increased rate of revision in fracture patients can be explained by higher dislocation 
rates22. However the reasons for increased revision rates in patients with rheumatoid arthritis and avascular 
necrosis remain unclear. 
 
Figure 1.1.1: Graph showing survival outcomes (Kaplan Meier) for THR since primary procedure by diagnosis (Avascular Necrosis - AVN; 
Developmental Dysplasia of the Hip – DDH; Fractured Neck Of Femur - FNOF; Rhematoid Arthritis – RA; Osteoarthritis OA) . Reproduced 
from Australian NJR 2008 report
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1.2 Success of Arthroplasty 
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Defining success in THR is fraught with difficulty, and there is no uniform agreement as to what constitutes a 
well functioning arthroplasty. The success of a joint replacement can be difficult to define. Measures of 
success can be broadly categorised into : 
 Patient reported or other outcome measures 
 Measures of longevity 
 Radiographic measures of success 
There is little agreement amongst authors as to what the best measure is, and consequentially there are many 
different criteria and research instruments in each of these categories. 
 
Patient reported outcome measures are questionnaire based outcome scores, they differ from other outcome 
measures in that they do not include review by the clinician. They rely on responses to a number of subjective 
questions, the results of which are summed to provide an eventual score. Although many of these scores have 
been validated as a measure of functional improvement following joint replacement surgery, little is known 
about the sensitivity of these measures in detection of survivorship or a failing arthroplasty in the longer term. 
The most commonly used outcome scores are the Harris Hip Score25, Oxford Hip Score26, Merle d’Aubigne27 
and the Hospital for Special Surgery Score28. Although these scores are in widespread use and many published 
articles rely on quality as assessed by these scores1-3;29 very few have been independently validated and there 
are few data to suggest these scores are predictive of loosening or failure of a prosthesis. The majority of 
commercially available THRs have similar post operative scores when using any of these instruments with 90-
95% good or excellent results. 
 
Radiographic evaluation of THR allows for a measure of quality of the surgical procedure through evaluation of 
cement mantles30, component position31 and evaluation of any osteolytic lesions2. There are a number of 
radiographic criteria that have been developed to define failure the most commonly used being those of 
Hodgkinson32, Harris31;33 and Kobayashi34. The validity of these individual scores as a predictor of 
intraoperative findings of a ‘loose component’ probably varies with prosthesis type and criteria. Hodgkinson 
validated his own criteria against intraoperative findings of 200 acetabulae and found 94% to be loose when a 
complete radiolucent line was present when compared to only 7% with a radiolucent line in a single zone. 
Harris’ criteria for radiological loosening when applied to a six year radiograph were found by Ollivere et al2 to 
be predictive of revision by their 12 year follow up. Not all authors however agree on the validity of these 
scoring systems, and no national joint registries include this data. 
 
Measures of longevity quantify the working life of a prosthesis. Whilst the majority of THRs all produce 
similarly good results in the short term, as reflected in their clinical outcome scores, there are wide variations 
in longevity of the prosthesis. Patients undergoing arthroplasty are becoming younger and the demands 
placed on their prosthesis and the likely working life have extended4. Consequentially the success of THR is 
increasingly being measured as survivorship at a fixed time point (usually 10 years). Whilst revision surgery (or 
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changing the prosthesis) is a definite end point it is also a coarse one, and there is increasing concern that the 
measure of revision surgery as failure may not reflect the true number of failing prosthesis2. 
 
This lack of general agreement surrounding what is defined as a ‘failed’ THR has led most authors to use the 
end point of revision surgery as their outcome measure when evaluating performance of a THR. Further study 
is required in this area to clarify the value of radiographic and patient reported outcomes not only in long term 
follow up, but also as tools to detect failing prostheses. 
 
1.3 Long Term Results 
The natural history of total joint arthroplasty is of an increasing rate of failure as the interval between 
implantation increases. The mode of failure however changes over time. During the first few years after 
implantation early infection and dislocation predominate. However as time progresses aseptic loosening 
(osteolysis) and periprosthetic fractures predominate as the primary modes of failure.  
 
The results for each prosthesis differ and the success rates are measured either as failures per 1000 observed 
component years35, absolute survival at a ten year bench mark, or most commonly using a Kaplan-Meier 
survival analysis model1;2;36. With modern joint replacements a survivorship of 90% at ten years for all causes 
of revision across all patients is considered by the National Institute for Clinical Excellence (NICE) a minimum 
standard. 
 
1.4 Causes of Failure in Arthroplasty 
Osteolysis (or loss of bone) is currently the commonest cause for revision surgery and late failure of any 
prosthetic joint. The rates of revision surgery are continuing to increase and in 2003, 36,000 revision hips were 
performed for 200,000 primary procedures37, giving a current lifetime incidence of at least 18%. Revision 
surgery is undertaken for a variety of reasons including: 
 Periprosthetic fracture 
 Dislocation 
 Bearing surface wear/fracture 
 Aseptic loosening 
 Infective loosening 
 Implant failure 
 Technical surgical error 
 
Aseptic loosening is a process where the generation of particulate debris from a prosthesis results in an 
inflammatory response leading to bone resorption (osteolysis). Failure due to aseptic loosening of one or both 
of the components of a THR is the most common reason for revision surgery. The precise incidence of the 
individual indications for revision surgery varies between prosthesis and between published series. However 
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national registries give an indication of the overall incidence of failure (Table 1.1), and in every published 
registry aseptic loosening is the leading cause of failure1;2;35;36. 
 
Reason for reoperation 1979-2002 2003 2004 2005 2006 2007 Share  
Aseptic loosening 14,869 1,105 988 996 1,018 952 58.30%  
Dislocation 2,584 255 320 265 256 290 11.60%  
Deep infection 2,185 240 288 281 286 305 10.50%  
Fracture 1,666 168 172 181 164 191 7.40%  
2-stage procedure 993 107 99 98 78 80 4.30%  
Technical error 834 17 17 19 15 36 2.70%  
Miscellaneous 793 21 36 26 15 27 2.70%  
Implant fracture 338 35 33 23 23 23 1.40%  
Pain only 270 11 16 8 15 11 1.00%  
Secondary infection 0 0 1 1 0 3 0.00%  
(missing) 36 0 1 6 1 4 0.10%  
Total 24,568 1,959 1,971 1,904 1,871 1,922 100%  
Number of reoperations per reason and year 
primary THRs performed 1979-2007 
Table 1.1 : Causes for reoperation in THR. Reproduced from the Swedish Arthroplasty Register
3 
 
Whilst there is general agreement that aseptic loosening is due to the production of wear debris from the joint 
articulation, this is where the consensus of opinion ends. There is no clear agreed definition of aseptic 
loosening2. Furthermore there is variability in the outcome of; and revision rates within published groups of 
patients implanted with the same prosthesis within the same hospital. Objective scientific study into the 
causative factors, natural history and incidence of this condition is therefore difficult. 
 
It is however clear that the incidence of aseptic loosening increases with time38, and that all varieties of total 
hip replacement suffer from aseptic loosening2;4;29;33;39;40 and subsiquentosteolysis. 
 
1.5 Implant Designs 
Total joint arthroplasty has been in widespread successful clinical use in the UK for in excess of 40 years41. The 
continual evolution of hip replacement prosthesis has resulted in a multitude of different designs often 
changing in iterative steps. Designs vary in their method of fixation, either cemented or uncemented, bearing 
surfaces and method of lubrication. The most successful designs41;42 involve replacement of both sides of the 
articulation with a stemmed femoral component articulating a stainless steel head against an ultrahigh 
molecular weight polyethylene (UHMWPE) acetabular cup.  
 
The components are either cemented into place, or implanted with uncemented fixation techniques. The 
earliest designs of uncemented prosthesis such as the Austin-Moore relied on a ‘press fit’ technique where the 
component is forced into the bone and friction at the interface provides the stability. More modern designs 
have relied on either bone on-growth or bone in-growth to the bone prosthesis interface through use of 
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porous coatings which provides a ‘biological fix’.. However despite the attractive prospect of a biological fix the 
long term registry survivorship analysis demonstrates inferior results when compared to the cemented designs 
(Fig 1.5.1) 
 
 
Figure 1.5.1 : Kaplan-Meier survivorship graph of total hip arthroplasty. A comparison of different fixation types. Reproduced from the 
Australian Joint Registry 2008 report
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Cemented designs rely on bone fixation using a layer of bone cement between the prosthesis and the bone. As 
cemented metal-on-plastic articulations are the most successful and commonly used design of THR’s they will 
form the basis for study.  
 
1.6 Aseptic Loosening 
Aseptic osteolysis is now the single biggest limitation to joint longevity in the UK2 and accounts for 
approximately 60% of all revision surgery1;35;36. The rate of aseptic loosening increases with time, and the 
process results in both loss of bone and loss of fixation of the prosthesis. 
 
Aseptic loosening is characterised by loss of fixation at the bone/cement or prosthesis/cement interfaces and 
is often associated with large osteolytic bone defects (Fig 1.6.1). The American Academy of Orthopaedic 
surgeons classifies these as two distinct but potentially related entities43. 
 
Despite the wide spread use of THR as a treatment for osteoarthritis and the increasing health-economic and 
social burden of revision joint surgery there is little published literature concerning the likely risk factors for 
osteolytic failure. Reports are emerging of successful results in selected cases at in excess of 30 years following 
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implantation with no signs of loosening6;41 whilst other patients from the same cohort have failed many years 
earlier. 
 
Figure 1.6.1 : Pelvic anteroposterior radiograph of two osteolytic total hip replacements showing typical appearance of an osteolytic 
total hip replacement: radiolucent lines (1), cement fracture (2) and cavitatory bone defects (3). 
 
1.7 Mechanical Theories of Loosening 
It was originally described by Wolff44 that bone responds and remodels to mechanical forces. Mechanical 
loading of bone can cause remodelling and compensatory growth45. There are widespread reports in the 
literature of proximal femoral resorption with distally fixing prostheses. It is likely that these are in part 
responsible for the characteristic patterns of loosening described by Gruen46 with the forces passing from the 
pelvis through the stem and into the distal femur bypassing the proximal femora. The subsequent stress 
shielding of the proximal femora results in bone loss and the characteristic failure pattern of ‘cantilever 
bending’46 associated with distally fixed prostheses. 
 
It is important to distinguish the form of mechanical loosening, which is a function of failure to load the 
proximal femora, from the process of osteolysis which is an active process and is a biological response to wear 
debris. Both result in a common mode of failure through loss of fixation and stem stability but through very 
different processes.  
 
2 
1 
3 
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1.8 Biologic Theories of Osteolysis 
Osteolysis is an active biological process that results in the loss of bone as a direct response to stimulation of 
macrophages by biologically active particles. Aseptic loosening is also closely associated with osteolysis, an 
active process of bone destruction and loss which is cell mediated47.  
 
It is commonly accepted that mechanical wear of the articulating surface releases particulate debris. This is 
phagocytosed, activating the macrophages and osteoclasts resulting in bone resorption. This mechanism and 
the existence of an underlying biological process of aseptic osteolysis was first hypothesised by Willert & 
Semlitsch48 in 1977.  
 
Early in the development of total hip arthroplasty bone cement was adopted as the fixation method of choice 
for both the femoral and acetabular components. Bone cement is composed of polymethylmethacrolate 
(PMMA) and is similar to dental cement. The earliest descriptions of osteolysis were following revision of 
cemented total hip replacements. Areas of bone loss and osteolysis were found in association with large 
granulomas filled with PMMA particles48;49 and the incorrect association was made between the cement and 
osteolysis. 
  
Although originally described as “Cement Disease”48;49 it is now understood that any particulate debris may 
result in an osteolytic reaction. Ultrahigh molecular weight polyethylene (UHMWPE), bone cement 
(polymethylmethacrylate - PMMA), Co-Cr, Ti2O3, ZrO2 particles have all been extensively shown to produce 
biologically active wear debris47.  
 
1.9 Generation of Particles 
The generation of wear particles occurs primarily at the primary articulating surface of the femoral head 
against the acetabulum, mainly through adhesive wear 50. These biologically active particles form the majority 
of the burden of wear debris, although metal ions and PMMA particles have also been identified from fretting 
at the head stem interface51 and abrasion at the cement-prosthesis interface52.  
 
1.9.1 Morphology of Wear Particles 
The size of wear particles has a profound effect on their biological activity. The majority of polyethylene wear 
particles are submicron (<1 micrometer) in size. This makes visualisation with light microscopy difficult due to 
the wavelength of visible light (0.4 – 0.7 micrometer)47. This led to an initial underestimation of the number 
and volume of particles in periprosthetic tissues. The use of proteolytic enzymes on periprosthetic tissues and 
subsequent density-gradient centrifugation53-55 has allowed accurate characterization of smaller particle 
numbers and size by use of a particle analyser. More recently electron-microscopy has allowed accurate 
visualisation of these particles (Fig 1.9.1). Several electron microscopy studies have confirmed that the 
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majority of wear debris particles are submicron in size with 70-90% of polyethylene particles measuring 
approximately 0.5 m 54-56.   
 
 
Figure 1.9.1 : Scanning electron micrograph of periprosthetic tissues. The section contains florid polyethylene debris (5-10m) in the 
soft tissues. Reproduced from Shanbhag A. S. et al
55
 
 
1.9.2 Biological Effects of Particulate Debris 
The relationship between the intensity of the biological response, and the number, size and type of particles 
has been extensively investigated. Phagocytosable particles (<10 m) appear to be more biologically active, 
although, at high concentrations, particulate debris becomes cytotoxic and provokes apoptosis in the 
macrophage.  
 
The initial supposition that osteolysis was due to cement particles led to a large number of in vitro 
experiments with PMMA particles. These demonstrated PMMA particles to be phagocytosable by monoclonal 
macrophages at less than 7 microns in size, and a resultant release of TNF-, whilst larger particles were not 
phagocytosable57. These findings were corroborated in a rat model by Gelb58 who also demonstrated 
metalloproteinase and PGE2 release in response to smaller PMMA particles. 
 
Subsequent investigation with other particle types has established that all types of metal wear debris (stainless 
steel, cobolt-chromium-molybdenum, titanium-oxide)59;60, polyethylene wear debris and ceramic debris all 
invoke a similar cell mediated response. Whilst some types of wear debris have been shown to be more 
cytotoxic than others55;59, and the type of cytokine release has been found by some investigators to depend on 
the type of wear particles60, the current body of evidence suggests that all wear particle provoke a similar 
immunologically mediated response47.   
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Although all types of particles are capable of provoking a biological response in vitro the precise nature and 
type of the response depends greatly on the size and concentration of the particles studied. The size of 
particles has a profound effect on the nature of the biological response. Contrary to original thinking 90% of 
particles are small and fall in the <10m size54. These particles are less likely to be cytotoxic61 and are 
therefore likely responsible for a macrophage initiated and possibly mediated response. Kubo62 demonstrated 
higher levels of biological activity to polyethylene particles of 11 m than larger controls. The activity level is 
not linearly related to number of particles, or size, but most likely the biologically active surface area of 
particles. The activity of macrophages in response to polyethylene debris has been shown to be both size and 
concentration dependent60;63 with the apoptotic rate reaching a plateau at concentrations of more than 150 
particles per macrophage.  
 
1.10 The Process of Osteolysis 
Osteolysis is an active biological cascade which is a response to particulate wear debris. There are a huge 
number of studies investigating the process. There is no currently universally agreed consensus as to the 
precise mechanism, precipitating factors and regulatory factors of this cascade. Rather there are many studies 
examining the process from different perspectives. These can be divided into : 
 Histopathological and in vitro studies examining the cellular interactions 
 Tissue explants studies examining sampled tissue using a variety of protein and mRNA detection 
techniques 
 Animal studies using simulated animal models 
In addition to studies examining the “traditional” theory of macrophage driven osteolysis there are other 
newer studies examining the potential role of alternate macrophage activation pathways and extrinsic cascade 
regulation. 
 
1.10.1 “Traditional” Pathways of Osteolysis 
There are a complex and poorly understood series of interactions between multiple cell types which regulate 
the pathway of osteolysis. A summary of the recognised signalling pathways and cascade of osteolysis is given 
(Fig 1.10.1). The individual interactions are well understood, but the effect of changes on the whole pathway is 
poorly understood. 
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Figure 1.10.1 : A schematic summary of the cellular interactions occurring in the biological pathway of osteolysis.  
Modified from Purdue et al
64
 
 
1.10.2 Cells involved 
Histopathological studies have shown profuse macrophage infiltration into periprosthetic tissues and the 
interstitial membrane48;65 in addition polarised light microscopy studies have identified large volumes of peri-
prosthetic polyethylene debris undergoing phagocytosis66. There is histopathological evidence for involvement 
of macrophages, osteoblasts, osteoclasts, fibroblasts and other antigen presenting cells have all be implicated 
in osteolysis. The role of each is outlined below. 
 
1.10.3 Macrophages 
Activation of a macrophage mediated response is central to the initiation of an osteolytic response65. In vitro 
studies using cultured monoclonal macrophage cell lines challenged with a variety of wear particles 
demonstrate phagocytosis of the wear debris67-69 and production of pro-inflammatory signal molecules. 
 
Stimulation of cultured macrophages in this way has been found to modulate the activity of a range of 
inflammatory mediators including prostaglandin E2 (PGE2), tumour necrosis factor alpha (TNF-)70, interleukin 
1 beta (IL1-)71;72 and interleukin 6 (IL-6)67. In addition to regulation of immunomodulators there is 
accumulating evidence that matrix regulatory proteins are implicated in macrophage mediation of osteolysis. 
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Metalloproteinase expression has been demonstrated to be up regulated in response to wear debris in 
cultured monoclonal macrophages73 and subsequently high rates of expression of a number of matrix 
metalloproteinases (MMP)74;75 have been demonstrated in periprosthetic tissues.  
 
Differing macrophage populations have been previously shown in vitro to respond to wear debris in different 
manners. Glant & Jacobs demonstrated a differing response between peritoneal macrophages and 
transformed cell lines (P388D and IC-21) and their response to controlled doses of titanium particles76. 
 
The results from these studies and animal and tissue models suggest the macrophage plays the key initiating 
role in osteolysis. In a recent review Purdue et al64 identified the exposure of macrophages to particulate wear 
debris as the critical initiating event in osteolysis. 
 
1.10.4 Osteoblasts 
Osteoblasts differentiate from the common osteoprogenitor cell lineage. Osteoprogenitor cells in the 
periosteum are induced to mature into osteoblasts under the influence of BMPs, fibroblast growth factors 
(FGFs), platelet derived growth factors (PDGFs) and transforming growth factor  (TGF-). Osteoblasts play a 
critical role in bone turnover, remodelling and metabolism in conjunction with osteoclasts. They are 
responsible for generation of and mineralisation of the bone matrix. Disorders in osteoblast and osteoclast 
function or balance can result in a range of metabolic bone diseases.  
 
There are few studies exploring the role of osteoblasts in osteolysis despite the potential for inhibition of 
osteoblast function to result in bone loss64. Lohmann et al77 established that not only can osteoblasts 
phagocytose wear debris, but that this can modulate differentiation and cytokine expression of cultured 
osteoblasts.  
 
The composition of the wear particles the osteoblasts are exposed to has been shown to vary the subsequent 
response. Exposure to UHMWPE reduces production of bone matrix by down regulating both collagen type I 
and III production78;79. There is also some evidence from cell culture studies that certain types of particulate 
debris may also inhibit osteoblast differentiation80. 
 
Although the current data are inconclusive they do implicate regulation of osteoblast activity and 
differentiation in osteolysis, and for a complete understanding of the process this gap in knowledge should be 
addressed in future studies.  
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1.10.5 Osteoclasts 
Osteoclasts are derived from a common cell lineage with macrophages and are multinucleated cells derived 
from osteoclast precursor cells in the general circulation. Not surprisingly as osteoclasts are the only cell 
lineage capable of active bone resorption81 much research surrounding osteolysis has been directed at 
establishing the role and function of osteoclasts in aseptic loosening. 
 
Histological studies have demonstrated extensive infiltration of osteoclasts and multinucleated giant cells into 
tissue surrounding loose implants82;83. Osteoclasts are recruited from precursor cells through expression of 
monocyte chemotactic protein (MCP-1) and macrophage inflammatory protein (MIP-1 the expression of 
both of these has been found to be up regulated in periprosthetic tissues64;84;85. 
 
Although there are some studies demonstrating a direct biological effect of wear debris on osteoclasts 86;87 it is 
likely that the majority of their modulation is via signal pathways from activated macrophages64, chiefly 
through up regulation of IL1, TNF- and IL686, all of which play a part in regulation of osteoclastic activity. 
 
Much emphasis has been placed on the importance of the Receptor Activator of Nuclear Factor κ B (RANK) and 
its ligand (RANK-L) in osteolysis91;92. The RANK receptor is a membrane receptor found predominantly on 
osteoclasts. Ligand binding at this receptor is the initiator for osteoclast differentiation. Osteoprotegerin (OPG) 
is the antagonist for this pathway93;94. It is secreted by osteoblasts and regulates osteoclast activity by 
providing an alternate binding site for RANK-L. The RANK pathway is a key modulator of bone turnover93;94. 
Alteration in ratio of RANK-L to OPG is reflected in changes to the rate and type of bone turnover and 
consequentially has been implicated in many metabolic diseases of bone95.  
 
Numerous studies have quantified the expression of RANK-L in periprosthetic membrane tissues. RANK-L 
expression is raised in tissue surrounding loose osteolytic components, that expression has been localised to 
macrophages, giant cells and fibroblasts96-98. This up regulation of RANK-L is therefore of likely significance in 
osteolysis. Modulation of RANK-L activity through increased expression of OPG99;100 or use of knock-out mice 
with a deficient RANK receptor101 results in down regulation of osteolysis in a mouse model. Further, exposure 
of fibroblasts102, osteoblasts103 and a murine calvarial model101 to particulate wear debris resulted uniformly in 
an increase in the RANKL/OPG ratio. 
 
1.11 Tissue Explant Studies 
Tissue explant studies are a method for investigating the process of osteolysis through removal of tissue intra-
operatively and analysis through: 
 Light or electron microscopy to identify particulate debris and cells 
 Immuno-histochemistry and in-situ hybridisation techniques 
 Quantitative rt-PCR and protein expression analysis 
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The histopathological picture of periprosthetic osteolysis (Fig 1.11.1) are well characterised and the 
periprosthetic tissues surrounding a loose implant contain abundant macrophages, evidence of particulate 
debris and giant cells82;83.  
 
 
Figure 1.11.1 : Photomicrographs of periprosthetic interface tissue. Submicrometer birefringent polythelyne particles (a) and dark 
metal particles (b) are seen within the cells (Magnification, x50). (Reproduced from: Glant, T. T.; Jacobs, J. J.; Mikecz, K.; Yao, J.; 
Chubinskaja, S.; Williams, J. M.; Urban, R. L.; Shanbhag, A. S.; Lee, S.; and Sumner, D. R.: Particulate-induced prostaglandin- and 
cytokine-mediated bone resorption in an experimental system and in failed joint replacements. Am. J. Ther., 3: 33, 1996) 
 
1.12 Animal models 
These ex-vivo studies have been corroborated with selective animal studies. This allows the standardisation of 
most factors and the majority of studies are designed to quantify and characterise the response of living cells 
and tissues to a challenge of particulate wear debris. 
 
In one of the earliest animal studies Goodman104 observed a reactive fibrous-tissue layer in response to 
implantation of UHMPE, metals and PMMA when implanted as a single large implant. However when the same 
materials were implanted in particulate form a more aggressive inflammatory response was noted. 
Histological examination showed infiltration of macrophages, giant cells and a profuse inflammatory infiltrate. 
This was similar to that seen surrounding loose implants61;104 confirming the findings of other tissue culture 
and ex-vivo studies60;62;64;82;105. 
 
(a) (b) 
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More advanced animal models of osteolysis have also been developed. Experimental models exist in the rat106, 
mouse107, dog108, rabbit108;109 all of which have been able to replicate previous experimental findings in an 
animal model setting. 
 
Aseptic osteolysis has been demonstrated in animal models as a response to particulate polyethylene 
debris106. Tissue culture from animal experimental models has confirmed up regulation of IL-1, PGE2
108;109 and 
TNF-. The more refined air-pouch model of Gelb et al58 allowed them to conduct a series of experiments to 
quantify the in vivo effect of the size, morphology and surface area of PMMA particles when inducing an acute 
inflammatory response.  
 
The development of mouse models specific for individual components of the osteolytic signal pathways has 
allowed the effects of various cytokines to be evaluated in animal models. Yang et al110 conducted a series of 
experiments demonstrating decreased osteolytic function in a mouse model with induced expression of anti-
inflammatory cytokines. A retroviral vector was used to induce expression of IL-1Ra and IL-10. In both cases 
the osteolytic pathway was significantly suppressed in the animal model.   
 
These animal experiments confirm and add weight to the body of cell culture and ex-vivo experimental work. 
Although useful in providing corroborative evidence for the process of osteolysis by their very nature they 
cannot tell us about the likely variation between individual patients in response to the same particulate debris. 
 
1.13 Pathway regulation 
The events leading towards osteolysis have been better explained by cell and organ culture studies than 
biomaterials research. Particulate wear debris has been shown to be phagocytosed by macrophages and to 
release a plethora of mediators. It seems likely that IL-1, IL-6, TNF- and PGE2 are the most important factors 
in the promotion of osteolysis47. These mediators stimulate cell proliferation and have been shown to be 
capable of stimulating activity of osteoclasts and therefore resorbing adjacent bone. Catabolism of bone 
matrix has been linked to the production of matrix metalloproteinases such as collagenases and stromelysin111. 
  
TNF- has been implicated as the primary mediator released by activated macrophages. Osteoblasts are 
stimulated to release GM-CSF and IL-6 as a response to TNF-which in turn recruits more macrophages (GM-
CSF) and increases their state of activation. 
 
Matrix-metalloproteinases (MMPs) have also been implicated in osteolysis and MMP-1, MMP-2 and MMP-11 
have been shown by Vidovszky112 to be present in areas of osteolysis. This may be through either direct 
stimulation of fibroblasts by secondary actions of particulate debris (which has been demonstrated in explant 
studies) or through activation via macrophages and osteoclasts. 
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1.14 Alternate Activation Pathways  
Macrophages are able to respond to a single stimulus through the activation of multiple signalling pathways. 
The classical or M1 macrophage activation pathway results predominantly in TNF  and IL1 production. It is 
seen in response to Th1 cytokines (typically IFN-) which are typically produced in response to microbial 
stimulation113.  
 
However macrophages are capable of a broad spectrum of responses and these alternate (or M2) responses 
are responsible for activation of alternate signally pathways such as NFkB, and the MAP kinases (p38, JNK and 
ERK) 86;87. This M2 activation results predominantly in production of other inflammatory mediators cytokines 
such as PGE2. The alternate activation pathway is driven by response to the Th2 cytokines (predominantly IL4 
and IL13). 
 
There is accumulating evidence that these ‘alternate’ activation pathways are important in the host response 
to conditions such as Gaucher’s disease114-116, multiple sclerosis117, atherosclerosis118 and tuberculosis.   
 
Whilst evidence surrounding the role of alternate macrophage activation in osteolysis is far from complete 
there is accumulating evidence that this process may have a role. Koulouvaris et al105 demonstrated high levels 
of alternate macrophage activation markers chitotriosidase and CCL18 when comparing periprosthetic tissue 
from failed hips to primary controls105. These same markers have been implicated in alternate macrophage 
activation in Gaucher’s disease119-121 and sarcoidosis122. Macrophages are responsible for formation of giant 
cells in granulomatous diseases and both DC-STAMP 123 and TREM2124 have been found to be elevated in 
periprosthetic tissue. 
 
It seems likely that the M2 responses play as crucial a role in the osteolytic response as they do in other 
granulomatous and macrophage driven diseases. The implication of M2 responses may help to explain 
difficulties in reproducing the in-vitro cell culture experiments in-vivo or ex-vivo. Recent work has shown that 
in prolonged incubation with wear debris macrophages move through an M1 (TNF  & IL6) response which 
peaks at an hour and returns to normal within 24 hours86. Further incubation periods appear to result in a 
gradual increase in M2 cytokines with a slow increase in markers such as chitotriosidase. It seems possible that 
the balance between these two responses may play a role in the differential activation of the osteolytic 
cascade seen from patient to patient. 
 
1.14.1 Differential Responses 
The majority of in vitro experiments have been performed using monoclonal macrophages, and the observed 
response presumed to be generalisable to humans. Giant et al investigated the effects of different cell lines to 
the same wear debris and demonstrated markedly different responses with significantly different responses 
between macrophage populations when exposed to different wear debris particles76. 
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SECTION 1.15 CANDIDATE GENES 
 
In addition to those genes previously identified in periprosthetic osteolysis a thorough literature search was 
undertaken to identify genes which previous work had identified in other musculoskeletal conditions as 
markers of : 
 Arthritis disease activity 
 Cellular function (macrophage, osteoblast and osteoclast) 
 Bone and matrix turnover 
 Apoptosis 
 Macrophage differentiation and activation 
This led to the inclusion of 92 candidate genes and 4 housekeeping genes in the current study. An overview of 
the function and reason for selection of each candidate gene is outlined below. 
 
1.16 Housekeeping Genes 
Housekeeping genes are expressed uniformly across tissues, and hence may be used to correct tissue 
expression studies for the inaccuracies associated with RNA extraction and expression analysis from tissue 
samples. 
 
Use of multiple house-keeping genes allows for normalisation to the most stably expressed gene, and analysis 
with appropriate software such as geNorm or NormFinder allows normalisation to the most suitable 
housekeeping genes125. We identified four housekeeping genes previously demonstrated125-127 to have stable 
expression in musculoskeletal tissues and therefore to be good candidates for housekeeping genes in this 
study.  
 
18S – The 18S ribosomal subunit is the most commonly used housekeeping gene. It forms part of the 
translation apparatus and the ribosome. It is stably expressed in many mammalian tissues. 
 
Actin (ACT) – is a non-muscle isoform of actin which is found throughout the body. It is an important 
cytoskeleton protein and as such is found expressed at relatively stable levels in the majority of tissues.   
 
GAPDH - glyceraldehyde-3-phosphate dehydrogenase is indirectly responsible for the catalysis of glucose in 
the glycolytic pathway. It is has relatively stable expression across all tissues as glycolysis is an essential 
pathway in most tissues. 
 
SDHA - Succinate dehydrogenase forms a co-enzyme complex (Co-Q) and is expressed in the mitochondria. It 
has stable expression properties in tissues involved in aerobic respiration. 
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1.17 Bone Regulatory Proteins & Markers of Degradation 
Bone is a tissue that undergoes continuous turnover and regulation, and is capable of healing without scar. 
The remodelling process originally described by Wolff and a variety of other mechanical128, bioelectrical129 and 
endocrine130;131 factors have been implicated in bone turnover. 
 
There is little current evidence to support a role of bone regulatory proteins such as bone morphogenic 
proteins (BMPs) in processes of osteoarthritis or osteolysis. However there is accumulating evidence that 
these are important factors in osseoinduction and fracture repair132-135. 
 
Bone Morphogenetic Protein 4 (BMP4) 
The BMP family of proteins are a group of proteins that regulate bone formation and growth. Most are a 
subset of the TGF- family of proteins. Originally seven members of the family were identified, BMP 1-7. They 
are aside from BMP-1 (an astacin metalloproteinase)all TGF- super family proteins. There are now 20 
identified BMP proteins135.  
 
BMPs bind to cell surface receptors BMPr’s and induce the SMAD secondary messenger pathway. BMPs and 
the SMAD pathway have also been implicated in developmental pathways133. BMP-4 has been shown to be the 
most potent stimulator of bone growth and has clinical applications in induction of fracture healing. 
 
Collagen Synthesis – COL 
The COL group of genes encode for a variety of collagen chains. Most human collagen molecules contain two 
 and one  chain. Measurement of COL gene expression may be related to collagen synthesis rate. 
However the collagen molecule has considerable post-transcriptional and post-translational regulation with 
cleavage of pro-peptides, cross linking and glycosylation prior to eventual fibril formation. This should be 
remembered when interpreting COL gene expression as a surrogate marker for collagen synthesis. 
 
 Changes in expression of COL genes have been shown to be associated with osteoarthritic change in a horse 
model136. Measurement of collagen synthetic rate will give an indication of the formation rate of new bone 
and connective tissue137. Measurement of expression of COL1A1, COL1A2 and COL3A1 mRNA has been shown 
along with other markers of gene expression in cartilage to relate to the severity of osteoarthritic change138.  
 
COL1A1 & COL1A2 
The COL 1A1 and COL 1A2 genes encode the components of type 1 collagen found as the major component in 
the extra cellular matrix of bone. COL1A1 encodes the major component of type 1 collagen and has been 
previously implicated in osteogenesis imperfecta139. COL1A2 encodes an additional copy of the alpha chain, 
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the two genes are not always co-regulated. Both COL1A1 and COL1A2 have been implicated in osteogenesis 
and in Ehlers-Danlos syndromes140;141. 
 
COL3A1 
COL3A1 encodes for the alpha chain of type III collagen which is found in association with type I collagen in 
bone and connective tissues. Type III collagen is also associated with fibrocartilage formation and as such is 
implicated in the cartilaginous repair process142. 
 
1.18 Toll Like Receptors (TLR 1-5) 
Toll like receptors (TLR) are named due to their genetic similarity to the Drosophila protein Toll. They are a 
group of cell membrane proteins responsible for co-activation of a number of immune responses and play a 
key part in mediation of innate immunity. They usually function as a co-signalling receptor responsible for 
recognition of microbial molecules (such as bacterial lipopolysaccharides) they have the poteintial activate a 
number of intracellular inflammatory pathways. 
 
The exact function of each TLR is unclear and although traditionally associated with response to infection143 
there is some evidence that TLRs are associated with aseptic loosening144-146. TLR-3 expression has been 
demonstrated in inflammatory arthritides to be associated with activation of the RANK-L pathway and hence 
potentially macrophage activation and aseptic loosening147. The breakdown of cartilage by matrix 
metalloproteinases (MMPs) and glycosidases produces breakdown products that are known to activate the 
TLR pathway148. 
 
1.19 WNT Pathway (WNT10B, WNT5A, WNT7B) 
The WNT signalling pathway is a well described and much studied149-151 signalling pathway which has been 
implicated in tumour genesis152, embryological skeletal development and in the disease process of 
osteoarthritis. WNT genes are related to the wingless gene originally characterised in Drosophila spp. The 
family of proteins codes for the WNT secreted signalling ligands and a wide range of effects have been 
associated with a variety of WNT ligands. The WNT pathway functions through activation of frizzled (FZD) cell 
surface receptors. The frizzled surface receptor is responsible for the signal transduction of WNT pathway. 
Frizzled and associated proteins have been implicated in bone turnover.  
 
The WNT family of genes have been implicated in a huge range of cell regulatory and disease processes. 
However WNT5A153, WNT7B154 and WNT10B151;153 have been particularly implicated in pathogenesis of arthritis 
and osteolysis.  
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Activation of the WNT/Frizzled pathway results in subsequent activation of three different downstream 
pathways : Wnt/β-catenin (canonical pathway); WNT/Ca2+ and WNT/polarity. It is not clear how the 
subsequent pathway activation is determined however it is likely that this is determined by a combination of 
WNT ligand and the Frizzled receptor present.  
 
The WNT/β-catenin pathway is the most studied pathway as it results in regulation of gene expression. The 
WNT β-catenin pathway has been shown to modulate bone resorption and may play a key role in the 
pathogenesis of osteoarthritis and osteolysis. Activation of β-catenin results in up regulation of Dishevelled 
(DVL) and production of a non-phosphorylated form of β-catenin which localizes to the nucleus. This is thought 
to induce the expression of downstream target genes152. 
 
1.19.1 SFRP-1, SFRP-2 & SFRP-3 (secreted frizzled-related protein) 
SFRPs are a family of secreted proteins that share the receptor binding domain for the Frizzled receptor with 
the WNT pathway. Hence SFRPs function as secreted ligands and are able to bind WNTs extracellularly and 
thus modulate their activity. The SFRPs are capable of down regulating the activity of the WNT pathway. 
Modulation of the WNT/-catenin pathway has been implicated in the pathogenesis of osteoarthritis149. 
 
Frizzled related protein is a WNT antagonist and has been potentially implicated in periprosthetic osteolysis155. 
Genotype variations in FRZB have been shown to predispose patients to both osteolysis and heterotrophic 
ossification. However differences in gene inheritance rate were not significant155. 
 
There are two major antagonists that act on the WNT pathway, Dickkopf (DKK) and the secreted frizzled-
related proteins (SFRPs) this regulatory function is critical to the activity of the WNT pathway. In order to 
adequately assess the activity of the WNT pathway the activity of these regulators must also be known. 
 
1.19.2 Dickkopf (DKK1, DKK2, DKK3) 
The Dickkopf (DKK) family of proteins are extracellular secreted proteins which act to inhibit the activity of the 
WNT signalling cascade. DKKs have been shown to be involved in embryonic tissue differentiation and also 
implicated in osteolytic lesions associated with myeloma. Suppression of DKK1 has been shown to profoundly 
affect the process of osteolysis in myeloma156. Inhibiting DKK1 prevents the suppression of bone formation and 
in doing so is effective in prevents the development of osteolytic bone disease in animal models of myeloma. 
DKK1 has additional roles in rheumatoid arthritis, where it regulates bone loss, and also in osteoarthritis where 
it is associated with osteophyte formation. 
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1.20 Interleukins & other Cytokines 
Interleukins and other cytokines previously implicated in the osteolytic cascade (as outlined above) have been 
included as candidate genes. In addition to those factors previously identified some modulators of cytokine 
function and other family members have been included. 
 
1.20.1 Interleukins 
The role of interleukins is well established in both the osteolytic cascade and inflammatory arthropathies. In 
addition to the widely recognised and previously discussed IL1, IL4, IL6 and IL13 a number of other receptors 
and modulators have been included as candidate genes.  
 
Beraudi and colleagues157 performed a series ex-vivo studies of limited cytokine expression analysis in tissue 
surrounding osteolytic hip replacements. They examined and documented variations in the levels of IL1-, IL1-
, IL6, IL8 and IL10 using an ELISA technique. They did not evaluate any well fixed stems, but concluded that 
that cytokines had an important role to play in periprosthetic osteolysis. Interleukin 1 has been shown to be 
implicated in the osteolytic cascade and function of IL1 is modulated by both IL1RA (interleukin 1 receptor 
antagonist) and results in activation of IRAK3 (interleukin-1 receptor-associated kinase 3). 
 
IL11 has been demonstrated to have a marked effect on bone turn over and has been implicated in 
metastatic158 associated osteolysis, in regulation and differentiation of osteoclasts159 and has been implicated 
in osteolysis160. Bone destruction (cyst formation) in rheumatoid arthritis has been associated with elevation in 
the expression of interleukins IL12, IL12 and IL17161. It is likely that this occurs through an interaction with 
OPG and perhaps also through the actions of natural killer (NK) cells. 
 
1.20.2 IFN(interferon-gamma) – IFN- is a soluble cytokine which is the sole member of the type II interferon 
family. IFN- is critical in activation of macrophages, and as such is likely to be involved in any macrophage 
mediated response such as osteolysis.  
 
1.20.3 TNF Family-(TNF-, CD120A, CD120B, FASLG, OPG, RANK, RANK-L) 
TNF  has been previously implicated in the process of periprosthetic loosening. A range of TNF family 
receptors and modulators have been included as candidate genes in this study. A major TNF- receptor 
subtype, TNFRSF1A (CD120A) is known to be a key mediator of the inflammatory response and is responsible 
for activation of the NF- pathway and consequentially plays a key role in the induction of apoptosis, a 
pathway which itself has been linked to osteolysis162;163.  
 
A number of key cellular receptors are responsible for apoptosis, and if apoptosis does indeed play a role in 
osteolysis then these receptors and ligands may be expected to play a pivotal role. The CD120A related 
receptor TNFRSF1B (CD120B) is thought to be involved in induction of the apoptotic cascade. Activation of 
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CD120B has been previously shown to up-regulate c-IAP1 and c-IAP2 which then function as anti-apoptotic 
signals164 although not previously implicated in osteolysis its structural and functional similarity to CD120A 
make it an ideal candidate gene.  
 
FAS Ligand (FASLG) is a TNF family cellular receptor which is responsible for mediation of apoptosis. Binding of 
FAS-Ligand to its receptor is the final common pathway for apoptosis, and as such FASLG forms a marker of 
overall apoptotic rate, and should apoptosis be responsible for cell death In osteolysis FASLG expression 
should be raised. 
 
The OPG/RANKL/RANK pathway is the final common mediator of osteoclastogenesis. OPG is a soluble, decoy 
receptor belonging from the TNF receptor super family and blocks RANK-L, the key mediator of 
osteoclastogenesis. RANK-L is found endogenously as both a membrane-bound form and as a soluble form. The 
RANK-L, binds the  RANK receptor found predominantly on osteoclast cells and is responsible for modulation of 
bone metabolism. 
 
1.21 Chemokines (CCL2, CCL3, CCL18, CCR1, CXCL9, CXCL10, CHIT 1) 
Chemokines are small secreted chemo-attractant molecules which play an essential role in directing the 
migration of a variety of inflammatory and immune cells. Chemokines have been shown to be involved in 
leukocyte migration in juvenile idiopathic arthritis (JIA) and facilitate the formation of an infiltrate of activated 
inflammatory T cells, as well as B cells, macrophages and dendritic cells165. 
 
Chemokine receptor expression is specific to subsets of leukocytes and hence the secreted chemokines and 
chemokine receptors are likely reflective of activated, effector and memory T cells166-169. Chemokine receptor 
expression can be used to distinguish Th-1 T cells (which typically express CXCR3 and CCR5) from Th-2 
populations (typically CCR3 positive). CCL2 (monocyte chemotactic protein-1) has been implicated in the 
activation of the osteolytic cascade and regulation of osteoblastic function in the pathogenesis of 
periprosthetic osteolysis166. Previous RT-PCR analysis of periprosthetic soft tissue from osteolysis patients has 
demonstrated activation of chemokines associated with alternative macrophage activation markers (CHIT1, 
CCL18)170.  
 
Macrophages are responsible not only for the initiation and maintenance of the inflammatory process, but 
also for the inhibition and resolution of inflammation. Switching of activated macrophages from one state to 
the other is influenced by secreted chemokines (CCL3, CCL18)171. If macrophage switching were to occur in 
osteolytic tissues it might be central to suppression of the osteolytic cascade. 
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1.22 Cluster of Differentiation (CD2, CD58, CD14, CD28, CD80, CD86, CD36) 
The cluster of differentiation (CD) protein family includes a wide range of cell surface markers expressed on T 
and B cells. The group is heterogeneous and includes molecules responsible for cell signalling, cellular 
adhesion and differentiation. CD proteins may act as either receptors or ligands and those included here have 
all been implicated in the inflammatory process associated with osteolysis. 
 
CD 2 is a cell surface receptor found on T cells and also on NK cells. It functions as an adhesion  molecule, but 
may also be used as a surrogate maker for T cell activation due to its secondary role as a co-stimulatory 
molecule172;173. CD 2 binds to CD58, another cellular adhesion molecule expressed on antigen presenting cells 
(APC), particularly macrophages. 
 
Lymphocyte function-associated antigen (CD58) functions as a macrophage specific cell adhesion molecule and 
is expressed as part of the initial activation of T-cells by the antien presenting cell (APC). The CD58 binds to 
CD2 and plays and important role in strengthening cell adhesion between the macrophage and the T-cell it is 
working to activate. CD58 has not been implicated previously in osteolysis, but has been shown to have 
variable expression in rheumatoid patients, and specifically increased expression has been shown to be related 
to clinical outcome174. Previous studies demonstrating a variation in expression levels in patients undergoing 
primary joint replacements make this a candidate gene. 
 
CD14 is a cell surface receptor expressed on macrophages and dendritic cells. It forms a co-receptor with Toll 
like receptor 4 (TLR4) for bacterial lipopolysaccharide175. CD14 is found both bound to the cell membrane 
(mCD14) and insoluble form (sCD14)176. Expression levels of CD14 are analogous to macrophage and dendritic 
cell function, and would be expected to mirror that of TLR4. Expression of CD14 is analogous to macrophage 
function and makes this a candidate gene. 
  
The CD28-80-86 co-stimulatory pathway is responsible for T-cell activation. CD28 is the cell surface receptor 
for CD80 and CD86. Activation of antigen presenting cells (APCs) and B-cells results in increased expression of 
CD80 and CD86 and a resultant stimulation of T-cell activation via the CD28 pathway. Activation of this 
pathway results in IL2 and IL6 production. This pathway is likely the mediator for the protective effects of 
oestrogen on bone loss seen in a mouse model177. Up regulation of osteoprotegerin (OPG) in response to CD28 
stimulation inhibits the activity of osteoclasts. Some authors have identified  the CD28 pathway as involved in 
peri-acetabular osteolysis178. Given the previous implication of this pathway in osteolysis and the key role 
these proteins play in activation of the T and B cell response these candidate genes may give an indication of 
an individual’s likelihood to activate the osteolytic cascade. 
 
CD36 is a collagen binding receptor, and is a marker of collagen turnover. It has been implicated in a number 
of collagen disease processes including atherosclerosis and more recently as a marker of chondrocyte 
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activity179. CD36 has been implicated as an important anti-inflammatory factor critical to cartilage repair in 
inflammatory arthritidies179.  Osteoarthritis involves the destruction of articular cartilage and it is possible that 
CD36 is implicated in this. Additionally given previous implication as providing a protective effect against 
degenerative joint disease it is possible that CD36 activation will also protect against the effects of osteolysis a 
process in which the destruction of bone and collagen matrix is key to the disease process. 
 
1.23 MMPs, ADAMTSs (MMP1,12,13, ADAMTS 2,3,14, TIMP 1) 
The matrix metalloproteinases (MMPs) are a family of 23 enzymes found in man that are the only enzymes 
able to degrade the collagen triple helix under physiologic conditions .As osteolysis involves lysis of collagen 
within bone it seems likely that collagen and matrix collagenases will have a role to play in the process. Several 
MMPs have been shown to have a collagenolytic effect. Initially MMP-1, -8, and -13 were identified as having 
this activity. More recently, MMP-2 and MMP-14 have also been shown to perform this function but with 
lower efficacy. 
 
Extracellular matrix metabolism is also regulated by a further family of proteins, a disintegrin and 
metalloproteinase domain with thrombospondin motif (ADAMTS). There are 19 identified members of the 
ADAMTS family in humans. ADAMTS are known to function both as procollagen N-propeptidases (ADAMTS-2, -
3, and -14) and aggrecanases (ADAMTS-1, -4, -5, -8, -9, and -15), the function of other members of the family 
are unclear. 
 
There are four specific inhibitors for the MMP and ADAMTS family of collagenases. The tissue inhibitors of 
metalloproteinases (TIMPs). It appears that the 4 members of the TIMP family are able to inhibit the majority 
MMPs but only TIMP3 is capable of inhibiting ADAMTS 4 & 5.  
 
1.24 Cell Growth Factors & Regulatory Proteins 
Particle-challenged cells release cytokines and chemokines, which contribute to periprosthetic osteolysis. 
Released growth factors from particle challenged macrophages are responsible in part for recruitment and 
differentiation of macrophages (CSF1) osteoblasts and osteoclasts. Osteoblast growth and differentiation is 
dependent on fibroblast growth factor (FGF-18), platelet derived growth factor (PDGF  and ) and 
transforming growth factor  (TGF-1, 2 & 3). Other growth factors including vascular endothelial growth 
factors (VEGF , VEGF ) and insulin like growth factor (IGF 1) have also been demonstrated to be up regulated 
in murine models of osteolysis180. 
 
1.25 Other Potentially Involved Genes 
There are a number of other gene regulators or families that have either been identified as involved in the 
osteolytic pathway, or given their known functions and sites of action are likely candidate genes. 
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1.25.1 Proteinases 
Other than the matrix metalloproteinases there are also several other proteinases which are important in 
degradation of the organic portion of bone matrix. The cathepsins are proteases that have been implicated in 
bone turn over. Cathepsin G (CTSG) is secreted from activated mast cells and has been localised in the 
prosthetic bone interface in aseptically loose hips181. Cathepsin K (CTSK) is a related protease which can may 
degrade collagen and has been strongly associated with bone metastasis and osteolysis182-184. Cathepsin K also 
plays a role in and has been used as a marker of osteoclast differentiation184. Higher levels of expression of 
either of these proteins are likely to indicate increased breakdown of the bone matrix. In support of this, 
activation of macrophages has been shown in the presence of the cathepsins, to facilitate osteolysis by the 
macrophage population themselves185. SERPINA3 (serpin peptidase inhibitor 3) is antichymotrypsin that has 
been shown to inhibit the function of the cathepsins.  
 
1.25.2 Apoptotic Factors 
Apoptotic pathways probably play a major role  in the process of osteolysis. Although a number of apoptotic 
molecules have been included as members of other families, the regulatory proteins BAK1 and BCL2 can 
modulate the apoptotic pathway and are important to interpret other results in the correct context. 
Additionally the caspase group of proteins (CASP3) play a central role in execution of apoptosis and are also 
included as candidate genes. 
 
TP53 (p53) is a transcription factor and tumour suppressor gene that has been implicated in BAK/BCL2 
associated apoptosis. P53 expression has been identified in association with BAK in peri-prosthetic tissues 
using immune-histochemical techniques186. 
 
1.25.3 Markers of cellular Function 
Several genes have been included as markers of cellular function. ITGAM (CD-11 integrin) is a marker of 
macrophage function and acts to activate the complement cascade. Integrin 2 (ITG-2) is also a component 
of the complement system and forms the  subunit of CD11, CD11 and CD11c. 
 
MARCO (macrophage receptor with collagenous structure) is rarely expressed in healthy tissues. It is a 
scavenger receptor and has been demonstrated to be up regulated in response to wear debris challenge in 
vivo187. CILP (cartilage intermediate layer protein) is seen as breakdown product in early cartilage 
degeneration. It is unclear if CILP is a marker of osteolytic change. 
 
CTLA4 is expressed on the surface of T helper cells and functions in a similar way to the co-stimulatory protein 
CD28. Both molecules bind CD80 and CD86 on the surface of antigen-presenting cells, and this interaction has 
been demonstrated to have an immunomodulatory effect188. 
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ACP5 (tartrate-resistant acid phosphatase 5 - TRAP) is essential for osteoclastic function and plays a key role in 
bone remodelling. Whilst TRAP is highly expressed in osteoclasts although it is also found in neurons and 
activated macrophages. TRAP has been implicated as a marker of osteoclastic function189. TM7SF4 (DC-STAMP) 
is also a marker of osteoclast differentiation and has been implicated in osteoclastic differentiation and the 
production of multinucleated cells which are key to periprosthetic osteolysis189. 
 
ERCC1 (excision repair cross-complementing, complementation group 1) is an endonuclease enzyme 
responsible for the 5’ incision during DNA repair. It has been used as a surrogate marker for DNA repair 
potential in a range of settings including periprosthetic osteolysis. ERCC1 is one of the only markers that has 
been previously found to be sensitive and specific for early osteolytic change190. 
 
Sclerostin (SOST) is an inhibitor of the WNT signalling pathway and the BMPs. Sclerostin is able to inhibit BMP-
induced bone formation a process mediated by WNT signalling, but not BMP signalling pathways150. 
 
2M  (-2-microglobulin) forms part of the MHC-1 complex and as such is expressed on all antigen presenting 
cells. While it has been previously evaluated as a housekeeping gene, it is used in this context as a marker of 
overall APC activity. VDR (vitamin D receptor) is a nuclear hormone receptor for vitamin D3 and gives an 
indication of vitamin D function in bone. 
 
PTGS2 (prostaglandin-endoperoxide synthase), known as cyclooxygenase (COX) catalyses a key step in the 
production of all prostanoids (including prostaglandins, prostacyclin and thromboxanes). There are two 
isoforms of PTGS: a constitutive PTGS1 and an inducible PTGS2, which differ in their regulation of expression 
and tissue distribution. The discovery of COX-2191 and differing tissue distributions for COX-1 and COX-2192 
resulted in the development of COX-2 specific anti-inflammatories which preferentially target COX-2. Bone and 
joint tissues have been shown to have a higher proportion of COX-2 activity. COX-1 and COX-2 inhibition has 
been shown to inhibit bone healing and remodelling in fracture193. 
  
 Section 1 : Background Page 26 
 
SECTION 1.26 RISK FACTORS FOR OSTEOLYSIS 
 
The natural history of total joint arthroplasty is well studied. There are a number of complete population 
studies in the form of joint arthroplasty registers1;35;36 and many  longitudinal cross sectional and cohort 
studies reporting the survivorship of individual prosthesis4;6;40;194. 
 
Failure due to aseptic loosening of one or both of the components used in this procedure is the most common 
long-term complication after surgery. The incidence of aseptic loosening is known to increase with time38 and 
published reports suggest there is variability in outcomes and revision rates even within groups implanted with 
the same prosthesis and within the same hospital29. 
 
The ability to identify patients who have risk factors  for osteolytic change at the time of their surgery would 
allow for more targeted and successful follow up programmes reducing the risk of catastrophic silent failure. 
 
Published cohort based studies and the national joint registries have identified a number of variables which 
have an impact on survival: implant, cement, surgeon, procedure as well as patient related factors such as age, 
BMI, diagnosis, smoking and sex 195-197.  The completeness and size of the joint registries allows for ever more 
detailed analysis and the recent report from the Swedish National Hip Arthroplasty Register suggests an 
increased risk of revision surgery associated with stem size and neck offset198. However although increasingly 
complete, joint registries have a limited data set on the patients they include, are not able to access patients 
hospital records and no registry currently includes information relating to radiographic or clinical scoring. This 
limits the sensitivity with which they are able to detect association between risk factors for failure. 
 
This gap is addressed with more complete cohort or cross sectional studies reviewing individual patients. 
Careful control for known confounders or case matching has allowed the possible impact of BMI, tobacco use 
and non-steroidal anti inflammatory (NSAID) use to be quantified. Malik reported in 2004 in a retrospective 
cohort review of 224 patients that tobacco and NSAID use had no association with aseptic loosening196.  
 
1.27 Smoking as a Risk Factor 
Smoking is known to have a detrimental effect on fracture healing and bone remodelling199-203. Smokers are 
known to have a longer anaesthetic and surgical time as well as have an increased risk for heart attack, stroke 
and respiratory disease in the post operative period204. Smoking has also been demonstrated to interfere with 
bone metabolism, revascularisation and bone formation205.  A single cadaveric retrieval study206 identified 
vascular injury and subsequent compromise of the implant-bone interface as a risk factor for failure in THR. 
Smoking is known to affect blood supply, making this a potential risk factor for failure. However only a single 
published review of 147 patients at a minimum of five years post THR reported a greater risk of implant 
loosening in smokers197.  
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1.28 Co-morbidities as a Risk Factor 
Co-morbidities may be expected to affect patient reported outcomes where many scores contain general 
functional questions which may be affected by other co-morbidities. However the impact of co-morbidity on 
longevity of total joint replacement is still unknown.  
 
In a case matched prospective series 219 patients undergoing THR were matched to a cohort from the 
population who were not207.   At short term follow up (3.6 years after surgery) similar quality of life scores 
were demonstrated. They also noted patients with other musculoskeletal co-morbidities had less long term 
functional improvement after THR. This study also suggested that preoperative existing co-morbidities did not 
predict a worse functional outcome207. At such short follow up the impact of co-morbidities on survivorship 
cannot be estimated. 
 
Charnley proposed that the involvement of other joints also influences the outcome208 and this has been 
confirmed by other investigators204;209. However these studies again do not investigate the impact on long 
term outcomes, only on post operative outcome scores, where a lower score will be expected due to the 
nature of the questionnaires. 
 
Charlson and colleagues proposed and validated210;211 a co-morbidity score, which has been validated for use 
in oncology patients. Their score has been shown to be an independent predictor of survival in oncology 
patients, but has never been applied to joint arthroplasty. It is one of only a few co-morbidity indexes that 
have been validated. 
 
1.29 Obesity 
The effect of obesity on longevity of joint replacement is controversial. However objective review of the 
literature clearly shows no link between obesity and poorer functional result or longevity of the THR212-214. This 
lack of evidence surrounding the effects of obesity and longevity of total joint replacements may represent 
poor study methodology as  there are no studies containing a representative normal range  of BMIs which 
correct for other known confounding factors.  
  
Several studies have shown that the rate of post-operative complications is linked to obesity. There are several 
studies indicating higher rates of  infection following joint replacement in the obese215;216. Biomechanically 
there is concern that increased weight increases joint reaction forces hence increasing wear of the 
polyethylene. However since obese patients tend to have lower functional demands it is unlikely that obesity 
increases wear of polyethylene components217. The improvement in outcome following THR appears to be 
similar for the obese and the non obese as is the satisfaction and function218;219.  
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Despite the large number of studies relating to outcomes in total joint arthroplasty it is still not clear if patient 
related risk factors are likely to have an outcome of periprosthetic loosening. This is due to the short term 
follow up of the majority of case series, and lack of radiographic data in the joint registries. 
 
1.30 Surgeon Related Factors 
The biggest predictor of outcome in total joint arthroplasty is the surgeon, surgical team and implants 
selected1;35;36. High hospital and high surgeon volume has been demonstrated to reduce early post operative 
complications220, however this does not appear to affect functional outcomes at three years221.  A recent 
systematic review of the literature found that higher hospital volume had the effect of lowering patient 
mortality and rates of hip dislocation; where higher surgeon volume only had the effect of lowering rates hip 
dislocation222.  
 
There are few follow up studies in the literature establishing if grade of surgeon has any effect on the longevity 
of the joint replacement. 
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SECTION 1.31 DIAGNOSIS OF IMPLANT FAILURE 
 
Establishing a definite diagnosis of implant failure or loosening relies on : 
 Clinical history and examination 
 Radiographic evaluation 
Joint loosening is often asymptomatic, and although proposed criteria for radiographic failure32-34 do exist 
there is no consensus of opinion as to when a joint replacement is loose, even less when an implant requires 
revision2. 
 
The decision to revise an implant due to loosening is rarely made at the patients request, but more commonly 
during a routine follow up appointment. The British Orthopaedic Association recommends regular 
radiographic and clinical follow up for all patients who have undergone a total joint replacement223. 
 
At these follow up appointments plain radiographic films are recommended to evaluate fixation of the 
prosthesis and clinical review. Increasingly clinical outcome scores are becoming part of this review, and are 
recommended by the Department of Health as a performance indicator. It is however unclear, and there is 
little literature surrounding, the best method for establishing the diagnosis of implant failure. There is no 
evidence surrounding the use of clinical scores224, and there is little evidence as to which radiographic 
assessment is likely to be most sensitive for osteolysis.  
 
Changes on x-ray may precede symptoms of loosening and therefore presentation of the patient for revision 
surgery; however, there is not always consensus as to what x-ray changes actually represent definite 
radiological loosening. Radiological findings as predictors of implant failure are rarely reported. 
 
1.31 Radiographic Diagnosis of Implant Failure 
Osteolysis is normally diagnosed on plain x-rays, the patients themselves may present with pain, dislocation or 
periprosthetic fracture, but most are asymptomatic. Osteolysis is difficult to establish on plain radiographs 
such as those taken in follow up clinics. Temerman & Raijmakers225 evaluated the sensitivity and specificity of 
plain films, subtraction arthrography, nuclear arthrography, and bone scintigraphy in a retrospective study of 
86 patients with aseptic acetabular loosening. Anteroposterior (AP) and lateral films were used and plain 
radiography had a sensitivity of 85% (95% confidence interval, 71 to 94) and a specificity of 85% (95% 
confidence interval, 66 to 96) however intra-observer reliability was poor ( value 0.37) 
 
Pfahler & Schidlo39 evaluated 326 serial patients revised for aseptic loosening of their hip arthroplasty. Patients 
did not have a standardised imaging protocol, but in those just receiving plain films accuracy of plain films was 
found to be 89% specific for aseptic loosening. In this series only 40% were evaluated on plain films alone, the 
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majority being supplemented with a combination of digital subtraction arthrography or bone scan if the 
diagnosis was uncertain. 
 
The explanation for poor sensitivity and specificity is likely due to the shape of the pelvis. On an AP view there 
is much overlying bone, and although the posterior and anterior acetabular walls are distinguishable they are 
not clearly visible. The standard lateral hip radiograph views the superior acetabulum tangentially, but does 
not ‘shoot through’ at the ideal angle to view the acetabulum, or anterior/posterior columns.  
 
Southwell & Bechtold226 constructed a computer simulation to produce computer-generated images to assess 
the effectiveness of standard radiological views in depicting periacetabular osteolysis surrounding a metal 
backed acetabular component. They additionally undertook radiological analysis of simulated defects in a 
cadaveric pelvis. AP view alone showed only 38% of the simulated defects and failed to depict a 3 mm lesion 
over 83% of the area of the cup, however addition of the 45 degree obturator-oblique and iliac-oblique 
projections increased the detection rate, showing 81% of the defects. They did not analyse, or follow up any 
real patients.  
 
Kawate et al227 undertook the only investigation to compare different acetabular views to assess cement 
mantle, however they did not investigate patients with osteolysis. They performed AP, lateral, iliac- and 
obturator-oblique views in assessing adequacy of cement mantle.  
 AP View Alone  25% incidence thin cement 
 AP & Lateral  37% incidence thin cement 
 Four views  57% incidence 
They concluded that “Thin cement mantles were mainly seen on the iliac oblique radiographs”. It is similarly 
likely that aseptic loosening is under diagnosed on plain radiographs, and that investigation of the use of 
further projections is warranted to increase detection of osteolysis. 
 
Evaluation of the available plain radiographic films to establish the best projection for arthroplasty follow up 
would potentially increase the sensitivity and specificity of arthroplasty follow up and consequentially improve 
our ability to diagnose and hence understand this condition. 
 
1.32 Patient  Outcome Measures and Failure 
The benefits of total joint arthroplasty have been quantified by a variety of scores. Over time some of these 
have been refined and validated, and some have fallen by the wayside. Most scores have not been designed 
and validated from the outset, but rather invented and then retrospectively validated.  
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Hip outcome scores come in two varieties; patient administered and surgeon administered. Patient 
administered scores are a series of questions designed to quantify the current status of the hip joint based on 
a series of questions. Although varying from score to score most rely on multiple questions across several 
domains, usually pain, function and occasionally some functional or psychosocial questions. Patient 
administered scores do not include range of movement or other objective outcome measures, but are not 
subject to administrator bias as the patient themselves completes the questionnaire. Most scores rely heavily 
on pain often scored as a descriptive variable, however this method has been shown to be inaccurate in 
comparison with a visual analogue scale228.  
 
Charnley recognised that these outcome measures often rely on function of the whole limb, and as such 
results could be reflective of a diseased knee or a lumbar stenosis, not the joint in question. He argued that 
the results of differing groups of arthroplasty patients could only be compared if the groups are similar in 
other respects. He defined three different categories208. Patients in the A group had monoarticular disease; B 
had bilateral disease and C other diseases such as rheumatoid arthritis. Systematic reviews of primary total hip 
replacement outcomes229;230 have concluded that the quality of evidence in this field is poor and that use of 
objective validated scores is likely to improve the evidence base. 
 
There are many validated scoring systems in current use for the evaluation of hip replacement. However all of 
these scores have been designed as a measure of clinical outcome, and none have been validated to monitor 
for failure. Whilst it seems to make sense that a failing hip replacement is likely to perform more poorly than a 
successful one and therefore have an appropriately lower hip score there is no data to assess the sensitivity or 
reliability of patient reported outcome scores (PROMS) in arthroplasty surveillance, a use for which most 
scores were not originally designed. 
 
Some scores in common use are generic quality of life measures, and others have been specifically designed to 
assess the patient’s health status before and after hip replacement. For an outcome measure to be fit for 
purpose it must be reliable, valid, sensitive and easy to administer231.  
 
The 12 question Oxford Hip Score (OHS)232 was developed recognising the problems of measuring specific 
forms of pain and mobility in older people for reasons other than hip disease. It was specifically designed as an 
outcome measure for use in large studies. The questions assess the patient’s perceptions of pain, mobility and 
function in relation to problems with their hip. The questionnaire has been shown to be reliable with most 
respondents completing all the questions and with an overall good response rate. Each question is scored out 
of a possible 5 with 5 being the worst case scenario thus a perfect health scenario would give a OHS of 12 and 
a worse case 60.  
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Ferguson and Howarth233 designed the first widely accepted hip outcome measure or hip score for grading 
disability after a slipped upper femoral epiphysis. The Merle d’Aubigne and Postel27 score (MDA) is a 
refinement of the Ferguson and Howarth score and is still in widespread use. The score is based on questions 
in pain, range of movement and walking domains. Scored 1-6 in each domain and the scores are summed to 
give a single score. 
 
The Harris Hip Score234 (HHS) is the most widely used hip outcome score. Although it has been subsequently 
validated it was initially reported as an unvalidated score. The initial cohort of patients the score was designed 
to assess were young males who had sustained a high energy acetabular fracture. The Harris hip score asks 
questions relating to pain, function, deformity and range of motion. Initially a surgeon administered score the 
HHS has since been modified to be a patient administered score.  
 
The Hospital for Special Surgery Score28 was designed to provide a linear score which was responsive for both 
pain and function. It has been widely used in assessment of function post surgery for fracture of the neck of 
femur235, but also in reporting the results of arthroplasty236. 
 
Despite the widespread use of these scores in reporting the outcomes of total joint arthroplasty none of these 
scores has been demonstrated to be sensitive or specific for osteolysis or failure in total joint replacement, and 
as such cannot be relied upon as an indicator of success in the longer term. It has been shown that hip scores 
deteriorate with time3;236, whilst this may be reflective of early failure it may also represent falling functional 
level as the studied population ages.  
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SECTION 1 : SUMMARY 
Biology 
The biological cascade initiated by particulate wear debris is well characterised in tissue culture, ex-vivo and 
animal model studies. Gene therapy studies have demonstrated inhibition  in the cascade when specific 
cytokines are knocked out. 
   
Whilst the pathway itself is well characterised in established osteolysis there is little work that looks at the 
differences in response between patients who undergo an aggressive osteolytic response and those who do 
not. Some small scale studies have demonstrated differences in the presence of certain SNPs in cohorts of 
patients with osteolytic and well fixed joint replacements. 
 
There is however no extensive characterisation of the local biological environment in end stage osteoarthritis 
into which the particulate debris is released, and no extensive studies quantifying the differences between 
patients with aggressive osteolysis and those without.  
 
Diagnosis 
The diagnosis of osteolysis is fraught with difficulty and no agreed radiographic or clinical diagnostic criteria 
exist. Whilst clinical outcomes are often reported using patient reported outcome scores the value of these 
scores in detection of prosthetic failure is unclear. 
 
It is likely that the radiographic projections used to follow up joint arthroplasty have a profound impact on the 
sensitivity of the test. However there are no studies evaluating the use of different projections in diagnosis of 
osteolysis. 
 
Hip outcome scores although in widespread use have not been validated for detection of early clinical failure, 
but rather as quality outcome measures. The value of these scores and the differences between the scores in 
the longer term setting has not been established. 
 
In order to understand the natural history of the disease it is important to establish accurate agreed diagnostic 
criteria. The first step in this process is evaluation of the methods currently available. 
 
Risk Factors 
Identification of patients who are at risk of arthroplasty failure is not an easy task, and although a number of 
factors have been identified through use of registries and case controlled series there is little high quality data 
on the way patient epidemiological factors affect the osteolytic process over a period of many years. 
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SECTION 2 : STUDY QUESTIONS & PROPOSAL 
 
The aim of this MD project is to explore the contribution of patient related factors to osteolysis, and the best 
measures both radiographic and clinical to identify osteolytic hip joints. 
 
Study Questions : 
1. Does the osteolytic cascade vary from patient to patient? 
2. What are the patient characteristics most likely to predispose to joint loosening? 
3. What is the best radiographic evaluation of osteolysis? 
4. Is it possible to use a patient administered outcome scores to identify osteolytic arthroplasties? 
 
In order to answer these questions four studies are to be undertaken exploring the cellular biology of 
osteolysis, the epidemiology of loosening and the value of radiographs and PROMs in detecting osteolysis 
 
Section 2.1 Laboratory Study 
Hypothesis : “There is a difference in the activation of biological cascade between patients subjected to 
polyethylene wear debris as evidenced by cytokine expression” 
 
A laboratory study has been designed to test the experimental hypothesis using RNA expression analysis. 
Initially gene RNA expression analysis will be undertaken used to quantify gene expression in human patients 
at the time of their hip surgery. In order to address the hypothesis a number of smaller research questions 
must first be answered : 
1. Can we reliably measure gene expression in osteoarthritic human joints? 
2. Does osteoarthritis differ in biological environment from patient to patient? 
3. Is there any observed variation local or global within the joint? 
4. Do joints with osteolytic change have a different gene expression pattern to native hip joints? 
5. Are these changes due to the joint replacement in situ, or to loosening itself? 
6. Are observed biological changes wear debris related or do they represent a tendency to loosen? 
 
2.2 Patient Risk factors for Osteolysis 
Hypothesis : “Patient characteristics such as age, BMI, smoking and co-morbidities will have a measurable 
effect on the survivorship of total hip prosthesis over long term study” 
 
In order to test the hypothesis  a long term cohort study with the end point of prosthesis failure was 
undertaken.  Careful prospective follow up  of a cohort of patients having undergone a similar procedure at a 
similar time in the same institution is required to reduce the likelihood of confounding factors. At the Norfolk 
& Norwich University Hospital all patients who have undergone a total joint arthroplasty procedure are 
 Section 2 : Study Questions & Proposal Page 35 
 
entered into a joint review programme. Prospective data has been carefully collected and institutional and 
ethical review of this process has already been undertaken. 
 
A cohort of patients who had undergone their total joint arthroplasty in 1995 were due to have their 12 year 
follow-up appointments at which point they would all receive surveillance radiographs and clinical scores and 
a decision on the survival of the prosthesis or need for revision would be made. 
 
The data from these patients was used in conjunction with some additional radiographs (after ethical consent, 
see below) to establish if any identifiable patient characteristic factors present at the time of their surgery that 
may contribute to the survival or failure of their arthroplasty. Survivorship analysis was used to establish any 
significant differences in survival based on epidemiological factors. 
 
2.3 Radiological Study 
Hypothesis : “The addition of iliac oblique radiographs to radiographic follow up films will increase the 
sensitivity of radiographic follow up for osteolytic lesions”   
 
To test the hypothesis and establish the sensitivity of plain film radiographs for prosthesis loosening a 
complete set of all combinations of radiographs is required in a cohort of patients known to be likely to have a 
high rate of radiographic failure. 
 
Ethics permission was sought, and given, to perform after consent additional radiographic examination of a 
cohort of patients undergoing their 12 year radiographic follow up appointments. At 12 years approximately 
10% of THRs can be expected to have failed or be in the process of early failure. 
 
The radiographs were evaluated by two independent observers and scored using recognised radiographic 
scoring systems. The contribution of each project was then assessed to establish the value of each projection 
and combination of projection. 
 
2.4 Patient Outcome Scores Study 
Hypothesis : “Although increasingly used for arthroplasty surveillance no single patient outcome score has 
been designed for that process. There will be differences in the ability of widely used scores to detect clinical 
failure of a THR” 
 
In order to establish the sensitivity and reliability of each widely used outcome score several cohorts of 
patients would be required all being followed up with different arthroplasty scores. Use of multiple surgeons 
and different prosthesis is important to make the data as generalisable as possible. 
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Patients with a known outcome (i.e. surviving or failed prosthesis) undergoing their ten year arthroplasty 
follow up at two different institutions received one of five different outcome measures. Their resultant scores 
were analysed for sensitivity and specificity for outcome using receiver operator characteristic (ROC) statistics. 
 
Using this method the value of scores in general, the different domains of each score and a comparative 
analysis between scores could be undertaken. 
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SECTION 3 : GENE EXPRESSION PROFILING 
 
3.1 Introduction 
The aim is to establish what range of cellular interactions are occurring in human hip tissue under different 
conditions. In order to establish this, tissue was taken of capsule (C) and ligamentum teres (LT). TaqMan 
analysis aims to establish the range of gene expression between patients in  these two tissues. Having 
established this, the study then needs identify which pathways of cellular interactions differ between loose 
and well fixed total hip replacements in order to answer the hypothesis. The aim to establish which pathways 
are variable between patients with end stage osteoarthritis, those with  osteolysis, and which are modulated 
in response to long term exposure to wear debris, but not osteolysis. This study is not aiming to elaborate the 
details of any pathways, but to identify known pathways which may be differentially activated from patient to 
patient. 
 
There are a range of techniques that can be used to establish what the activity of a gene, or rather the protein 
it encodes is. The activity of a protein or pathway can be measured at any point between the genomic DNA 
and measurement of the activity of the protein (eg measurement of breakdown or synthetic products). 
Commonly gene expression is measured at a DNA, RNA or Protein level. Each has its own strengths. 
 
DNA Analysis – The most commonly used technique for DNA expression analysis is through evaluation of single 
nucleotide polymorphisms (SNPs). SNPs are individual base pairs at a known locus that vary between 
genotypes so act as markers for known genetic polymorphisms. A large number of SNPs are defined and the 
genotype of an individual can be ascertained. SNPs have the advantage that the genotype can be established 
from a peripheral blood test and that large numbers of genes can be tested from a single sample. However 
SNP analysis focuses on the genotype of the patient, not the activity of the gene. For this study SNPs would be 
inappropriate as this technique does not allow up or down regulation of gene expression in response to wear 
debris challenges to be characterised.  
 
RNA Analysis – The most commonly used RNA expression analysis technique is the TaqMan technique (Figure 
3.2.8.1). TaqMan relies on reverse transcription of mRNA into DNA and then use of a PCR reaction for the DNA 
with a fluorescently labelled probe. The process is quantitative in that the levels of gene expression can be 
measured and compared relative to each other. The process also allows multiple different genes to be 
analysed from the same tissue sample. However it does have a number of draw backs. There is some 
downstream regulation of protein activity during folding, and the site of expression cannot be determined. 
However despite these drawbacks TaqMan remains the most versatile technique for this kind of quantitative 
study. 
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Protein Analysis – Protein expression analysis is the most accurate way of determining how much of a protein 
is expressed. Use of specific assays or in situ immunofluorescence techniques allow not only for quantitative 
analysis of protein expression, but also to allow for localisation of that expression within the tissues. However 
these techniques are expensive and specific assays are required for each protein to be investigated. This limits 
greatly the number of studies that can be done. This type of analysis is therefore most suited to localise 
expression after an RNA or DNA study has been performed. 
 
Protein products – Some of the specific assays for proteins do not assay the protein itself, but rather 
breakdown products. This allows for activity of the protein to be established. They have the same drawbacks 
as other protein based studies. 
 
Animal models – A validated animal model provides the closest laboratory model possible to human tissue. 
They allow for manipulation of the environment through use of knock-out mice or addition of inhibitors to the 
model. However animal models are best suited for elaborating pathway and establishing the likely biological 
mechanism for previous observations. They do not as a rule allow for variation between individuals to be 
characterised. 
 
The study aims to establish what the activity in explanted hip tissue if of previously identified pathways and 
how this varies between patients. A TaqMan technique is best suited for this purpose. Levels of RNA 
expression in tissue samples obtained directly from the hip during surgery will be determined using a TaqMan 
technique. Messenger RNA expression is analogous to protein production, although there can be some 
modulation of transcription downstream from the mRNA production step. It is important to ensure that mRNA 
expression for known inhibitors and co-factors is also quantified to allow the results to be interpreted in 
context. 
 
3.2 Materials & Methods 
3.2.1 Ethics 
Ethical approval for this section of the study was sought from the ‘Cambridge 3’ regional ethics committee, 
under the application “Osteolysis in total joint replacement – are patient factors important” (reference 
07/H0306/80). Ethical approval was granted in December 2007. During the preparation of the ethics 
submission a number of consultant surgeons were approached and an informal peer review process 
undertaken.  Approval was also sought from both the research and development committee and a site specific 
assessment was also carried out, as the study was to make use for the tissue bank facilities at the Norfolk & 
Norwich University Hospital (NNUH). 
 
The full ethics submission, patient information sheets and consent forms are included in the Appendix. 
 
 Section 3 : Gene Expression Profiling Page 39 
 
3.2.2 Tissue Sampling & Storage 
Tissue samples were taken intra-operatively from patients undergoing primary joint replacement for 
osteoarthritis (primary group – P), patients undergoing revision for aseptic loosening (loose group – L), or 
patients undergoing revision for other reasons (well fixed group – F).  
 
Tissue was taken according to a standardised protocol (Appendix 2) by a consultant orthopaedic surgeon 
during the procedure. The primary group had samples of ligamentum teres (LT), hip capsule or both excised 
during surgery. The patients undergoing revision surgery had samples of capsule (both groups) and samples of 
femoral or acetabular membrane tissue (loose group) as appropriate. All samples were stored at room 
temperature submerged in an RNA stabilising agent (RNALater; Qiagen Ltd, Crawley, UK) for an hour prior to 
storage at -80ºC in the tissue bank. 
 
The NNUH has an existing tissue bank based in the Histopathology department that has full ethical and 
Research & Development approval. Tissue stored in the tissue bank are anonymised to a tissue bank number. 
There is a separate consent procedure required for storage of human tissue and previously approved tissue 
bank consent forms and information sheets were used for this purpose. The tissue bank itself is overseen by a 
consultant histopathologist and rigorous procedures are in place to safeguard the tissue and confidentiality. 
  
Sample collection took place over a six month period, and all samples were collated prior to eventual analysis 
to reduce errors associated with laboratory technique and RNA degradation over time. 
 
3.2.3 Consent Process 
Informed consent is vital when undertaking any research in which human tissue is to be used. In order for 
informed consent to be obtained patients must be fully informed about the study, risks and potential benefits 
to either themselves or the wider community. Patients must be approached at an appropriate time so that 
they have time to read the information sheet, ask any appropriate questions and make a decision having fully 
understood the study. Patients were approached by a specialist nurse and supplied with an information sheet 
and a copy of a study consent form to review at their pre-operative assessment visit. All of the study materials 
had been approved by the ethics committee. 
 
Patients were identified by their operating surgeon at their pre-operative assessment visit. Written 
information was supplied to the patient, and a nurse specialist met with the patient, explained the study and 
invited the patients to take part. Although study materials were provided at this point patients were not asked 
to make a decision until their admission for surgery six weeks later. 
 
Patients were visited on the morning of the surgery by both the operating surgeon and a nurse specialist. They 
were invited to ask any questions regarding the study, and if they wished to proceed they consented for study 
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participation on both the tissue bank and study consent forms. All patients approached about participation in 
the study agreed to take part. A copy of both completed consent forms is retained by both the tissue bank at 
the NNUH and in the Academic Department of Orthopaedics. 
 
Copies of the consent and information forms are included in the Appendix. 
 
3.2.4 Patient Identification and Data Collection 
Potential study participants were identified from the waiting lists of six consultant Trauma and Orthopaedic 
surgeons with an interest in hip arthroplasty. The patients were initially identified by the consultant surgeon as 
they were placed on the waiting list as potential participants, and approached at their pre-assessment clinic. 
Patients were considered suitable for inclusion in the study if were : 
Primary Group : Undergoing primary hip arthroplasty for osteoarthritis 
Osteolytic Group : Undergoing revision hip arthroplasty for an osteolytic metal-on-polyethylene 
cemented THR 
Well Fixed Group : Undergoing revision surgery of a well fixed metal-on-polyethylene cemented THR 
for other reasons (e.g. dislocation) 
Patients were excluded from the study if they had evidence of autoimmune arthropathy, infection, alternate 
bearing surfaces, fracture round a loose stem, were receiving immune-modulating drugs (e.g. steroids) or had 
any known immunosuppressive condition. 
 
Patients were anonymised at recruitment to a study number, and all data thereafter was referenced only by 
study number.  For patients in the primary arthroplasty group data were collected concerning the patient’s 
demographics (age and sex), pre-operative diagnosis and concomitant medical conditions. In addition 
preoperative radiographs were reviewed and scored for osteoarthritic change. In addition patients underwent 
an Oxford Hip Score and EQ4D quality of life index. 
 
Patients in the two revision groups (osteolytic and well fixed) had the same demographic data and 
preoperative scores collected, but in addition details of the previous surgery and reason for revision surgery 
was recorded. Following surgery the results of routine intra-operative tissue samples for infection were also 
reviewed to ensure no patient had subclinical infection. 
 
3.2.5 RNA Extraction & Purification 
RNA extraction was performed in an identical stepwise process from the tissue. The full protocol is detailed in 
the Appendix. Initially the tissue is homogenised, cells lysed and the RNA dissolved in solution. Phase 
separation by chloroform separates the RNA containing fraction from the residue and this is further purified in 
spin columns.  
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Tissue samples were defrosted to 4ºC and the excess RNA stabiliser removed. Tissue was kept at 4ºC on ice to 
reduce the rate of RNA degradation which is unstable at room temperature. 
 
Samples were weighed and 3g of tissue homogenised in 2mls phenol reagent (TRIzol; Invitrogen Paisley, UK) 
using an UltraTurrax homogeniser (UltraTurrax, IKA, Staufen, Germany). The phenol lyses the cells and the RNA 
passes into solution. The resultant particulates were centrifuged at 14,000 g for 10 minutes at 4°C and the 
supernatant was recovered. 
 
A total of 400L chloroform was added per 1 mL TRIzol and vortexed for 15 seconds. The TRIzol/chloroform 
solution was then centrifuged at 14,000 g for 10 minutes at 4°C and the aqueous layer was placed into a fresh 
Eppendorf tube.  
 
The resultant supernatant was mixed with 100% ethanol at 1:1. Samples were applied to spin columns (RNeasy 
Mini Kit; Qiagen, Crawley, West Sussex, UK), centrifuged at full speed for 15 seconds, and the flow through 
was discarded. Columns then were washed and eluted according to the manufacturer’s instructions. 
 
3.2.6 Nanodrop 
RNA samples were quantified using a spectrophotometer (NanoDrop; NanoDrop Technologies, Wilmington, 
DE) and subsequently stored at -80°C. The NanoDrop allows quantification of RNA, DNA and protein 
contamination by use of absorption spectrometry. Quantification of RNA was used to calculate concentration 
of RNA and standardisation of RNA quantity for the reverse transcription phase. 
 
The NanoDrop also allows for a quality control step to ensure the RNA purification is acceptable. Good quality 
RNA has a typical characteristic curve (Fig 3.2.6.1). The absorbance curve starts at 220 nm with a “reverse tick” 
climbing to a peak at 260 nm then diminishing to zero at around 310 nm.  
 
Calculation of the 260:280 absorbance ratio gives an indication of sample contamination eg with DNA. Samples 
were only included in subsequent analysis if >100 ng/l mRNA was present, and the 260:280 ratio was 
between 1.9 and 2.1 indicating low contamination 
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Figure 3.2.6.1  : Sample Nanodrop Spectrometer curve for Patient 6 demonstrating the classical ‘double tick’ spectroscopy. The 
spectrograph measures absorbance (y axis) against wavelength (x axis). 
 
3.2.7 Reverse Transcription 
Synthesis of complementary DNA was performed from 1g of total RNA through a reverse transcription (RT) 
reaction. This was added to an appropriate volume of RNAase free H2O to give a final 9L volume.  To this 2L 
pd(N)6 random hexamers (1 g l
-1) were added and incubated for 10 minutes at 70ºC. This anneals the 
random hexamers to the RNA chains and which then act as a primer. 
To each sample was added : 
 1 L (200U) SuperScript II reverse transcriptase 
 1 L RNase inihibitor (RNaseOUT Ribonuclease Inhibitor 40U) 
 4 L 5x Buffer 
 1 L dNTPs (10 mM of each deoxyribonucleotide) 
 2 L 0.1M DTT (dithiothreitol) 
The resultant mixture was incubated at 42ºC for an hour and then inactivated by incubating at 70ºC for 10 
minutes. Superscript II performs the reverse transcription step using the dNTPs to produce the cDNA chains. 
The 5x buffer gives optimum conditions for the RT enzyme and holds the pH at 8.3. The DTT acts as a reducing 
agent improving the efficiency of the reaction. Complementary DNA was subsequently stored at -20ºC until 
used in downstream PCR. The RT reaction is assumed to be 100% efficient and subsequent dilutions performed 
on this assumption. 
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Due to the potential to introduce error at any stage in the RT process, all samples underwent RT in the same 
batch, using the same Superscript II and reagent mix. This increases the reliability of the results and allows for 
comparison between groups. 
 
3.2.8 TaqMan Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) 
After RNA extraction and reverse transcription initial analysis was undertaken with manual TaqMan qRT-PCR 
to quantify housekeeping gene expression, and ensure the reverse transcription process had produced 
uniform cDNA libraries across each sample. 
 
The principle behind quantitative PCR is the repeated amplification of cDNA and during each cycle a 
fluorescent marker is released that is detected by the machine. During each low temperature cycle the primer 
anneals to the gene of interest (Fig 3.2.8) and the quenched fluoroscopic probe binds to a downstream 
sequence. The TaqMan polymerase enzyme then produces the complementary DNA chain and in the process 
degrades the probe to release the fluorescent molecule. This fluorescence is detected by the analyser. During 
the higher temperature cycle the DNA chain is denatured and single stranded DNA is ready for the next cycle. 
The number of cycles taken for the signal to rise above the background noise equates to the quantity of cDNA 
present at the beginning of the process. 
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Figure 3.2.8.1 : The TaqMan process. During the annealing phase the primer and probe bind to the DNA chain. During the extending 
phase the Taq polymerase polymerises the chain from the primer and in so doing cleaves the reporter from the probe. The 
fluorescence molecule is released and detected by the machine. Reproduced from Nature Reviews Drug Discovery 3, 749–761 (1 
September 2004) Koch. W: Technology platforms for pharmacogenomic diagnostic assays 
 
Initially TaqMan analysis was performed using primer probe sets designed using the universal human probe 
library. Oligonucleotide primers were designed (Primer Express 1.0 software; Applied Biosystems, Warrington, 
UK) using known sequences for candidate genes TNF-, IFN-, OPG, RANK, RANK-L and IL-6. In addition 
housekeeping genes 18S, GAPDH and -actin were also measured. 
 
Although the RNA extraction process and reverse transcription is designed to remove the majority of genomic 
DNA and precautions are taken to reduce DNA contamination a potential for error is inadvertent amplification 
of genomic DNA. To reduce this risk primers were designed placed within different exons and close to an 
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intron/exon boundary, with the probe spanning two neighbouring exons where possible.  This makes 
inadvertent amplification of a gene present on genomic DNA impossible. 
 
The 18S ribosomal RNA (18S) gene, GAPDH, succinate dehydrogenase (SDHA) and -actin were used as  
endogenous control, or housekeeping genes, to normalise for differences in the amount of total RNA present 
in each sample. All four of these genes have been previously shown to have a uniform expression in a range of 
musculoskeletal tissues and therefore to be suitable for use as housekeeping genes. Custom primer probe sets 
were purchased from Applied Biosystems. The relative quantification of genes was performed using the ABI 
Prism 7700 sequence detection system (Applied Biosystems) in accordance with the manufacturer’s protocol.  
 
The ABI Prism 7700 can analyse 96 samples concurrently on a 96 well plate. The TaqMan plates were prepared 
with either candidate gene, standard curve, negative control or housekeeping gene preparation prior to PCR.  
To candidate gene wells 5ng of cDNA was added with 15l of reagents. The reagents consisted of 8.33 l of 
TaqMan master mix, 5 pmol forward primer, 5 pmol reverse primer and 5 pmol of probe made up to 15l with 
nuclease free H2O. The housekeeping (18S) gene wells contained 1ng of cDNA as 18S is so highly expressed 
only 1ng is required. The negative control wells contained no cDNA, and as such no amplification should occur. 
 
In addition standard curves for each gene were constructed to correct for the efficiency of the primer/probe 
sets across different RNA concentrations. Serial dilutions were performed  which can then be used to calculate 
a relative concentration of RNA (ng/dL).  
 
The PCR reaction was performed over 40 cycles. The plates were initially incubated for 2 minutes at 50°C, 10 
minutes at 95°C and then 40 cycles each consisting of 15 seconds at 95°C and 1 minute at 60°C. The qRT-PCR 
method outputs fluorescence values against time (Fig 3.2.8.2). After adjustment for noise a threshold value is 
selected that intersects the most linear portion of the sigmoid curve the number of cycles to threshold (CT) is 
proportional to the quantity of cDNA present in the initial sample.  
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Figure 3.2.8.2 : Sample TaqMan mRNA amplification curves for IFN gamma. 
 
An approximate comparison across all genes measured can be obtained assuming the amplification reaction 
efficiency was identical across all primer sets. The raw CT values measured by the analyser are normalized to 
the housekeeping gene expression using a transformation proportional to normalized copy number (2^-CT), 
where CT is the change in CT (target gene) – CT (housekeeper).  
 
3.2.9 Housekeeping Genes 
Housekeeping genes are genes that are known to have very similar expression of mRNA across all samples, and 
their expression therefore correlates closely with the total mRNA present in the sample. Deviation from the 
median expression value likely represents errors introduced in the preparation stage due to poor laboratory 
technique. For this reason median expressions for housekeeping genes are calculated and samples included 
only if they fall within +/- 2 CT  of the median values to minimise the effects of laboratory errors. 
 
3.2.10 Standard Curves 
When comparing the expression of a single gene across sample groups a further potential error is introduced 
as the binding characteristics of the primer/probe sets are not linear with DNA concentration and vary 
between both genes and primer/probe sets. This problem can be overcome with production of standard 
curves for each gene. A standard curve is generated using the known concentrations of complementary DNA 
(cDNA) from one sample. Serial 2-fold  dilutions across an appropriate range are used to construct the 
standard curve. The standard curve can then be used to allow for the variable efficiency of the reaction and 
calculate ng/dL of mRNA. 
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3.2.11 Universal library Primer/Probe sets 
The universal probe library is a library of predetermined downstream probes that provides probe sites for the 
whole of the human genome. When paired with a custom primer set designed for use with the Universal 
Library gene expression can be measured for almost any gene. Whilst this adds flexibility the position of the 
probe cannot be as tightly controlled as with a custom primer/probe set and as such may not sit in an ideal 
position on the gene of interest. 
 
For initial analysis after RNA extraction primers were designed for the Universal Library probes to quantify 
expression of two housekeeping genes (18S,  Actin) and six candidate genes (TNF ; IFN ; IL1 ; IL6; OPG & 
RANK-L). TaqMan plates were run including standard curves for all samples for housekeeping genes, and for a 
selection of 16 patients (10 primaries and 3 revision from each group). 
 
The quality of RNA extraction was ascertained from the expression of the housekeeping genes, and the 
protocol fine tuned until all samples were within +/- 2 CT of the median value. 
 
3.2.12 Repeated Analysis 
To assess for intra- and inter- observer error repeated analysis was performed. Different portions of the same 
tissue sample were used for parallel extraction and RNA quantification to assess intra-observer error. This also 
allowed measurement of gene expression variation within the same tissue. A third party evaluated the inter- 
observer error using RNA extracted by the investigator and the same reverse transcription and TaqMan 
protocols.  Results were analysed for correlation with 18S expression and for CT values of the target genes. 
 
3.2.13 Custom Primer/Probe Sets 
One final quality control step was introduced prior to moving analysis to the custom low density arrays. 
Specific primer probe sets were designed for three genes IL6, IFN  and  Actin. These were used to prepare 
TaqMan plates using the technique outlined above to corroborate the results from the Universal Probe Library. 
Once this had been performed and the initial results confirmed further analysis was performed using a 
TaqMan Low Density Array (TLDA) technique. 
 
3.2.14 TaqMan Low Density Array (TLDA) 
The TaqMan low density arrays (TLDA) are custom manufactured microfluidic arrays. Each TLDA array is a 384-
well micro fluidic card that enables 384 simultaneous real-time PCR reactions. A custom designed TLDA array 
card allowed 96 genes from 4 samples. The TaqMan low density array cards are pre-loaded with custom 
primer probe sets and all reagents required for the reaction. 
 
Patient samples are loaded into the array through ports, and centrifugation used to distribute the samples 
across the wells. The PCR reaction is performed in an identical manner to the manual TaqMan using an Applied 
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Biosystems 7900HT Fast Real-Time PCR System. The TLDA array is optimised such that the custom designed 
primer-probe sets have as near uniform efficiency across cDNA concentrations. Although no independent 
standard curve analysis is performed the system is designed not to require this further analytic step.  
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3.3 LABORATORY RESULTS 
3.3.1 Standard Curves 
Standard curves were plotted from the known serial dilutions of mRNA (Fig 3.3.1). A best fit line was 
plotted for each. The raw CT values were converted to relative DNA concentrations in ng/l using the 
standard curve. The intercept and slope of the best fit line can then be used to calculate the relative 
expression of initial mRNA. Using this method corrects for the differing primer-probe set affinities. 
 
 
 
Figure 3.3.1 : Sample standard curves plotted for different genes. Serial dilutions of mRNA CT values are plotted on the y-axis against 
[log
10
 cDNA] and best fit lines calculated. 
 
3.3.2 Tissue Gene Expression Results 
The housekeeping gene 18S was used as a control to ensure comparable quantities of total RNA were 
processed from each sample, thereby allowing for comparison of results. 18S expression was 
comparable with all included samples falling between +/- 1.5 CT values of the median value (Fig 
3.3.2.1). No samples had to excluded at this stage due to variation in the 18S CT  values. 
y = -3.1745x + 19.086 
R² = 0.9988 
0
5
10
15
20
25
30
-2 -1.5 -1 -0.5 0
18S 
y = -2.3605x + 38.34 
R² = 0.7683 
35
36
37
38
39
40
-0.5 0 0.5 1 1.5
IL1
y = -2.9499x + 35.251 
R2 = 0.9841 
30
31
32
33
34
35
36
37
0 0.5 1 1.5
IFN y = -4.0562x + 37.642 
R² = 0.9931 
32
33
34
35
36
37
38
39
0 0.5 1 1.5
TNF
 Section 3 : Gene Expression Profiling Page 50 
 
 
Figure 3.3.2.1 : Plot of 18S Expression (CT values) for each sample tested, demonstrating acceptably uniform expression. 
 
3.3.2.1 Comparison of Tissue Gene Expression 
Tissue expression ranges, medians and quartile ranges are given for each tissue type (Fig 3.3.2.2).As 
can be seen the tissue expression ranges of the capsule (light bars) and ligamentum teres (hatched 
bars) is closely related between the two tissues, with similar medians, ranges and spread of the data 
about the median for all five genes. 
 
In all cases the gene expression is more tightly clustered about the median in the ligamentum than it 
is in the capsular samples. The closely mirrored distributions of each gene gives an indication that 
tissue expression is similar in each tissue within the joint. However the number of samples included 
in this part of the study (12) are too low for formal statistical analysis. 
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Figure 3.3.2.2 : Gene expression ranges, quartiles and medians capsule (solid bars) and ligamentum teres (shaded bars) for all 12 
samples. 
 
3.3.2.3 Variability of gene expression 
The variation in expression between each gene across both tissues is given (Fig 3.3.2.3). All genes 
tested for expression demonstrated high levels of variation between tissues, with all tested genes 
demonstrating at least 100 fold variation in tissue expression levels. This supports the original 
hypothesis that gene expression is variable within osteoarthritic hips. 
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Figure 3.3.2.3 : Gene expression ranges (median, range and quartiles) by gene for the whole group 
 
3.3.2.4 Range of Variation 
When sampling from a population of an unknown size it is difficult to know how many samples are 
required to capture adequately the complete range of expressed variation. The nature of a  cohort 
study makes it impossible to capture every possible variation in expression without performing a 
population study. However if gene expression is assumed to be a Gaussian distribution, and mean 
expression is being measured it is possible to assess the number of observations required to obtain a 
stable estimate of the mean through measuring changes in mean expression and standard deviation 
as additional observations are performed. This is in essence measuring the observed stability of the 
mean. 
 
Plotting mean expression of IL-1 and standard deviation against number of observations (Fig 3.3.2.4) 
shows stabilisation of both the mean and the SD after 10 observations. It is therefore likely that with 
the planned sample size of 30 observations that enough variation will be observed to be 
representative of variation in the wider patient population. 
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Figure 3.3.2.4 : Variation in mean and standard deviation of IL1 expression shown for increasing population size 
 
3.3.2.5 Reliability and Repeatability 
The nature of PCR related analysis is one in which errors in technique are multiplied many hundred fold. Due 
to the exponential nature of the PCR reaction any errors in pipetting or other aspects of experimental 
technique will be multiplied on each cycle of PCR. The sensitivity of this method necessitates meticulous 
laboratory technique, and errors introduced in this manner may outweigh any observed differences between 
samples. 
 
In order to assess the accuracy of the process and quantify the errors introduced in the laboratory two 
validation exercises were undertaken at this stage. Two of the samples (4 and 5) were divided in half and the 
whole process from RNA extraction to TaqMan expression analysis repeated independently on different days 
by the author. The expression of three candidate genes (IL1, IFN  and TNF ) was then quantified (Fig 
3.3.2.5). This intra-observer reliability test yielded a correlation co-efficient of =0.89 (Pearson’s test).  
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Figure 3.3.2.5 : Gene expression with repeated sample analysis by the same observer.  
Correlation co-efficient =0.89 
 
A second validation exercise was then undertaken to assess the inter-observer reliability. A second 
experienced independent investigator repeated the reverse transcription and TaqMan analysis of TNF  using 
RNA extracted by the author from the tissue. Expression rates of IL1 were calculated using the method 
described above (Fig 3.3.2.6).  The correlation co-efficient (Pearson’s method) was 0.93 representing excellent 
agreement. The improved agreement over repeated samples probably represents elimination of errors 
introduced during the RNA extraction stage or from minor variations in expression between the two sampling 
sites.  
 
 
Figure 3.3.2.6 : Repeated samples of different tissues for TNF  expression by a different observer performed independently from the 
initial experiments. Correlation co-efficient =0.93 
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3.3.3 TLDA Results 
3.3.3.1 Housekeeping Genes 
40 revisions and 27 primary joints were successfully analysed and expression characterised for all four 
housekeeping genes using the TLDA method. The primary and revision samples were analysed on the software 
as separate studies (due to the number of samples), so comparison of housekeeping genes is necessary, not 
just between genes, but also between studies to ensure accurate calibration of the analyser. 
 
The distribution of raw CT values is given as a scatter plot (Fig 3.3.3.1) with the median. The median CT value 
and standard deviation is given (Table 3.3.3.1). The expression for succinate dehydrogenase (mean 35.7 SD 
3.08) was significantly higher than the other genes, and the low levels of expression make it unsuitable for use 
as a housekeeping gene in this case. Standard deviations, coefficient of variation and standard errors were 
similar for each of the remaining three housekeeping genes (Table 3.3.1). 
 
 Revisions Primaries 
 18S ACTB GAPDH SDHA 18S ACTB GAPDH SDHA 
Values 40 40 40 40 27 27 27 27 
Minimum 16.04 26.1 27.64 31.37 17.2 27.58 28.36 32.92 
Maximum 30.71 40 40 40 30.96 40 40 40 
              
Median 20.87 31.5 32.71 35.7 19.73 30.39 31.73 35.7 
Std. 
Deviation 
4.508 4.69 4.218 3.082 2.626 2.611 2.177 2.091 
Std. Error 0.7127 0.7416 0.667 0.4873 0.5054 0.5025 0.419 0.4024 
Coefficient 
of variation 
21.60% 14.89% 12.90% 8.63% 13.31% 8.59% 6.86% 5.86% 
Table 3.3.3.1 : Housekeeping gene expression (CT values) for the whole sample from each tested cohort 
 
All housekeeping genes can be seen to have tightly clustered expression (Fig 3.3.3.1). The Pearson’s product 
moment correlation co-efficient for each housekeeping pair is given (Table 3.3.3.2). There was a high rate of 
concordance between 18S, GAPDH and ACTB with r values of 0.94 to 0.98 (Table 3.3.3.2). However there were 
poorer correlations between SDHA and all other housekeepers. 
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Figure 3.3.3.1: Scatter plot of CT values for housekeeping genes showing medians. All tested samples are included 
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Figure 3.3.3.2 : Scatter plot with medians. CT values for all housekeeping genes for samples included in eventual analysis are shown. 
Narrow spread about the median is seen in all 4 housekeeping genes. 
 Section 3 : Gene Expression Profiling Page 57 
 
 
 18S ACTB GAPDH SDHA 
18S   0.96 0.94 0.87 
ACTB 0.96   0.98 0.85 
GAPDH 0.94 0.98   0.84 
SDHA 0.87 0.85 0.84   
Table 3.3.3.2 : Calculated Pearson’s product moment correlation co-efficents of housekeeping gene expression. 
 
Uniform expression of housekeeping genes is required for adequate comparison of samples across each group. 
As there are some errors introduced in the laboratory protocols, the standardisation of housekeeping gene 
RNA expression as a measure of quality across the groups is essential if comparative analysis is to be 
undertaken.  
 
Samples were excluded from analysis if more than one housekeeping gene was found to deviate more than 
2CT values from the median value. There were nineteen revision samples that did not fulfil these criteria and 
so where excluded, and a further five primaries were excluded. Thus samples from 22 revisions (16 aseptic, 6 
well fixed) and 22 primary native hips were suitable for final analysis. 
 
This improved the co-efficient of variance and standard deviations for all housekeeping genes in all groups 
(Table 3.3.3.1). In addition the distribution of CT values for each housekeeping gene can be seen to be more 
tightly clustered around the median value (Fig 3.3.3.2). There were no significant differences (student’s t-test) 
between expression of 18S (p=0.85), -Actin (p=0.68), GAP-DH (p=0.83) or SDHA (p=0.63) between the primary 
and revision study groups. 
 
18S ACTB GAPDH SDHA 18S ACTB GAPDH SDHA
Values 22 22 22 22 22 22 22 22
Minimum 17.42 27.72 28.36 32.92 17.07 27.45 28.17 31.37
Maximum 20.52 31.3 33.41 37 23.95 32.2 34.03 40
Median 19.02 29.61 31.16 35.01 19.1 29.75 31.27 34.75
Std. Deviation 0.94 1.06 1.17 1.1 1.68 1.22 1.54 2.23
Std. Error 0.2 0.23 0.25 0.23 0.37 0.27 0.34 0.49
Coefficient of 
variation 4.96% 3.57% 3.75% 3.15% 8.79% 4.11% 4.93% 6.43%
Primaries Revisions
 
Table 3.3.3.3 : Housekeeping gene expressions for the included sample cohort 
 
Gene expression was normalised to -Actin (ACTB) as this candidate has the lowest co-efficient of variation 
(3.75% primaries; 4.11% revisions) and standard deviation across both groups. -Actin is therefore more 
uniformly expressed across the cohort (Table 3.3.3.3). 
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3.3.3.2 Selecting Genes to Include 
Of the 91 candidate genes there was no measurable gene expression in 9 genes (BAK1, DKK1, DKK4, IL12A, 
IL12A, IL13, IL17A, IL4, NOS2), and less than ten samples amplified cDNA in 12 further genes (ADAMTS 3, CD80, 
CTLA4, DKK2, FASLG, IFN-, IL11, IL12B, IL1A, IL1B, SOST, TM7SF4). There was measurable DNA amplification in 
the remaining 70 candidate genes. There were seven genes (ADAMTS 14, CXCL10, FRZB, MMP12, PTGS2, 
TNF, TNFRSF1B) where less than fifteen samples amplified DNA and the results should be interpreted in this 
light. The median expressions, range, number of successfully run samples and standard deviations for raw CT 
values for all candidate genes are given in Appendix 3. 
 
It is impossible to determine if those genes in which only a few samples amplified DNA indicates there is no 
gene expression, or if it represents a failure of the primer-probe set to bind to the sample or effectively 
measure expression. It is however likely that in genes where expression is measured in some samples and low 
or no measurable expression is seen in others that this is an accurate observation. As a single sample is used in 
the TLDA technique for all genes and an automated primer-probe set, error in the preparation of the samples 
or array is likely to affect whole samples or genes. 
 
3.3.3.3 Multiple Sample Testing 
A further quality control measure was undertaken by analysis of two separate samples of the same tissue from 
two patients for all candidate genes. Each sample was collected and processed separately and thus not only 
gives an indication of local variation in gene expression, but also gives a measure of the total error in the 
process. Variations between the observations include sampling, tissue extraction, reverse transcription and 
the Taqman process. Observations were normalised to the housekeeping gene (-Actin) in each case and thus 
are a reflection of the overall accuracy of the method as well as local tissue variations is given. The two sets of 
observations for patient 4 are given in figure 3.3.3.3, and those for patient 5 in figure 3.3.3.4.  
 
Spearman’s correlation co-efficient and 95% confidence intervals were calculated for each pair of 
observations, and a best fit line calculated using linear regression. Spearman’s correlation co-efficient was 0.72 
(95% CI 0.58-0.81) for patient 4 and  0.84 (95% CI 0.75 - 0.90) for patient 5. Both these sets of observations 
represent excellent intra-observation reliability, and in both cases the correlations were statistically significant. 
 
In both cases relatively poorer correlations can be seen when one sample has borderline expression (i.e. a very 
high CT value). These observations represent genes in which very low levels of cDNA were detected. They have 
been included for completeness, but probably represents a breakdown in the reliability of the method where 
very high CT values are recorded. 
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Figure 3.3.3.3 : Scatter plot – Multiple tissue samples Patient 4 
 
Multiple Observations : Patient 5
0.0001 0.001 0.01 0.1 1 10 100
0.0001
0.001
0.01
0.1
1
10
100
1000
10000
Sample 2
S
a
m
p
le
 1
 
Figure 3.3.3.4 : Scatter plot – Multiple tissue samples Patient 5 
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3.3.3.4 Analysis of Results 
The data have been analysed for statistical significance using non-parametric analysis techniques. As the data 
are all a series of experiments it is important to analyse the data in the same way for comparison of 
significance levels. Whilst some of the data conform to a normal distribution (d’Agostino and Pearson omnibus 
normality test) the majority does not. It would be possible to transform the data to a normal distribution or to 
utilise a statistical correction for skew (e.g. Welch’s correction). However due to the size of the data sets 
different transformations would be needed for each group making comparison difficult. It was therefore 
decided to use non-parametric testing for significance. These tests have less power, and are therefore more 
likely to lead to a Type II error, but allow for non-parametric data making a type I error less likely. 
 
Significance testing was performed using a stepwise approach. The three cohorts were tested for significant 
difference in median values using a Kruskal-Wallis test with an  error (p value) of 0.05. If this were significant 
then Dunn’s multiple comparison test (as post-hoc testing to the Kruskal-Wallis) was used to determine 
significance between the two groups. The Dunn’s test was performed for significance levels of <0.05 (defined 
as significant) and <0.10 (defined as borderline significant). Dunn’s test makes an adjustment to allow for the 
likelihood of false positives seen when undertaking multiple tests. 
 
Genes where no statistical significant variances were found between groups were excluded from further 
analysis. Further analyses were performed according to the differences pattern seen between each cohort the 
possible differences and their likely causes (Table 3.3.3.7).  
 
For any given gene it is possible that differences in observed mRNA expression between the cohorts may 
represent either up regulation in gene expression, or that natural variation between individuals may result in a 
predisposition to loosening. In the latter case it is likely that expression in the osteolytic or well fixed cohorts 
will be a subset of the gene expression in primary osteoarthritis. 
 
It is likely that changes in observed gene expression will represent up-regulation or down-regulation of the 
individual protein expression, and as such there will be a statistically significant difference between the 
primary osteoarthritis cohort and one or more of the replaced cohorts. This could represent either changes 
due to the effects of joint replacement or changes due to osteolysis.  
 
Alteration in regulation of gene expression (up or down regulation) can be assessed through significance 
testing as previously described. However a tendency towards one or other outcome is poorly quantified in this 
manner. Genes tend to work as families, and high or low expression of one cytokine, receptor or modulator 
might not reach significant difference as they work together with other factors. More information can often be 
gained through either multi-variant analysis (looking at several factors which may be associated) or through 
quantifying association.  
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Multi-variant analysis is a powerful statistical technique in which complex relationships can be explored 
between multiple factors and known outcomes. Whilst multi-variant analysis increases the power of the 
analysis and allows modelling of contributory factors the analysis requires high numbers of observations in 
order to be valid. For each factor to be analysed roughly 20 observations are required. There are simply not 
enough observations in this study to use multi-variant techniques. 
 
Receiver operator curves (ROC) is an alternative method, and quantifies association. ROC curves may be 
calculated for any continuous variable which may be predictive of a known outcome. ROC analysis is a well 
recognised and widely used technique and can be applied to a variety of data including scoring systems and 
observed characteristics. A curve is plotted of sensitivity vs. (1 – specificity) whilst the discrimination threshold 
is varied. The area under the curve (AUC) is analogous with the association with the strength of association 
with a value of 1 equating to perfect association and 0.5 to random chance. ROC statistics have been used in 
this study to assess the association between gene expression and outcome. 
  
3.3.3.5 Variation in Gene Expression in Osteoarthritis 
Osteoarthritis is was historically considered as due to “wear and tear” and therefore different from 
inflammatory arthropathies and a biologically “inactive” disease. Although there are many studies looking at 
gene expression in early and late cartilage degeneration and the role that proteases and other proteins may 
play there are few studies looking at variability of expression in end stage disease. 
 
If there is little variation in a gene’s expression from patient to patient then it is unlikely that any potential 
tendency towards eventual loosening is due to that individual gene. Distribution of gene expression is given as 
a box and whisker plot (Figure 3.3.3.5) for primary osteoarthritis in our cohort. The co-efficient of variation 
was calculated for each gene (Table 3.3.3.4). Co-efficient of variation was used in preference to standard 
deviations as this allows for better comparison between groups as co-efficient of variation is a dimensionless 
number and therefore can be used to make comparison across groups with different scales, and does not 
require parametric data. 
 
Co-efficient of variation ranged from 3 to 202 with different genes (Table 3.3.3.4). The box and whisker 
diagram is colour coded to indicate the co-efficient of variation. It is clear that whilst some genes vary greatly 
(MMP13, CXCL9, MMP9, CCL3, TNF, MMP1, CHIT1, FGF18, CTSG, IL1RN, BCL2A1, IL6, CXCL10, CD2, FRZB, 
MMP12) others have a much more linear expression (TGFB1, VEGFB, TNFRSF1A, B2M, ERCC1, COL1A2, ITGB2, 
CD58, CD14, CSF1, PDGFA, CTSK, COL3A1, COL1A1, ADAMTS 2). This initial variation must be taken into 
consideration when interpreting the results. A gene which demonstrates little pre-operative variation in 
expression, but greater post operative variation is likely to have been regulated. Similarly a gene with large 
pre-operative variation and a smaller significantly different variation in expression between osteolytic and 
well-fixed cohorts is likely to indicate a tendency towards loosening. 
 Section 3 : Gene Expression Profiling Page 62 
 
 
 
 
 
Figure 3.3.3.5 : Box and whisker plot giving an overview of all gene expression ranges for the whole co-hort. Coded for co-efficient of 
variation within the group. 
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M in 25% Percentile M edian 75% Percentile M aximum
Coefficient 
Variation
18S 17.42 18.1 19.2 19.81 20.52 4.96
ACP5 0.002207 0.05116 0.107 0.2454 1.15 134.37
ACTb 27.72 28.8 29.64 30.45 31.3 3.57
ADAM TS 14 0.0003123 0.002164 0.004121 0.01792 0.05239 138.14
ADAM TS 2 0.00625 0.07795 0.1743 0.2801 0.5651 79.27
B2M 0.2217 1.469 2.012 3.036 5.965 56.93
BCL2A1 0.0003123 0.001491 0.002387 0.005893 0.06802 192.61
BM P4 0.002034 0.005915 0.03177 0.08138 0.163 110.81
CASP3 0.0003123 0.02366 0.0792 0.1355 0.3837 99.63
CCL18 0.005433 0.06702 0.1423 0.3988 1.291 112.65
CCL2 0.01103 0.06193 0.1511 0.3022 0.7287 90.29
CCL3 0.001508 0.005336 0.02843 0.07465 0.4705 162.86
CCR1 0.001079 0.009392 0.0552 0.107 0.2055 88.74
CD14 0.03068 0.1596 0.3432 0.5066 1.049 69.33
CD2 0.0003123 0.002164 0.005343 0.03875 0.3049 207.64
CD28 0.0003123 0.008612 0.05295 0.09263 0.2019 88.9
CD36 0.0006615 0.01849 0.07742 0.1672 0.5777 123.56
CD58 0.002828 0.03744 0.06297 0.1079 0.1804 69
CD86 0.002207 0.008559 0.03633 0.08713 0.2892 123.02
CHIT1 0.000945 0.002164 0.002933 0.008368 0.07392 164.96
CILP1 0.04443 0.09882 0.1486 0.6625 2.188 130.67
COL1A1 0.3513 2.703 4.512 8.987 19.15 77.13
COL1A2 0.1494 1.295 2.029 3.035 6.367 65.47
COL3A1 0.1531 1.863 3.245 6.322 11.5 74.89
CSF1 0.01529 0.1065 0.1664 0.4296 0.5287 70.23
CTSG 0.001079 0.009144 0.03886 0.0908 0.7331 177.29
CTSK 0.08026 0.2171 0.387 0.6796 1.609 73.87
CXCL10 0.0003123 0.001401 0.002647 0.007281 0.09342 202.66
CXCL9 0.0006615 0.002164 0.004121 0.04256 0.1422 158.3
ERCC1 0.002828 0.03629 0.1268 0.1824 0.2405 65.24
FGF18 0.001079 0.004907 0.01984 0.0515 0.3258 169.17
FRZB 0.0003123 0.001723 0.004235 0.04105 0.3263 208.1
GAPDH 28.36 30.46 31.22 31.91 33.41 3.75
IGF1 0.005433 0.1566 0.2865 0.8556 1.273 90.45
IL10 0.0003123 0.002252 0.008311 0.03494 0.06183 105.9
IL1A 0.0003123 0.001349 0.00228 0.003726 0.01037 80.67
IL1RN 0.0003123 0.002855 0.1411 0.3223 2.057 186.33
IL6 0.0003123 0.002985 0.01272 0.03462 0.3523 201.26
IL8 0.0003123 0.002673 0.008311 0.05579 0.1271 119.32
IRAK3 0.0003123 0.009223 0.1247 0.2255 0.4097 90.13
ITGAM 0.003753 0.0293 0.1349 0.2427 0.6324 94.16
ITGB2 0.01383 0.1222 0.1904 0.2768 0.678 67.63
M ARCO 0.002466 0.0292 0.1192 0.3858 0.557 102.35
M M P1 0.0003123 0.001741 0.02095 0.07639 0.3649 164.73
M M P12 0.0003123 0.001491 0.002301 0.005041 5152 469.04
M M P13 0.0003123 0.002694 0.07939 0.2118 1.166 151.83
M M P9 0.002207 0.3536 0.8924 3.093 14.67 159.14
Normalised 28.36 30.46 31.22 31.91 33.41 3.75
PDGFA 0.003038 0.05229 0.1012 0.2035 0.3366 73.16
PDGFB 0.002207 0.01254 0.05676 0.09339 0.2115 91.67
PTGS2 0.0003123 0.002164 0.004121 0.02039 0.07977 147.99
SDHA 32.92 34.2 35.18 35.71 37 3.15
SERPINA3 0.001439 0.03662 0.05961 0.1757 0.3608 95.02
SFRP1 0.005433 0.08882 0.1839 0.3685 1.069 98.62
SFRP2 0.005433 0.6119 1.547 1.97 7.924 101.44
TGFB1 0.01197 0.126 0.1947 0.2357 0.3217 48.52
TGFB2 0.002308 0.006046 0.03405 0.07654 0.3163 130.91
TGFB3 0.002034 0.01129 0.04816 0.1176 0.1727 87.29
TIM P1 0.04906 0.6947 0.8948 1.37 5.034 90.16
TLR1 0.0003123 0.002164 0.00308 0.02967 0.07304 146.35
TLR2 0.0003123 0.002427 0.009758 0.03215 0.1114 128.46
TLR3 0.001079 0.02194 0.1153 0.1971 0.5923 111.31
TLR4 0.005433 0.03395 0.1107 0.1832 0.7256 113.38
TLR5 0.0003123 0.009342 0.02654 0.061 0.1294 92.92
TNF 0.001079 0.002305 0.005172 0.0233 0.1106 164.72
TNFRSF11A 0.0003123 0.002272 0.008441 0.04571 0.1285 131.48
TNFRSF11B 0.002466 0.03275 0.05462 0.1395 0.8375 145.87
TNFRSF1A 0.03566 0.1934 0.3521 0.5054 0.8031 55.76
TNFRSF1B 0.0003123 0.00198 0.003974 0.01348 0.04042 128.09
TNFSF10 0.001079 0.01706 0.0468 0.07532 0.1588 84.03
TP53 0.002034 0.03064 0.05543 0.1183 0.287 89.03
VDR 0.002034 0.006131 0.0301 0.0732 0.2103 113.41
VEGFA 0.002466 0.01086 0.04464 0.06995 0.2364 103.34
VEGFB 0.0691 0.1675 0.2803 0.3921 0.6478 54.52  
Table 3.3.3.4 : Coefficients of Variation for primary cohort  
 Section 3 : Gene Expression Profiling Page 64 
 
3.3.3.6 Other potential causes of variation 
It is possible that some of the variability seen in gene expression is related to variation in sampling method or 
laboratory technique. Whilst this seems an unlikely explanation it is important to consider. It has been 
established in this study by conducting intra- and inter- observer reliability that repeated sampling from the 
same tissue type leads to high correlations and little differences in expression across genes. Additionally during 
the manual TaqMan expression profiling stage multiple samples from the same tissue, and samples from 
different tissues from the same patient were evaluated all showing excellent correlations. 
 
It is important to ensure that none of the observed variation is due to differential responsiveness of the primer 
probe sets to variation in differences in tissue sampling site. All patients had two different tissues sampled at 
the time of surgery (ligamentum teres and hip capsule). In six cases both of these samples were run on the 
TLDA microarray cards (Fig 3.3.3.6). Correlation plots were constructed for each paired set of samples and 
Spearman’s test performed to determine the correlation co-efficient. Correlations were then tested for 
statistical significance. Spearman’s r and significance values are given on each correlation plot. Correlation 
coefficients varied between r=0.77 and r=0.987. Correlations were all found to be excellent, and in all cases 
the correlation was statistically significant.   
 
There is some clustering along the origin of the X and Y axis, which is likely due to genes which only just 
reached threshold in one sample. This is a technique dependent process, and this finding is not unexpected.  
The ‘funnel’ shape of the cluster plots, with more variation at lower expression levels is simply due to the 
logarithmic scale of the charts, the variation from best fit line is actually linear in each case.  
 
It has been previously established that site of tissue sampling may be unimportant, and that similar results 
have be obtained from multiple sites within the same tissue in this study. This should be interpreted in 
combination with the finding that tissue sampling from different tissues within the joint yields highly 
concordant gene expressions. This raises the possibility that each osteoarthritic hip has a biological status that 
is similar across the whole joint. 
 
When taken in combination with the initial finding of variability in gene expression between patients it can be 
concluded that there are differing biological environments from patient to patient, but that there is a similar 
biological status across each individual hip joint, irrespective of sampling site.  This is a new observation, and 
suggests that osteoarthritis is an active process with a unique environment which is similar across the 
investigated joint tissues. 
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Correlation Plot : Patient 5
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Correlation Plot : Patient 17
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Correlation Plot : Patient 23
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Correlation Plot : Patient 24
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Correlation Plot : Patient 29
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Figure 3.3.3.6 : Multiple tissue samples from the same patients. Correlation plots of 2^
-CT expression. Spearman’s correlation co-
efficient (r values) and significance value (2 tailed T-test are shown) 
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3.3.3.7 Subgroup Gene Expression 
Having established that gene expression does vary between patients with primary osteoarthritis the 
interpretation of expression results in the remaining two subgroups should be interpreted within this broader 
context. 
 
The distribution of gene expression for each cohort has been plotted as a Box and Whisker diagrams (Figure 
3.3.7 – Figure 3.3.12), and the median values marked. The median values for each cohort, standard deviation 
and Kruskal-Wallis test is given for each gene (Table 3.3.3.6), and the statistical analysis was performed as 
previously described. With visual inspection of the results in combination with interpretation of the statistical 
testing several patterns of gene expression emerge.  
 
3.3.3.7.1 Markers of Joint Replacement 
In a number of cases both the well fixed and osteolytic groups had up or down regulation of gene expression. 
This is likely to represent a gene that is either up regulated in osteoarthritis and falls post joint replacement, or 
a gene where expression is increased due to the presence of wear debris. If there is no apparent or statistical 
difference between the well fixed and osteolytic groups these genes cannot be used as markers of loosening, 
but probably represent genes where activity is modulated in response to the presence of an arthroplasty and 
the associated wear debris, not the process of loosening. 
 
The genes which fall into this category and where there was statistically significant change between subgroups 
(Kruskal-Wallis test) are MMP12, MMP9, COL3A1, COL1A2, TIMP1, CD120A, TRAIL, PDGFA, FGF18, CSF1, CD14, 
CD36, CD86, IL1RN, BCL2A1, ERCC1 & MARCO. 
 
3.3.3.7.2 Genes not involved in wear debris response 
There were some genes in which no significant changes were seen between any subgroup. Although selection 
of genes after a careful literature review makes this finding less likely there were 29 genes in which there were 
no statistically significant differences between subgroups. These genes were CASP3, CCL2, CCR1, CD120B, 
CD14, CD2, CD28, CD86, COL1A1, CTSG, CXCL10, CXCL9, FRZB, GMCSF, IL1RN, IL10, IL6, ITGAM, MMP1, 
MMP13, PDGF, PTGS2, RANK-L, TLR1, TLR2, TLR4, TNF, TP53, VDR & VEGFA. 
 
The Kruskal-Wallis test determines difference between all the subgroups, due to the non-parametric nature of 
the test it is less powerful than ANOVA. With all statistical testing significance is more likely to be reached with 
larger groups, resulting in changes in the osteolytic cohort more readily detected than those in the well fixed 
group. In some cases there was no significant difference detected across the whole group, but the median 
values moved in a different direction between the two groups. This may represent a difference the study is 
underpowered to detect. The direction of median deflection from the primary group and corresponding 
significance levels is given (Table 3.3.3.7). 
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In the case of CD120B, FRZB, GMCSF-1, IL10, PDGF, PTGS2, TP53 and VDR the medians have moved in 
opposite directions, and it seems likely that the lack of significance is due to a type 2 error i.e. lack of power in 
the study and statistical testing.  
 
3.3.3.8 Face Validity 
An indication of the reliability of the results can be made by assessing face validity. As most of the candidate 
genes come from well studied pathways, and their interactions are known, it is possible to make an 
assessment of the value of the results by exploring some of the interactions between genes. For example 
specific ADAMTS are known to have different function to specific MMPs, so one would not expect up 
regulation of MMPs and ADAMTS in the same subgroup of patients. If a gene is a known synergist then the 
ratio of expression will be expected to remain relatively constant. 
 
Primary Osteolytic Primary Osteolytic
MMP 9 0.26 8.5 COL1A2 4.512 1024
ADAMTS 2 0.174 0.00725 COL3A1 3.24 1294
Ratio 1.494253 1172.4138 Ratio 1.392593 0.7913447
Primary Osteolytic Primary Osteolytic
OPG 0.054 0.00725 SFRP1 0.1839 0.017
RANK-L 0.0084 0.0165 SFRP2 1.547 0.0807
Ratio 6.428571 0.4393939 Ratio 0.118875 0.2106568
Antagonistic Expression Synergistic Expression
 
Table 3.3.3.5 : Median Expression and ratios of selected genes 
 
Table 3.3.3.5 gives median expressions and expression ratios for two known antagonistically regulated genes 
(MMP 9 & ADAMTS 2; OPG & RANK-L) and two known synergistically regulated genes (SFRP1 & SFRP2; 
COL1A2, COL3A2). As one antagonist is up regulated the other is down regulated, where the synergists move 
together. Similarly the ratio of median gene expression is relatively constant in the synergists, and markedly 
different in the antagonist pairs. 
 
Whilst these observations remain simply observations the finding of face validity makes it more likely that the 
results of the study represent the true biological picture. 
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Figure 3.3.3.7 : Gene expression by subgroup (median marked) a) MMPs b) BMPs and collagen 
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Figure 3.3.3.8 : Gene expression by subgroup (median marked) a) TLRs b) WNT pathway 
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Figure 3.3.3.9 : Gene expression by subgroup (median marked) a) ADAMTs and TIMPs b) Cytokines 
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Figure 3.3.3.10 : Gene expression by subgroup (median marked) a) Chemokines b)Growth Factors 
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Figure 3.3.3.11 : Gene expression by subgroup (median marked) a) CD b) Interleukins 
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Figure 3.3.3.12 : Gene expression by subgroup (median marked) other genes 
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Kruskal-Wallis
Median St Dev Median St Dev p vs (P) Median St Dev p vs (P) p vs (O) Difference (p=)
MMP1 0.0043 0.019 0.0015 0.012 >0.05 0.013 0.038 >0.05 >0.05 0.3674
MMP9 0.26 1.41 8.5 26.88 <0.05 4.9 5.72 <0.05 >0.10 <0.0001
MMP12 0.00086 241 0.0031 0.0085 <0.05 0.0024 0.011 <0.10 >0.10 0.009
MMP13 0.0092 0.1226 0.0092 0.30 >0.05 0.057 0.051 >0.05 >0.05 0.5808
ADAMTS 2 0.1743 0.158 0.007252 0.04069 <0.05 0.002234 0.01814 <0.05 >0.10 <0.0001
ADAMTS 14 0.004121 0.01605 2.437 3.952 <0.05 0.721 0.9646 <0.05 >0.10 <0.0001
TIMP1 0.8948 1.118 2.463 4.05 <0.05 1.841 2.06 >0.10 >0.10 0.0058
BMP4 0.03177 0.05477 0.01166 0.03472 >0.10 0.001328 0.01404 <0.05 >0.10 0.0129
COL1A1 4.512 4.608 3.665 6.744 >0.05 2.845 1.721 >0.05 >0.05 0.488
COL1A2 2.029 1.497 1.024 1.036 <0.05 0.6877 0.5899 <0.05 >0.10 0.0085
COL3A1 3.245 3.109 1.294 0.9377 <0.05 1.122 0.6311 <0.05 >0.10 0.0005
FRZB 0.004235 0.07244 0.017 0.05802 >0.05 0.002234 0.006911 >0.05 >0.05 0.1129
SFRP1 0.1839 0.2663 0.017 0.04717 >0.05 0.00283 0.008989 <0.05 >0.10 <0.0001
SFRP2 1.547 1.655 0.08074 0.09347 <0.05 0.02587 0.36 <0.05 >0.10 <0.0001
TLR1 0.00308 0.02456 0.017 0.05532 >0.05 0.01266 0.01207 >0.05 >0.05 0.1137
TLR2 0.009758 0.03131 0.017 0.1306 >0.05 0.0534 0.2682 >0.05 >0.05 0.0716
TLR3 0.1153 0.1592 0.007327 0.03332 <0.05 0.002234 0.007204 <0.05 >0.05 0.0004
TLR4 0.1107 0.1607 0.08265 0.1076 >0.05 0.02224 0.06471 >0.05 >0.05 0.0803
TLR5 0.02654 0.03578 0.1532 0.4113 <0.10 0.03608 0.04388 >0.10 <0.10 0.0268
TNFa 0.005172 0.03159 0.006026 0.02876 >0.05 0.03803 0.04041 >0.05 >0.05 0.8696
CD120A 0.3521 0.2023 0.1491 0.1519 <0.05 0.1487 0.08271 <0.10 >0.10 0.0047
CD120B 0.003974 0.01288 0.00816 0.04119 >0.05 0.00283 0.1476 >0.05 >0.05 0.2328
OPG 0.05462 0.1832 0.007252 0.02759 <0.05 0.001324 0.00156 <0.05 >0.10 <0.001
RANK-L 0.008441 0.03116 0.01651 0.06068 >0.05 0.01035 0.02194 >0.05 >0.05 0.4854
TRAIL 0.0468 0.04712 0.2321 0.1625 <0.05 0.1683 0.1126 <0.05 >0.10 0.0057
CCL18 0.1423 0.3251 1.273 3.131 <0.05 0.1958 0.7341 >0.10 >0.10 0.0064
CCL2 0.1511 0.1968 0.1549 0.09986 >0.05 0.3104 0.3248 >0.05 >0.05 0.2067
CCL3 0.02843 0.1142 0.4389 0.9693 <0.05 0.1198 1.488 <0.05 >0.10 0.0009
CCR1 0.0552 0.05793 0.1543 0.3397 >0.05 0.07627 0.1094 <0.05 <0.05 0.332
CXCL9 0.004121 0.03849 0.06714 0.3498 >0.05 0.005067 0.4137 >0.05 >0.05 0.1045
CXCL10 0.002647 0.02651 0.01212 0.06601 >0.05 0.005067 0.103 >0.05 >0.05 0.1314
PDGF 0.1012 0.09264 0.02438 0.04879 <0.05 0.02368 0.01218 <0.05 >0.10 0.0034
PDGF 0.05676 0.05779 0.07192 0.1792 >0.05 0.03111 0.02698 >0.05 >0.05 0.1206
IGF-1 0.2865 0.3959 0.05834 0.05301 <0.05 0.01029 0.02171 <0.05 >0.10 0.001
FGF 18 0.01984 0.06799 0.006952 0.02802 >0.10 0.001324 0.00156 <0.05 >0.10 0.001
TGF-1 0.1947 0.08773 0.3186 0.3192 >0.10 0.2865 0.1341 >0.10 >0.10 0.0706
TGF-2 0.03405 0.07047 0.01177 0.03516 >0.10 0.00283 0.01341 <0.05 >0.10 0.0125
TGF-3 0.04816 0.05877 0.02195 0.04724 >0.10 0.005067 0.01635 <0.05 >0.10 0.0317
VEGFA 0.04464 0.06186 0.08849 0.148 >0.05 0.04514 0.3991 >0.05 >0.05 0.374
VEGFB 0.2803 0.1593 2.248 2.628 <0.05 0.82 0.6305 <0.10 >0.10 0.0001
GMCSF-1 0.1664 0.1744 0.1255 0.1923 >0.10 0.1002 0.0457 <0.05 >0.10 0.0298
CD2 0.005343 0.07242 0.01637 0.1592 >0.05 0.02838 0.01685 >0.05 >0.05 0.1411
CD14 0.3432 0.2554 0.5519 1.048 >0.05 0.6213 0.7487 >0.05 >0.05 0.2253
CD28 0.05295 0.0523 0.007327 0.04835 >0.05 0.01384 0.0277 >0.05 >0.05 0.1997
CD36 0.07742 0.1578 0.2983 0.2362 <0.05 0.2236 0.1771 >0.10 >0.10 0.0093
CD58 0.06297 0.05023 0.2004 0.8912 <0.05 0.1095 0.242 >0.10 >0.10 0.0112
CD86 0.03633 0.07832 0.08219 0.1864 >0.05 0.05676 0.0979 >0.05 >0.05 0.2797
IL1 RN 0.1411 0.4352 0.08791 0.06012 >0.05 0.09495 1.191 >0.05 >0.05 0.5498
IL6 0.01272 0.0788 0.006026 0.0302 >0.05 0.002234 0.1235 >0.05 >0.05 0.3196
IL8 0.008311 0.03701 0.07164 0.1777 <0.10 0.4329 38.16 <0.05 >0.05 0.0008
IL10 0.008311 0.02045 0.006682 0.02795 >0.05 0.01164 0.053 >0.05 >0.05 0.6602
IRAK 3 0.1247 0.1237 0.03232 0.06207 >0.10 0.08354 0.002234 <0.05 >0.10 0.0156
SERPINA 3 0.05961 0.1018 0.01177 0.3296 >0.10 0.00283 0.01645 <0.05 >0.10 0.0064
ACP5 0.107 0.244 1.813 4.045 <0.05 0.8059 2.019 <0.10 >0.10 0.0003
B2M 2.012 1.311 9.011 20.63 <0.05 4.479 6.057 >0.10 >0.10 0.0037
BCL2A1 0.002387 0.01485 0.1322 0.5382 <0.05 0.09534 0.7871 <0.10 >0.10 0.0002
CASP 3 0.0792 0.09957 0.01064 0.03861 >0.05 0.0117 0.01483 <0.10 >0.10 0.104
CHIT 1 0.002933 0.01846 8.686 29.19 <0.05 0.4379 6.72 <0.05 >0.10 <0.0001
CILP1 0.1486 0.5708 0.04197 0.3067 <0.05 0.006287 0.0186 <0.05 >0.10 0.0002
CTSG 0.03886 0.1577 0.01969 0.09609 >0.05 0.02163 0.4619 >0.05 >0.05 0.7653
CTSK 0.387 0.3404 1.663 2.608 <0.05 0.4657 0.2824 >0.10 >0.10 0.0397
ERCC1 0.1268 0.07787 1.211 3.152 <0.05 0.8464 0.3581 <0.05 >0.10 <0.001
ITGAM 0.1349 0.1592 0.3402 0.6097 >0.05 0.1613 0.3537 >0.05 >0.05 0.0711
ITGB2 0.1904 0.1486 1.603 2.579 <0.05 0.7127 0.7301 <0.05 >0.10 <0.0001
MARCO 0.1192 0.191 0.3081 1.082 <0.10 0.4281 0.4291 >0.10 >0.10 0.0415
PTGS2 0.004121 0.02114 0.007245 0.03056 >0.10 0.001324 0.1393 >0.10 <0.10 0.0853
TP53 0.05543 0.06541 0.1053 0.1347 >0.05 0.04756 0.04778 >0.05 >0.05 0.1821
VDR 0.0301 0.06238 0.01987 0.1248 >0.05 0.04363 0.1025 >0.05 >0.05 0.5854
Primary (P) Osteolytic (O) Well fixed revision (F)
 
Table 3.3.3.6 : Gene expression by subgroup, standard deviations and significance tests 
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Primary Primary
Well 
Fixed Gene Osteolytic (p=)
Well 
Fixed Gene Osteolytic (p=)
↑ ACP5 ↑ 0.0003 ↑ IL10 ↓ 0.6602
↑ ADAMTS 14 ↑ <0.0001 ↓ IL6 ↓ 0.3196
↓ ADAMTS 2 ↓ <0.0001 ↑ IL8 ↑ 0.0008
↑ B2M ↑ 0.0037 ↓ IRAK 3 ↓ 0.0156
↑ BCL2A1 ↑ 0.0002 ↑ ITGAM ↑ 0.0711
↓ BMP4 ↓ 0.0129 ↑ ITGB2 ↑ <0.0001
↓ CASP 3 ↓ 0.104 ↑ MARCO ↑ 0.0415
↑ CCL18 ↑ 0.0064 ↓ MMP1 ↓ 0.3674
↑ CCL2 ↑ 0.2067 ↑ MMP12 ↑ 0.009
↑ CCL3 ↑ 0.0009 ↑ MMP13 ↑ 0.5808
↑ CCR1 ↑ 0.332 ↑ MMP9 ↑ <0.0001
↓ CD120A ↓ 0.0047 ↓ OPG ↓ <0.001
↓ CD120B ↑ 0.2328 ↓ PDGF ↓ 0.0034
↑ CD14 ↑ 0.2253 ↓ PDGFb ↑ 0.1206
↑ CD2 ↑ 0.1411 ↓ PTGS2 ↑ 0.0853
↓ CD28 ↓ 0.1997 ↑ RANK-L ↑ 0.4854
↑ CD36 ↑ 0.0093 ↓ SERPINA 3 ↓ 0.0064
↑ CD58 ↑ 0.0112 ↓ SFRP1 ↓ <0.0001
↑ CD86 ↑ 0.2797 ↓ SFRP2 ↓ <0.0001
↑ CHIT 1 ↑ <0.0001 ↑ TGF-1 ↑ 0.0706
↓ CILP1 ↓ 0.0002 ↓ TGF-2 ↓ 0.0125
↓ COL1A1 ↓ 0.488 ↓ TGF-3 ↓ 0.0317
↓ COL1A2 ↓ 0.0085 ↑ TIMP1 ↑ 0.0058
↓ COL3A1 ↓ 0.0005 ↑ TLR1 ↑ 0.1137
↓ CTSG ↓ 0.7653 ↑ TLR2 ↑ 0.0716
↑ CTSK ↑ 0.0397 ↓ TLR3 ↓ 0.0004
↑ CXCL10 ↑ 0.1314 ↓ TLR4 ↓ 0.0803
↑ CXCL9 ↑ 0.1045 ↑ TLR5 ↑ 0.0268
↑ ERCC1 ↑ <0.001 ↑ TNFa ↑ 0.8696
↓ FGF 18 ↓ 0.001 ↓ TP53 ↑ 0.1821
↓ FRZB ↑ 0.1129 ↑ TRAIL ↑ 0.0057
↑ GMCSF-1 ↓ 0.0298 ↑ VDR ↓ 0.5854
↓ IGF-1 ↓ 0.001 ↑ VEGFA ↑ 0.374
↓ IL1 RN ↓ 0.5498 ↑ VEGFB ↑ 0.0001  
Table 3.3.3.7 : Subgroup expression direction of change of median and significance levels 
 
3.3.3.9 Genes Associated with Osteolysis (Significance Testing) 
The Kruskal-Wallis test identifies any significant differences between the three groups. The majority of genes 
were found to be statistically significantly different (Figure 3.3.3.6). There were 37 genes that reached 
statistical significance. This is not an unexpected finding as all of these genes have been previously implicated 
in osteolysis. 
 
There were however 28 genes (VDR, TP53, ITGAM, CASP 3, IL10, IL6, IL1RN, VEGFA, PDGF, CCR1, CXCL9, 
CXCL10, CCL2, RANK-L, TLR1, TLR2, TLR4, COL1A1, MMP1, MMP13) where no significant differences were 
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found between the subgroups. This may be attributed to either a type 2 error, or (given the large sample size) 
is most likely an accurate observation. It is therefore likely that these genes are up regulated as part of the 
osteoarthritic process, not in response to the presence of a joint arthroplasty. 
 
Using Dunn’s correction each subgroup was also tested for significance against each other (Figure 3.3.3.6) with 
the majority of genes being significantly different in the two arthroplasty groups as compared to the 
osteoarthritis group. There were however no genes in which a statistically significant difference were found 
between the well fixed and osteolytic groups (Table 3.3.3.6). There were two genes, TLR5 and PTGS2 in which 
border line significance was found (p<0.10). Statistical significance only evaluates the likelihood that any 
observed change in the mean (or median) value is due chance alone. It does not evaluate the magnitude of 
any difference, quantify the likely clinical effect of any change or demonstrate the strength of association 
between a factor and any given outcome. 
 
As there were no genes reaching significant differences between the well fixed and osteolytic subgroups a 
further pairwise analysis was undertaken (Table 3.3.3.7) using multiple Mann-Whitney U tests. It must be 
remembered in interpreting these results that without a post hoc correction for multiple testing there is the 
potential to introduce a type 1 error. The test however has more statistical power and thus is able to detect 
significant changes in smaller sample sizes. Using this method 39 genes demonstrated statistically significant 
differences between the well fixed and osteolytic subgroups. 
 
There are many reasons why an observed difference may not reach statistical significance including -error (as 
assessed by the p value), but other factors include inappropriate statistical testing and too small sample sizes 
(-error). In this case it is likely that the eventual sample size of 7 well fixed patients was too small, so although 
patterns can be observed in median expression and distribution there were no significant differences when 
compared to the osteolytic group. In other words it is likely that the analysis suffers from a Type II or  error. 
 
Further analysis is warranted in genes where the medians diverge between the two groups (section 3.3.7.2) 
and in those where there is an apparent difference in gene distribution between groups. Genes falling into 
both of these categories are VEGFA, VEGFB, IGF 1, IGF18, CCL3, CCL18, CCR1, ADAMTS, CXCL9, CXCL10, TNF , 
CD120 , OPG, RANK-L, TLR3, TLR5, FRZB, SFRP, SFRP2, BMP4, MMP1, MMP13, IL8, IRAK3, ACP5, BCL2A1, 
CHIT1, CTSK, TP53, PTGS2. A further analysis has been performed on all of these genes to measure the 
strength of association between known gene expression and known outcome (i.e. osteolytic or well fixed). 
 
3.3.3.9.1 Measuring Strength of Association 
Statistical testing of median gene expression may not be the most appropriate test when interpreting gene 
expression data between similar groups. Genes tend to work in families, and are often associated with other 
co-stimulatory or inhibitory pathways. A complex web of interactions is more usual than a simple cause and 
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effect model between a gene and an outcome. In this case measuring strength of association is the most 
appropriate statistical technique. This can be done at the most simple level with positive predictive values, 
negative predictive values, sensitivity and specificity where an arbitrary cut off for expression is taken. 
 
Although positive and negative predictive values are a measure of strength of association they use an arbitrary 
threshold value. Use of this kind of threshold value does not allow quantification of strength of association 
across the full range of gene expression, only interprets values as “high” or “low” expression. Receiver 
Operator Characteristic (ROC) is a method of analysis that measures strength of association of a continuous 
variable with a known outcome. Originally developed during WWII for tuning radar to detect aircraft 
effectively it is a method for quantifying and characterising the strength of an association when an outcome is 
known. Use of ROC not only allows an association to be characterised, but also the strength of association 
across the full range of observed values. 
 
The sensitivity and specificity are calculated for all possible threshold values across the range of observed gene 
expression for both groups. This data can then be used to plot a ROC curve of Sensitivity vs. 1-Specifity. The 
curve shows the association of gene expression with outcome (in this case osteolysis). Calculation of the area 
under the curve (AUC) can be used to compare association between genes and outcome. A maximum value of 
1 is 100% sensitive and specific, where a value of 0.5 represents random chance. 
 
The calculated ROC curve, and hence strength of association, can be tested for significant difference from 
chance. This is a more appropriate way to investigate associations in this data. 
 
3.3.3.9.2 ROC Analysis 
ROC analysis was carried out to explore the association between candidate genes and osteolytic loosening. 
Genes were included when median expression and distribution differed between the F and O groups, but no 
statistically significant difference had been found with Dunn’s test.  
 
ROC analysis was performed with the intention of quantifying association between gene expression and 
loosening, hence genes were excluded if median expression of the F group was outside the range of expression 
seen in the primary (P) group. If both F and O groups appeared to differ in expression from the primary group 
a further separate ROC analysis was carried out. When comparing these two analyses it should be possible to 
determine the value of each candidate gene as a marker of osteolytic change as compared to response to wear 
debris from a total joint replacement.  
 
ROC analysis was performed for 30 of the candidate genes (Table 3.3.3.8). Differences in gene expression was 
predictive of loosening in sixteen genes with an AUC>0.7. The complete ROC tables for all candidate genes are 
presented in the appendix. 
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Seven genes were seen to be predictive of osteolytic change with a statistically significant ROC curve and an 
AUC>0.77. These were BMP4, FRZB, FGF18, IL8, IRAK 3, OPG and PTGS2. All of these genes had a co-efficient of 
variation (CoEV) over 90% in the P subgroup. It seems likely that variation in expression of these genes has a 
role to play in development of osteolytic change. Nine genes were highly predictive of osteolytic change, but 
their ROC curves did not reach statistical significance. These genes were predictive of osteolytic change (AUC 
>0.7), but not statistically significantly different from chance : VEGFB, SFRP, TLR3, TLR5, TP53, IGF1, CTSK, CHIT 
1, CCL 18. 
 
There were two genes were the median significances (as tested with the Kruskal-Wallis test) and the ROC 
analysis did not agree. FRZB and PTGS2 were found to be statistically significantly different with ROC analysis, 
but not on comparison of the medians. This can be an expected finding with more complex statistical analysis. 
The ROC analysis tests the significance of the predictive value of gene expression for the known outcome 
(loose or not loose). This analysis includes values across the whole observed range. The Kruskal-Wallis  test 
simply compares the median observed values.  
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Figure 3.3.3.13 : ROC Curves with calculated AUC and p values for (a) VEGF (b) VEGF (c) IGF1 (d) FGF-18 (e) CCL3 (f) CCL18 
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Figure 3.3.3.14 : ROC Curves with calculated AUC and p values for (a) CCR1 (b) ADAMTS 14 (c) CXCL9 (d) CXCL10 (e) TNF (f) CD120 
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Figure 3.3.3.15 : ROC Curves with calculated AUC and p values for (a) OPG (b) RANK (c) TLR-3 (d) TLR-5 (e) FRZB (f) SFRP 
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Figure 3.3.3.16 : ROC Curves with calculated AUC and p values for (a) SFRP-2 (b) BMP 4 (c) MMP 1 (d) MMP 13 (e) IL 8 (f) IRAK-3 
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Figure 3.3.3.17 : ROC Curves with calculated AUC and p values for (a) APC5 (b) BCL2A1 (c) CHIT-1 (d) CTSK (e) TP53 (f) PTGS2 
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Gene AUC p=
ACP 5 0.61 0.36
ADAMTS 14 0.68 0.16
BCL2A1 0.58 0.55
BMP 4 0.8 0.023
CCL 18 0.71 0.11
CCL 3 0.54 0.74
CCR1 0.63 0.31
CD120B 0.65 0.26
CHIT 1 0.7 0.12
CTSK 0.74 0.072
CXCL 10 0.59 0.64
CXCL 9 0.63 0.32
FRZB 0.77 0.038
IGF 1 0.71 0.1
FGF 18 0.83 0.011
IL8 0.77 0.038
IRAK 3 0.81 0.019
MMP1 0.69 0.16
MMP13 0.59 0.5
OPG 0.88 0.004
PTGS2 0.79 0.045
RANK 0.59 0.5
SFRP 0.75 0.061
SFRP2 0.64 0.29
TLR3 0.72 0.11
TLR5 0.78 0.32
TNF a 0.58 0.5
TP53 0.7 0.124
VEGF A 0.53 0.79
VEGF B 0.72 0.095  
Table 3.3.3.8 : ROC Analysis summary 
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3.3.3.10 Genes Reaching Significance (ROC Testing) 
The more detailed ROC analysis demonstrated that 16 genes were highly associated with osteolytic change 
(AUC >0.77), of these seven genes reached statistical significance for the strength of association. Each gene is 
discussed with an overview of how this observation may fit with what is currently known about the pathway.  
 
Bone Morphogenic Protein 4 (BMP 4) 
Expression levels of BMP 4 are lower in patients with a well fixed prosthesis than the two other groups. BMP 4 
is known to be an active stimulator of bone growth and has been used in clinical trials to stimulate bone 
healing237. BMP 4 is also known to play a role in ectopic bone formation238.  BMP-4 has been previously studied 
in animal models and shown to be up regulated in response to stimulation by particulate wear debris. The 
observation in this study of lower BMP4 expression in the well fixed group fits with previous work. 
 
BMP-4 functions to induce differentiation of the osteoblast from the osteoprogenitor cell239. It has been 
demonstrated to up regulate osteocalcin expression and to induce bone formation, although not as 
aggressively as BMP2, 6 & 9240. BMP-4 is responsible in part for heterotrophic ossification, although this may 
be due to relative down regulation of the BMP inhibitor noggin241 rather than over expression of BMP-4. 
 
Given the regulatory role that BMP’s are known to have on TGF-  in the bone remodelling pathway  (Figure 
3.3.3.18) the finding of similar expression patterns in TGF-2 and TGF-3 lend weight to the finding that BMP 
expression may be important in osteolytic change.   
 
Figure 3.3.3.18 : An overview of the BMP pathway. Reproduced from Termaat & Den Boer
242
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 Frizzled Related Protein (FRZB or sFRP3) 
Frizzled related protein is highly expressed on chondrocytes. FRZB encodes the secreted frizzled-related 
protein 3 (SFRP3), which acts as an antagonist of extracellular Wnt ligands. Although Wnt signalling is 
implicated in multiple processes, like many cell surface receptors the interaction with intracellular pathways, 
and secreted signal proteins may significantly alter the eventual effect243. The Wnt pathway has the ability to 
modulate osteoblastic differentiation and is therefore potentially important in osteolytic change  (Fig 3.3.3.19). 
 
Frizzled related protein has been previously implicated in periprosthetic osteolysis155. Genotype variations in 
FRZB have been shown to predispose patients to both osteolysis and heterotopic ossification, however 
differences observed were not statistically significant155. The confirmation that higher expression of FRZB is 
associated with osteolytic prosthesis, but not with well fixed hip prosthesis, adds significantly to what is 
already known on this topic. As there is a spread of FRZB expression in the primary osteoarthritis group, and 
that both the osteolytic and well fixed groups are a subset of this expression it seems possible that 
preoperative FRZB expression levels may predispose a patient to osteolytic change. This theory is supported by 
similar although not conclusive findings in some genotyping studies155.  Further support for this hypothesis can 
be found from the variations seen in SFRP1 (described below) which is also a modulator of the Wnt pathway. 
 
It is not possible from the data collected in this study to determine which of the downstream pathways are 
responsible for osteolysis, as we did not characterise mRNA expression for all the pathways. However the 
WNT/β-catenin pathway seems the most likely candidate as it has been previously shown to modulate bone 
resorption and may play a key role in the pathogenesis of osteoarthritis and osteolysis. Activation of Wnt 
pathway results in up regulation of Dishevelled (Dvl) and production of a non-phosphorylated form of β-
catenin which localises to the nucleus. This is thought to directly induce the expression of downstream target 
genes152. 
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Figure 3.3.3.19 – The role of the Wnt signalling pathway in regulation of osteoblastic and osteoclastic differentiation. Reproduced from 
“Eating bone or adding it: the Wnt pathway decides” Steven R Goldring & Mary B Goldring Nature Medicine 13, 133 - 134 (2007) 
 
Fibroblast Growth Factor 18 - FGF18 
Fibroblast growth factor 18 functions in combination with BMPs and other growth factors to promote 
differentiation of osteoblasts from osteoprogenitor cells. The findings of significantly lower levels of FGF-18 
which is partly responsible for osteoblast differentiation is at first puzzling. FGF-18 along with a number of 
other growth factors have been shown to be associated with increasing bone thickness (Fig 3.3.3.20). Whilst 
one might expect increased bone formation in the well fixed group, the contrary is true. An osteolytic loose 
stem will be undergoing a high rate of bone turn over and remodelling in response to the osteolytic process. In 
a stable joint replacement one would not expecting a higher than normal rate of bone turn over to be seen. 
The raised levels of FGF-18 are probably indicative of reduced bone turnover in well fixed prosthesis. This 
suggestion is supported by similar findings with VEGFB.  
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Figure 3.3.3.20 : Growth factors effect on bone thickness. Reproduced from Mundy, Metastasis: Metastasis to bone: causes, 
consequences and therapeutic opportunities. Nature Reviews Cancer (2), 2002:584-593 
 
Interleukin 8 (IL 8) 
The role of interleukin 8 has been mostly evaluated as part of the effect of tumour associated osteolysis. 
Interleukin 8 has been shown to stimulate both human osteoclast formation and bone resorption244, although 
initially evaluated as part of the RANK/OPG pathway more recent work has demonstrated that IL 8 is able to 
stimulated osteoclast formation directly. The findings of raised IL8 expression associated with loose prosthesis 
fits with previous work. 
 
Beraudi and colleagues157 have performed a further series ex-vivo studies of limited cytokines and implicated 
IL-8 in osteolytic change through use of an ELISA technique. Although they did not evaluate any well fixed 
stems these findings suggest IL-8 may be implicated in periprosthetic as well as metastatic osteolysis through a 
similar mechanism. Our findings support this hypothesis. 
 
Interleukin 1 Receptor Associated Kinase 3 – IRAK 3 
IRAK 3 is an intracellular kinase which is associated with a range of intracellular pathways. IRAK is involved in 
signal transduction from the TLR and IL-1R receptors, and as such is a possible marker of the function of these 
pathways. The findings of lower expression of IRAK3 in the well fixed group suggests that IRAK3 mediated 
pathways may be key in the intracellular pathways responsible for the osteolytic response. 
 
Although not specifically previously implicated in periprosthetic osteolysis IRAK has been extensively studied in 
it’s role as an immune modulator. Activation of IRAK mediated pathways play a central role in reducing 
macrophage cytokine production245 and have been implicated in induction of macrophage tolerance through 
down regulation of the TOLL pathway246-248. IRAK-3 has been shown to be up regulated in response to repeated 
toxin exposure249, and the lower expression of IRAK-3 in the well fixed group likely corresponds to lower 
activity of the macrophages and antigen presenting cells when compared to the osteolytic subgroup.  
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Osteoprotegerin OPG 
Osteoprotegerin levels were significantly lower in the well fixed group, and high levels of OPG were predictive 
of a loose implant in this study. As has been previously discussed OPG is key to activation of osteoclasts (Fig 
3.3.3.21) and has been implicated in wear debris related osteolysis.  
 
The finding of lower levels of OPG in well fixed hips when compared to the osteolytic cohort is to be expected 
however under expression of OPG in the osteolytic group when compared to the primary osteoarthritis group 
is difficult to explain. However OPG is rarely taken in isolation, and should be considered in combination with 
the RANK receptor. When found in combination with the RANK ligand and RANK receptor OPG is a potent 
stimulator of the osteolytic process. Lower levels of OPG in the osteolytic cohort when compared to the 
primaries may represent either low osteoclastic activity, or as seems more likely the OPG could be more 
effective in the osteolytic group due to up regulation of the RANK and RANK-L expression in the osteolytic 
patients. This would increase the OPG:RANK ratio and the subsequent effect of the OPG. 
 
  
Figure 3.3.3.21 : OPG-RANK(L) interactions. Reproduced from http://www.Qiagen.com GeneGlobe Pathways view) 
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Prostaglandin-endoperoxide synthase 2 (PTGS2) 
Expression of PTGS2 was significantly lower in the well fixed revision cohort than the osteolytic group, but still 
seen as a subset of the primary group. Although not statistically significant the osteolytic group had higher 
median gene expression than the well fixed group.  
 
PTGS2 is the enzyme responsible for synthesis of the prostanoids, and PTGS2 is the inducible form (COX2). 
Previous studies have demonstrated that production of IL-6 and prostaglandin E2 in response to wear debris is 
mediated by PTGS2250. Further work has demonstrated that inhibition of PTGS2 has the potential to suppress 
periprosthetic osteolysis251;252.  
 
The finding of higher expression of PTGS2 in the osteolytic group as compared to the well fixed group, with 
both being subsets of the range of primary expression is interesting. Although it is possible that the observed 
raised PTGS2 in the osteolytic group is an induced effect it is also possible that this observation represents a 
tendency of patients with higher PTGS2 levels to undergo periprosthetic osteolysis in response to exposure to 
wear debris. 
 
3.3.3.11 Genes Highly Predictive of Osteolytic Change 
Some genes were identified in the ROC analysis where expression levels were predictive of osteolytic change, 
but the ROC curve was not statistically significantly different from chance. The genes discussed all had an AUC 
of >0.7, but a p value of >0.05. 
 
Vascular Endothelial Growth Factor  (VEGFB) 
VEGF is one of a range of growth factors that have been implicated in previous studies in osteolysis. Expression 
of VEGFB is not significantly altered in the well-fixed subgroup when compared to the primaries suggesting 
that the presence of an arthroplasty and wear debris is not responsible for its up regulation. However it is 
significantly raised in the osteolytic subgroup compared to the primaries, and borderline significance (p<0.10) 
when compared to the well-fixed group. This pattern likely associates the process of osteolysis with VEGFB. As 
the expression is up regulated this is likely an induced pattern. 
 
VEGFB has been associated with neovascularisation in the periprosthetic tissue, which has been hypothesized 
to augment and sustain the inflammatory response to wear debris253. The induction of VEGF release from 
macrophages in response to wear debris likely contribute to neovascularisation subsequent periprosthetic 
osteolysis and implant loosening (Miyanishi, Trindade 2003). 
  
VEGF has also been shown to have a role in the regulation of the RANK/RANK-L osteoclastogenic pathway 
(Ren, Markel, Zhang 2006), and in light of these previous findings the new data presented as part of this study 
confirms the importance VEGF signaling in the pathogenesis of prosthetic loosening. This data suggests that 
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VEGF is induced to high rates of expression, so although it may be useful as a surrogate marker for osteolytic 
change or a potential point for therapeutic intervention. VEGFB expression preoperatively is unlikely to 
indicate a tendency towards periprosthetic loosening.  
 
Secreted frizzled-related protein 1 (SFRP-1) 
Levels of SFRP-1 in the periprosthetic tissues are lower in the well-fixed group than in the osteolytic group. 
Whilst highly associated with outcome (AUC = 0.75) SFRP-1 was only borderline significance (p=0.075). SFRP-1 
is a secreted inhibitor of the WNT pathway. SFRP-1 shares a binding domain for the Frizzled pathway and 
therefore is able to function as a competitive inhibitor of the WNT pathway. SFRPs function as secreted ligands 
and are able to bind WNTs at an extracellular level and hence modulate their activity. The SFRPs are therefore 
capable of down regulating the activity of the WNT pathway. Modulation of the WNT/-catenin pathway has 
been implicated in the pathogenesis of osteoarthritis149. 
 
The WNT pathway functions to promote bone formation and mineralisation, therefore one might expect a 
reduction in an inhibitor to equate to increased function of the pathway. Other WNT inhibitors have been 
shown to promote bone resorption when levels are elevated156. Our findings would be consistent with this 
role, and although SFRP-1 has not been previously implicated in periprosthetic osteolysis. These findings taken 
in conjunction with those for FRZB (SFRP-3) provide strong evidence that the WNT pathway is strongly 
implicated in periprosthetic osteolysis. 
 
Toll Like Receptors (TLR 3 & TLR 5) 
Toll like receptors (TLR) are a group of trans-membrane receptor proteins which all act as a co-activation 
factors in a range of immune responses. TLR receptors are co-signalling receptor molecules usually activated in 
response to stimulation with microbial molecules (such as bacterial lipopolysaccharides) they modulate a 
broad range of intracellular inflammatory pathways (Fig 3.3.3.24). 
 
There are 11 Toll like receptors, and the 5 most commonly studied were included, as although their role is not 
fully delineated there is accumulating evidence that they are associated with aseptic loosening144-146.  Both TLR 
3 and TLR 5 were shown to be highly associated with failure (AUC 0.72 and 0.78 respectively), where the 
others were not. The strength of association for both TLR 3 and TLR 5 was not statistically significant. 
 
TLR-3 expression has been shown in inflammatory arthritidies to be associated with activation of the RANK-L 
pathway, and taken in association with the data for OPG also presented in this study it seems likely that TLR 3 
activation is associated with macrophage activation and aseptic loosening147.  
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The association of TLR 5 with aseptic loosening is a new finding. All of the TLR receptors function to activate 
subtly different pathways, although there is some overlap (Fig 3.3.3.25). TLR 3 is particularly associated with 
increased T cell stimulation through up regulation of CD40, CD80 and CD86, where TLR 5 activation lacks this 
function. TLR5 is thought to be stimulated by bacterial cell components and results in up regulation of cytokine 
expression (Fig 3.3.3.25). The finding that TLR 5 is up regulated in response to periprosthetic loosening 
warrents further study, as this may represent the pathway through which cytokine levels are increased in 
response to osteolytic change. 
 
Protein 53 (p53) 
The ROC analysis demonstrates an association between high levels of expression of p53 (AUC=0.70) and 
osteolytic hips. Interestingly both loose and well fixed group’s expression is a subset of primary expression, 
which may indicate that p53 expression levels represent a tendency to loosen, not as a result of loosening.  
 
p53 is a key signal protein situated at the crossroads of a network of signalling pathways that are essential for 
cell growth regulation254-256. In normal unstressed cells, the level of p53 protein is down regulated via the 
binding of proteins (eg MDM2, COP1 or PIRH2) that promote p53 degradation via the ubiquitin/proteasome 
pathway. As most of these genes are up regulated by p53, this leads to a regulation loop that will keep p53 
levels very low in normal cells.  
 
A large number of regulatory proteins are known to bind various regions of p53 in order to its activity.  
Regardless of the type of stress, the final outcome of p53 activation is either cell cycle arrest and DNA repair or 
apoptosis, but the mechanism leading to the choice between these fates has not yet been elucidated.  P53 has 
been shown to be associated with apoptosis in osteolytic hip replacements186;257. 
 
This study demonstrates for the first time that p53 is likely to be significantly involved in the process of 
osteolysis, and that endogenous expression levels of p53 may be linked to a tendency towards aseptic 
loosening.  
 
Insulin-like Growth Factor 1 (IGF 1) 
IGF 1 has not been previously implicated in periprosthetic osteolysis. Growth factors are known to modulate 
osteoblast formation, and have been implicated in the age related changes which occur in bone marrow.  IGF-
1 has also been shown to have a modulatory function on the activity of osteoblastic function promoting 
collagen deposition79.  
 
IGF 1 was found to have a high association with aseptic loosening (AUC=0.71), although the ROC curve did not 
differ significantly from random chance (p=0.10). IGF-1 levels were suppressed in both the osteolytic and well 
fixed group when compared to the primaries, but where lower in the well fixed group. 
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This novel finding that IGF 1 is not only involved in the process of aseptic loosening, but may also be predictive 
of failure warrants further investigation. The role of IGF 1 in promoting bone turnover through osteoblastic 
function has already been established, and the findings of this study warrant further investigation.  
 
Cathepsin K (CTSK) 
Cathepsin K (CTSK) is a protease which plays a central role in osteoclast mediated bone resorption (Fig 
3.3.3.26) and is also highly expressed by chondrocytes. CTSK function has been previously strongly associated 
with bone metastasis and osteolysis183;184;258 and osteoclastic differentiation184.  Activation of macrophages has 
been shown in the presence of the Cathepsins to facilitate osteolysis by activating the macrophage population 
themselves259.  
 
CTSK levels are higher in the osteolytic group, and there was a strong association between CTSK levels and 
loosening of the prosthesis (AUC=0.74 p=0.072). Interesting the ROC analysis demonstrated a sharp “tick” 
suggesting a tight threshold. Sharp threshold values have the potential to provide reliable predictive 
information, and in light of this finding CTSK may be a potential reliable biological marker for periprosthetic 
osteolysis. 
 
 
Figure 3.3.3.26 : CTSK mediated mechanism of osteoclastic bone resorption. Reproduced from J. Clin. Invest. 116:5 “Nothing but skin 
and bone”  
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Chitinase 1 (CHIT 1) 
Chitotriosidase is an enzyme secreted by activated macrophages that is able to catalyze the hydrolysis of both 
chitin and chitin-like substrates. Chitotriosidase are responsible for defense against of chitin-containing 
pathogens such as fungi, nematodes, and insects. Chitotriosidase have been demonstrated to be elevated in 
the serum of patients with certain granulomatous conditions260. There have been no studies evaluating the 
role of CHIT-1 as a marker of periprosthetic osteolysis, despite its implication in other granulomatous 
conditions. 
 
Although the ROC analysis did not find CHIT-1 to be a statistically significant predictor of outcome (p=0.12) 
there was a significant association (AUC=0.70). This in itself is an interesting finding as CHIT-1 is associated 
with alternative macrophage activation, a pathway in which there has been some significant interest in the 
recent osteolysis literature.  
 
CCL 18 
CCL-18 was found to be strongly predictive of a loose prosthesis (AUC=0.71, p=0.11) Tissue mRNA expression 
was significantly raised in the osteolytic group, with no change in the well fixed group when compared to the 
primary group. Given the ROC results demonstrating that CCL-18 may differentiate between a well fixed and 
loose prosthesis, and significantly raised median expression when compared to the primary group there it is 
extremely likely that CCL-18 is not only involved in the process of osteolysis, but may be used a marker for a 
loose joint replacement. 
 
Macrophages are responsible for the initiation and maintenance of the inflammatory process. Macrophage 
“switching” is the process by which macrophages are turned off, and then function to inhibit and resolve 
inflammation. CCL-18 has been implicated in macrophage switching171. If as these results suggest macrophage 
switching occurs in osteolytic tissues it may be central to suppression of the osteolytic cascade.  
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SECTION 3 : CONCLUSIONS 
 
These results support and extend the current state of knowledge surrounding pathways involved in 
osteolysis. The design of the study with a native joint group for comparison with a well fixed and 
osteolytic study groups allows for speculation not only about which genes are responsible for the 
response to wear debris, but specifically those that are likely to be associated strongly with 
osteolysis. 
 
It is unusual to find statistical significance between groups in biological studies, especially in those in 
which corrections for multiple testing have been made. The finding that seven genes were 
statistically significantly predictive of osteolytic change is an important finding and contributes to the 
current body of evidence surrounding this topic. 
 
Genes working in similar ways and likely to be co-regulated (e.g. SFRP-1 and SFRP-3) have been found 
to have similar changes in expression patterns between the osteolytic and well fixed cohorts of 
patients, this adds to the face validity of the results, and makes the observations less likely to have 
occurred through ‘random chance’. 
 
The additional finding that a further nine genes were predictive of osteolytic change but did not 
reach significance levels is encouraging that with further study and larger groups of patients these 
genes are likely to reach significance levels. 
 
It is not possible on the basis of these results to make a clear assertion if the expression of a 
particular gene makes osteolytic change more likely, or if it is the osteolytic change that causes a 
modulation in gene expression rates. This question is like the ‘chicken and the egg’ and difficult to 
prove either way. The finding that for some genes a subset of expression in the ‘primary’ patients is 
seen in either the ‘well fixed’ or ‘osteolytic’ groups makes it likely that regulation of gene expression 
causes osteolysis and not the other way around. 
 
Without a long term follow up study from primary arthroplasty through to failure it is impossible to 
say conclusively that a variation in a particular gene expression is associated with risk of loosening. 
The data presented here however does imply, although not prove, that variation in gene expression 
is associated with osteolytic change.  
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SECTION 4 : RISK FACTORS FOR OSTEOLYSIS 
 
4.1 Study design 
A prospective longitudinal cohort study was undertaken to establish patient related risk factors for osteolysis. 
The study was conducted using a previously identified and reported29 cohort of patients. All patients were 
operated on at the Norfolk and Norwich Hospital in 1995 and received a cemented THR.  The series consisted 
of 234 consecutive, non-selected primary total hip arthroplasties, performed in the calendar year 1995 on 217 
patients at the Norfolk & Norwich University Hospital. Patients who had bilateral hip replacements either at 
the same operation or as another procedure in the same year were included. 
 
All the patients received a cemented Elite Plus THR (De Puy Ltd, Leeds, UK) with a 28 mm Ortron 90 head (De 
Puy Ltd, Leeds, UK). The patients were recruited at the time of surgery and prospectively followed up in a post-
operative clinical and radiological surveillance programme initiated at the time of surgery. This consisted of 
regular clinical and radiographic review. Final review took place at a minimum of 12 years (range 144 to 156 
months) after surgery. 
 
Following approval by the local Research Ethics Committee and the Research Governance Committee at the 
Norfolk and Norwich University Hospital patients were written to inviting them to take part in the study. Prior 
to the mailing of the letter the hospital information system and the National Tracing Service were used to 
confirm the patient was alive and their current address as many had relocated since their initial surgery. 
Patients were supplied with a patient information leaflet, approved consent form and a contact number to 
address any concerns. 
 
The patients were identified from records held as part of the Joint Review Programme. This information is 
stored on a database, Medlog®, and contains patient demographic information, operative details and 
complete subsequent follow up data including details of radiograph and radiographic changes. Patients 
included were cross referenced with theatre log books to ensure all patients met the inclusion criteria. 
Patients were excluded if any of the following factors that may affect outcome were identified in any of their 
records: 
 Revision surgery 
 Prosthesis not Elite Plus  
 Bone grafting required at primary THR 
 
Data were gathered from patients notes, operative records and the joint review programme database. If data 
was incomplete the patients were contacted and asked to supply any missing records. Data collected for the 
purpose of this study included : 
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Surgical Teams 
 Grade of primary Surgeon 
 Surgical Approach 
 Cement type 
 Complications 
Demographics 
 Age 
 Sex 
 Diagnosis 
Co-morbidities 
 Smoking 
 BMI 
 Medications (NSAIDS) 
 Charleson co-morbidity score 
Data was anonymised by study number and entered onto an Excel (Microsoft Ltd, Richmond VA) database.  
 
As part of their routine follow up patients were offered clinical and radiographic review at 12 years which 
coincided with the timings of this study. The review was undertaken by the hospital’s independent 
arthroplasty review service. The review consisted of standardised AP and lateral hip radiographs, a 12 point 
Oxford Hip Score, and clinical examination. Review was undertaken  jointly with an arthroplasty care 
practitioner. Patients in whom concerns about radiographic loosening or clinical concerns were raised were 
referred back to their operating consultant or their immediate replacement for a decision regarding revision 
surgery. 
 
This study was undertaken after the 12 year review process was completed. For the purposes of this study the 
radiographs of all patients were reviewed by two independent observers using a PACS workstation (Centricity, 
GE Healthcare, Amersham, UK). The radiographs were assessed by two independent observers according to 
the criteria of Johnston et al261. Radiographs were reported in conjunction with post-operative and mid-term 
(mean 6.4 year) radiographs for the same patient. Agreement between both observers was necessary for data 
to be included and, when disagreement occurred, a consensus view was obtained with a third observer. A 
validation exercise was performed to determine intra-observer and inter-observer reliability of the data 
included. 
 
The immediate post operative films were reviewed to establish any evidence of poor operative technique. 
Cement mantels were graded on the AP projection according to the criteria of Barak30, stem varus/valgus 
alignment and leakage of cement below the restrictor was also assessed. 
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The radiographs were classified as well fixed, possibly loose or definitely loose according to recognised 
previously published criteria. Loosening of the femoral stem was defined according to the criteria of Harris33. 
The refined criteria of Kobayashi34 for loosening of the femoral stem were separately analysed. Loosening of 
the acetabular component was defined according to the criteria of Hodgkinson32. The survival of the prosthesis 
was calculated using these radiographic definitions and separately for revision as an end point. 
 
4.2 Statistical analysis 
Statistical analysis was performed using GraphPad Prism V5.0 (GraphPad Software, La Jolla, CA) and SPSS v 16 
(SPSS Software, Chicago, Illinois). Fisher’s exact test was used to ascertain significance levels for categorical 
data and a two tailed Student’s T-test for continuous data. Survivorship analysis was calculated using the 
Kaplan-Meier method, with Greenwoods method for calculation of confidence intervals. Survival curves were 
plotted and also tested for difference using the Mantel-Cox (log rank) test. A type 1 error level of 5% (p<0.05) 
was defined as significant in all cases. 
 
Mean survival and significance levels were calculated for all variables included in the study and survivorship 
curves plotted for each. Charlson co-morbidity scores210;211 were calculated both as raw and age adjusted 
values. These were used as a measure of overall medical co-morbidity. 
 
4.3 Results 
Of the 217 patients (234 THRs), 83 had died before our final review and nine were either lost to follow-up or 
no radiographs were available. Nineteen patients had been revised leaving 142 surviving hips in 133 patients 
available at the time of final follow up.  
 
Mean age at surgery 69.3 years (range 24-93 years), bilateral procedures at separate operations were 
performed on 30 patients. One hundred and thirty two hips were replaced on the right and 82 on the left. The 
preoperative diagnosis included osteoarthritis 200 (90%), rheumatoid arthritis 16 (7%), avascular necrosis and 
sequelae of childhood disorders seven (3%). Complications in the immediate postoperative period included 
two (1%) dislocation, superficial wound infection two (1%) thrombosis seven (4%), proven infection one 
(0.5%), medical complications nine (5%). 
 
4.3.1 Surgical Demographics 
One hundred and thirty seven operations were performed by consultants and 97 by specialist registrars. All 
but three procedures had been undertaken through a modified anterolateral approach. Standardised second 
generation cementing technique was employed by all surgical teams. 
 
A retrospective review of the immediate post-operative radiographs confirmed that 99.4% of THRs had a 
grading of A or B according to the criteria of Barrack, Mulroy and Harris30 and 0.6% of C or D. The position of 
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the femoral stem was neutral in 111 (69.8%) of THRs, while 30 (18.9%) of stems were in > 4° of varus and 18 
(11.3%) in > 4° of valgus. 
 
4.3.2 Revision 
Of the 234 arthroplasties, nineteen (8%) required revision during the 12 year follow up period (Table 4.3.1).  
One patient was revised for early deep infection and the remaining 18 for aseptic loosening. Kaplan-Meier 
survivorship analysis gives a 93.9% (CI 89.2 - 96.5%) survival at 10 years, and 88.0% survival at final follow up 
for all causes of revision (Fig 4.3.1). 
 
A subset analysis excluding all patients with low viscosity cement, poor cement mantle or poor component 
position gives a 93.3% (CI 88.1 - 96.2%) survival at 10 years. There was no statistically significant difference 
between this subset and the whole group analysis. 
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Figure 4.3.1 : Survival analysis at 12 years revision and radiographic failure 
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Revisions n = 19 
Gender 
Male 
Female 
 
7 
12 
Side 
Right 
Left 
 
12 
7 
Diagnosis 
OA 
Post traumatic OA 
 
18 
1 
Reason for revision 
Aseptic loosening 
Infection 
 
18 
1 
Table 4.3.1 : Demographic details for revision patients 
 
4.3.3 Radiographic Failure 
Complete radiographic analysis was possible in 142 arthroplasties at 12 years, and in a further 19 who had 
previously undergone revision. According to Harris, definite evidence of femoral loosening was present in 
28.8% of femora, and according to Hodgkinson, 46.5% of acetabulae were definitely loose. Fifty eight percent 
of patients had definite loosening of at least one component. At the time of final review 19 patients had 
undergone revision giving a combined failure rate of 63% (102 of 161) (Table 4.3.2). The validation exercise 
demonstrated the intra-observer reliability was excellent (=0.94) and inter-observer reliability was good 
(=0.89) 
 
Component Criteria 6 Year results  
(95% CI) 
12 Year result  
(95% CI) 
Femoral Harris
33
 16.4% 26.8% (n=38 of 142) 
(19.4% to 34.1%) 
 Kobayashi
34 18.2% 28.8% (n=41 of 142) 
(21.3% to 36.4%) 
Acetabular Hodgkinson
32
 11.9% 46.5% (n=66 of 142) 
(38.1% to 54.8%) 
Either Harris
33
 and/or 
Hodgkinson
32
 
27.0% 57.7% (n=82 of 142) 
(49.5% to 66.0%) 
Either Revision 5.1% 11.8% (19 of 161) 
(6.8% to 16.8%) 
Either Revision or 
Loosening 
31.0% 63% (102 of 161) 
(56% to 71%) 
Table 4.3.2. Failure rate at 12 years follow up. 
 
4.3.4 Patient Demographic Data 
Of the surviving 161 arthroplasties with known outcome at final follow up complete data for all fields was 
available in 87 patients. Complete data bar smoking and NSAID use was available in all 161 patients. 
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Twenty percent of patients were smokers and continued to do so from the time of surgery and 67% of patients 
used NSAIDs. Obesity (BMI>30) was diagnosed in 16% of patients at their pre-operative assessment, and the 
mean Charlson score was 1.04 preoperatively across the whole cohort. 
 
There were no statistically significant differences between any pre-operative co-morbid factor and post-
operative outcome. Age at the time of surgery was found to be statistically significantly different in the failure 
and survival group (Table 4.3.3). There was no statistically significant link found between mean pre-operative 
Charlson scores and survival either using the raw or age adjusted scores (Table 4.3.4). 
 
 Loose (%) Not loose (%) p value 
BMI  <30 
BMI>30 
51 (25.4) 
8  (32.0) 
150 (74.6) 
17 (68.0) 
 
p = 0.4768 
Charnley Grade 
A 
B 
C 
 
27(48.2) 
22 (39.3) 
7 (12.5) 
 
73 (43.7) 
70 (42.0) 
24 (14.4) 
 
 
 
p = 0.8330 
Table  4.3.3 Variables with potential relations to survival 
 
 Mean p value 
Charlson index 
Loose n = 51 
Not loose n = 129 
Charlson age adjusted 
Loose n = 51 
Not loose n = 129 
 
0.96 (SD0.7476) 
1.08 (SD 0.8263} 
 
2.51 (SD1.8052) 
2.96 (SD 1.9144) 
 
 
 p = 0.4134 
 
 
p = 0.2062 
Table  4.3.4 Charlson co-morbidity scores divided by patient groups 
4.3.5 Survivorship Analysis 
Kaplan-Meier survival analysis for the complete patient cohort is given in Figures 4.3.2 & 4.3.3. Survivorship is 
plotted with 95% CI. The two curves were tested for significant difference (Mantel-Cox test) and the p value is 
given. There was no significant difference between survivorship found when patients were stratified by their 
smoking status or use of NSAIDs.  
 
There were no significant differences between survivorship when patients were stratified by gender or initial 
diagnosis. However although not significant a higher failure rate was observed at ten years in patients with a 
high BMI (p=0.179). It is certainly possible that this trend towards significance will become a significant 
difference at further follow up. 
 
There was a significant difference (p<0.032) when patients were stratified into three age groups. Interestingly 
there were no differences observed between the 65-70 group and the 75+ group. This may be due to the small 
size of the 75+ group at final analysis.  
 
 Section 4 : Risk Factors for Osteolysis  Page 102 
 
There were statistically significant differences between patients with a low Charlson score and high Charlson 
score (p=0.012) when radiographic loosening was taken as an end point. Although this trend was maintained 
when revision was taken as an end point the differences were no longer significant (p=0.38). This is likely 
explained by the use of revision as an outcome. Although patients with a high Charlson score appear to 
demonstrate evidence of radiographic loosening at an earlier stage the decision to  perform a revision 
arthroplasty is not just a radiographic one. Patients with high Charlson co-morbidity scores have by definition 
higher risk associated with revision surgery and it may not therefore be in that patient’s interest to undergo 
revision surgery.   
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Figure 4.3.2 : Survival analysis for a) whole cohort and stratified by b) BMI c) Gender d) Diagnosis e) Charleson Score f) Charleson Score 
(radiographic failure)  
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Figure 4.3.3 : Kaplan-Meier Survival analysis for  stratified by a) Smoking status b) NSAID c) Age 
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4.4 Discussion 
Patient related risk factors for failure of a total joint replacement are well studied. Although revision is a firm 
end point the number of patients who are revised is relatively low, and given the patient population age a 
number of patients will be deceased before their joint replacement fails, making determining the risk factors a 
tricky task. In addition to this the decision to revise a joint replacement is not based purely on the stability of 
the stem, but also patient wishes, co-morbidities and general health. As such revision is a coarse but firm end 
point. 
 
Inclusion of radiographic definitions of loosening allows for a more sensitive definition of failure that is not 
subject to other patient factors such as fitness for surgery, however it does introduce some potential observer 
bias. Where appropriate both definitions of failure have been evaluated.  
 
4.4.1 Co-morbidities 
The Charleson co-morbidity score has been shown to be predictive of post operative radiographic survival. 
Patients with a high Charleson score (>3) have been shown to have a poorer survival at a ten year follow up 
with an outcome of revision, however the confidence intervals overlap (Fig 4.3.2) and Mantel-Cox testing did 
not show any significant differences. 
 
When definite radiographic loosening or revision is taken as the end point then a statistically significant 
difference is seen between the survival curves. Patients with significant co-morbidities (Charlson scores >3) 
had a statistically significantly higher rate of radiographic failure in their THRs. This is a slightly surprising 
finding. One would expect the fitter patients to be more active and as such to have higher demands, increasing 
the likelihood of wear debris related failure. However the contrary appears to be true.  All of the prostheses 
implanted were cemented Elite Plus prosthesis, so there can be no selection bias for prosthesis type, and 
observed failure rates are unlikely to be explained by any other factor. The patients with poorer co-morbidity 
scores tended to be older (although there was no significant difference), and as a young age is associated with 
failure this too is unlikely to explain the findings. 
 
It is possible that the difference can be explained by changes to the bone itself. It has been established that as 
bone ages its morphology changes262 and bone remodels with stress. Patients with high co-morbidity scores 
are likely to have had lower functional demands at the time of the surgery, putting them at risk of disuse 
osteoporosis263-265.   
 
The differences between the curves for radiographically defined failure and those hips that have been revised 
are also likely also due to the co-morbidity effects. Patients with a higher co-morbidity score are less likely to 
be suitable for revision surgery due to their co-morbidities. This likely explains the observed difference 
between patients potentially requiring revision and the numbers of revision procedures performed. 
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4.4.2 Smoking 
An attempt to explore the possible relationship between cigarette smoking and hip implant survival was has 
been made. Of the study group 40 hips (17.8%) of the 226 hips were smokers. At the review 13 hips of the 
smoking group had been revised, however this difference was not statistically significant p =0.2838. Similarly 
the Kaplan-Meier survivorship analysis (Figure 4.3.3) does not demonstrate poorer survival outcomes in 
patients who smoke. This study supports previous work that smoking does not affect the longevity of 
cemented joint replacements196.  
 
4.4.3 BMI 
The effect of BMI on the short and long-term outcome of THR is controversial in the literature. Whilst on the 
one hand the increased joint reaction forces caused by excessive load would be expected to result in increased 
abraded particles of polyethylene the lower functional demands, hence reduced number of wear cycles placed 
on the prosthesis by the more sedentary patient may more than counter this effect. 
 
A recent publication by McLaughlin et al212 concluded  that obese patients had no worse clinical radiographic 
outcomes nor did they have any increased complications following THR in comparison to a group of normal 
weight patients. Previous authors have shown that operating on morbidly obese patients (BMI >40) has an 
adverse effect on the outcome of joint replacement surgery218.  
 
The effects of obesity on joint replacement longevity were not found to be significant in this study. There was 
a higher failure rate observed in the overweight and obese cohort when compared to the normal weight 
patients (90% vs 97% survivorship), but this difference was not found to be significant. Recently there have 
been efforts to limit the option of joint replacement to the obese patient. The benefit to the obese patient of 
joint replacement is the same as to the non-obese patient218. There is no evidence for this rationing, and whilst 
anaesthetic risk may be increased we have demonstrated that in this series there is no statistically significant 
effect on longevity associated with total joint arthroplasty in the obese. 
 
4.4.4 Age 
The effect of age on total joint replacement is well studied. The increased activity levels associated with a 
younger group of patients who have undergone implantation of traditional metal-on-polyethylene 
components has resulted in a much higher observed failure rates in young patients1;36;206. 
The reproduction of this finding in a reliable manner in this cohort adds weight to the strength of the data. Not 
only was there a statistically significant difference between mean age in the failure and surviving cohorts but 
failure rate was consistent higher in the young cohort throughout the period of the study in keeping with the 
observations of population based studies. 
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4.4.5 Non steroidal anti-inflammatory Drugs (NSAID) Use 
The use of NSAID’s is widely accepted for the treatment of pain in osteoarthritis, however NSAIDS are known 
to interfere with bone metabolism. Whilst NSAIDs do have different mechanisms of action all commonly used 
NSAIDs have been found to have similar effects on bone. NSAIDs have been shown to inhibit fracture 
healing266-268, and COX-2 has been implicated in osteolysis268;269. Given this evidence, and coupled with some in 
vivo evidence that NSAIDs may inhibit important osteolytic pathways one might expect patients who are 
known to use NSAIDs to have a lower failure rate.  
 
There was no statistically significant difference between the rate of NSAID use in the surviving and failure 
groups (p=0.2233). One quarter of all patients in the study had taken NSAID’s at the time of operation, 
however it was not recorded if patients at their final review were continuing to take NSAID’s, or if they had 
taken them throughout the intervening years. It would be important to have access to this data to determine 
any relationship with aseptic loosening. 
 
Despite these limitations, and the lack of statistically significant difference there was a lower survivorship in 
the group not taking NSAIDs supporting, but not proving previous basic science studies and laboratory findings 
outlined elsewhere in this thesis. 
 
4.5 Conclusion 
The failure of THRs are predictable to certain extent from pre-operatively observed patient factors. We have 
demonstrated that in long term follow-up patients who are under 65 years of age and have a co-morbidity 
score >3 are at significantly higher risk of failure of their joint replacement. Overweight patients and those 
who smoke should be followed up more carefully as although not significant there was a higher failure rate in 
these groups. We have confirmed that there is no predisposition to failure of a joint replacement based on the 
patients age, sex, preoperative diagnosis or smoking status. 
 
The follow-up patterns for total joint arthroplasty should be determined to a certain extent based round 
patient factors. An awareness of those factors likely to make a patient more at risk of failure will improve pre-
operative decision making, providing an informed consent and will aid in designing post operative follow up 
protocols. 
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SECTION 5 : RADIOGRAPHIC DETECTION OF OSTEOLYSIS 
 
5.1 Background 
Radiographic assessment of osteolysis and radiolucent lines is an essential part of the routine follow-up of 
total joint arthroplasty. Although highly specific, anteroposterior (AP) radiographs have been shown to be only 
38%-41% sensitive for osteolysis 226;270. In some centres it is therefore established practice to take an 
additional lateral radiograph to both improve sensitivity and for evaluation of prosthesis position. Both 
computer simulations 226 and cadaveric bone studies 270 have demonstrated that the Judet iliac oblique (IO) 
views may be more sensitive than the lateral views in detecting radiolucent lines. Despite these findings there 
are no clinical studies evaluating the use of differing radiographic views in the routine surveillance of total hip 
arthroplasty.  
 
The aim of this part of the study was to assess the sensitivity of the iliac oblique, anteroposterior, and the 
lateral hip radiograph in detecting radiolucent lines in a cohort of patients undergoing 10 year follow up of 
their total joint arthroplasty (THR). Individual radiographs and possible combinations will be assessed against 
the “gold standard” of all three views to determine the most effective way to diagnose osteolysis on plain 
films.  
 
5.2 Materials & Methods 
The study was granted Ethics and Research Governance approval. The patient cohort had all undergone a 
cemented Charnley Elite Plus THR with a 28 mm Ortron 90 head and a cemented matched polyethylene cup in 
our institution in 1995. The patients were prospectively followed up in the local arthroplasty surveillance 
programme, and had had standardised AP and lateral films taken postoperatively, at 5 years and were then 
undergoing their 10-year follow-up. At their 10 year follow-up, in addition to their routine AP and lateral 
radiographs, a modified Judet iliac-oblique view was performed.  
 
The radiographs were all taken in a standardised manner. The AP pelvic films (Fig 5.1) were taken with the 
patients positioned supine; the anterior superior iliac spines were equidistant from the table top, the femora 
internally rotated and the heels separated. The film and beam were centred 2.5 cm above the symphysis pubis 
with a focal film distance of 115 cm and the beam collimated to include the proximal femora. A standardised 
exposure of 81kVp and 16mAs was used. The lateral films (Fig 5.2) were taken with a horizontal beam. The 
patients were placed supine with their feet vertical. The cassette was positioned parallel to the femur and the 
film centred midway between the femoral pulse and greater trochanter. A horizontal beam at 80kVp and 
70mAs exposure was used. The IO films (Fig 3) were taken with the patient supine, centred on the hip joint. 
The patient was positioned with the trunk rotated 45º towards the affected joint with the hip and knee in 30º 
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of flexion. A small pillow was placed under the contralateral buttock. The film was collimated to include the 
iliac crest and proximal femur and exposed at 81kVp and 20mAs. 
 
Figure 5.1 : Standardised AP Radiograph 
 
Figure 5.2 : Standardised Lateral Radiograph 
 
Figure 5.3 : Standardised Iliac Oblique Radiograph 
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All radiographs were assessed for signs of loosening separately by two independent observers according to the 
criteria of Johnston et al. Radiographs were reported in conjunction with post-operative and mid-term (mean 
6.4 year) radiographs of the same view. Agreement between both observers was necessary for data to be 
included and, when disagreement occurred, a consensus view was obtained with a third observer. Each film 
was evaluated for evidence of radiographic loosening. The presence, location46;271 and size of osteolytic lesions 
and radiolucent lines were recorded about both the acetabular and femoral components on each of three 
views. The sensitivity of each radiographic projection and each possible combination was then calculated with 
all three views in combination taken as a gold standard. 
 
Radiographs of all patients in all three projections were available for review on the PACS system. Seven 
femoral and three acetabular zones were examined in the three radiographic projections. Ninety six patients 
were entered into the study giving 672 individual femoral zones in each projection, and 288 acetabular zones. 
 
Statistical analysis was performed using GraphPad Prism (GraphPad Software Ltd, Chicago IL). Fisher’s exact 
test was used for categorical data. A ‘p’ value of less than 0.05 was defined as significant in all cases. A 
validation exercise was performed with 10 radiographs and showed excellent inter-observer reliability 
(=0.94). 
 
5.3 Results 
Evaluation of all three views demonstrated radiographic evidence of radiolucent lines or osteolysis in one or 
more zones on any view in 97% of the patients. However only 2% fulfilled Harris’ criteria for definite 
loosening33.  
 
Radiographic evidence of early loosening in either the femoral or acetabular component in a single zone or 
more was seen in 79% of AP, 18% of lateral and 87% of IO radiographs. The relative sensitivity of a single view 
showing evidence of loosening when compared to all three views was 0.81 for the AP, 0.18 for the lateral and 
0.9 for the IO radiographs (Table 5.1). If two views were reported together the relative sensitivity (when 
compared to all three views) of an AP and lateral view was 0.81 compared to an AP and IO sensitivity of 1.0, 
this difference was statistically significant (p=0.03).  
 
 
Views Taken 
AP Lateral IO 3 Views AP & Lat AP &IO 
% Positive 79% 18% 87% 97% 81% 97% 
Sensitivity 0.81 0.18 0.90 1.00 0.83 1.00 
Table 5.1: Sensitivity of each radiographic film and combination 
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5.3.1 Acetabular Components 
The radiographic appearance of the acetabulae are summarised in Table 5.2. Radiolucent lines were visible in 
43.4% (n=125/288) acetabular zones on the AP radiograph, 13.2% (n=38/288) on the lateral projection and 
29.8% (n=86/288) on the IO The AP was significantly more sensitive than the other views (p<0.0001) and the 
IO significantly more sensitive than the lateral (p<0.001). Osteolytic lesions were seen in seven patients (7 
zones) on the AP and lateral films, but in 16 patients (19 zones) on the IO films. The IO projection was 
therefore statistically more sensitive than the other views (p=0.0018). 
 
 Acetabulae (288 zones) 
Projection Radiolucent line Osteolysis 
Antroposterior (AP) 43.4% (n=125)*   2.4% (n=7) 
Lateral (Lat)   13.2% (n=38) 2.4% (n=7) 
Iliac Oblique (IO)   29.9% (n=86)# 6.6% (n=19)£ 
Table 5.2 : Acetabular radiographic evidence of loosening detected on each projection. 
*
Significantly better than any view p<0.0001. 
#
Significantly better than lateral view p<0.001. 
£
Significantly better than other views 0.0018 
 
5.3.2 Femoral Components 
The radiographic findings of the femora are shown in Table 5.3. The cement-bone and prosthesis-cement 
radiolucent lines were reported separately. Radiolucent lines were visible in 5.1% (n=34/672) of zones at the 
cement-bone and in 10.9% (73/672) of zones at the prosthesis-cement interface on the AP radiograph. The 
lateral film demonstrated radiolucent lines in 1.7% (n=12/672) of zones at both the cement-bone and 
prosthesis-cement interfaces. Evaluation of the IO films showed radiolucent lines at the cement-bone interface 
in 10.9% (n=73/672) of zones examined and 4.0% (n=27/672) at the prosthesis-cement interface. The IO was 
statistically significantly better than the other views for detecting radiolucent lines at the bone-cement 
interface (p<0.001) whilst the AP projection was significantly better at detection of prosthesis-cement 
radiolucencies (p<0.001). 
 
 Femoral (672 zones) 
Projection Radiolucent line Osteolysis 
Cement-bone Prosthesis-cement 
Antroposterior (AP) 5.1% (n=34) 10.9% (n=73)# 2.5% (n=17) 
Lateral (Lat) 1.8% (n=12) 1.8% (n=12) 1.0% (n=7) 
Iliac Oblique (IO) 10.9% (n=73)# 4.0% (n=27) 3.4% (n=23)* 
Table 5.3 : Femoral radiographic evidence of loosening detected on each projection. Significantly better than lateral or IO p<0.001. 
* 
Significant difference compared to lateral p=0.013 
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Osteolytic lesions were seen in the femora of 17 patients on the AP, 7 on the lateral films and 23 of the IB 
films. The IB projections was statistically significantly better than the lateral film for detection of femoral 
osteolysis (p=0.013). 
 
5.4 Discussion 
Accurate radiographic assessment is a key part of effective long term arthroplasty follow up, not only as a 
diagnostic aid for asymptomatic loosening, but also to plan revision surgery. Despite widespread use of plain 
radiographs for THR follow-up, there is no accepted consensus as to which projections, and how many should 
be performed. When used in combination plain AP and lateral films are reported to be only 85%-89%39;272 
sensitive. 
 
Whilst the rates of radiolucent lines and osteolysis in this study may appear high, the cohort of patients 
selected for this study has previously been reported to have a high rate of radiographic failure recognised at 
6.4 years post THR and this has been confirmed at 12 years post THR2. To establish the effectiveness of plain 
films as a screening tool for radiographic failure it is essential to use a cohort of patients with a high rate of 
expected failure.   
 
In this study use of a single AP radiograph demonstrated radiographic evidence of loosening in at least one 
zone in 79% of arthroplasties, as compared to 97% when all three views were utilised. The use of the IO film 
alone demonstrated radiographic change in 87% of arthroplasties, when compared to just 18% of lateral films. 
Addition of an IO film to an AP brings the positive rate to 97%, whilst combination of the AP and lateral 
demonstrated abnormalities in 81%. The addition of a lateral film to an AP projection does not significantly 
improve the sensitivity (p>0.05) of the AP alone. In this series the addition of the lateral film conveyed no 
additional information over a single AP film. 
 
Assessment of the acetabulum for osteolytic defects demonstrated focal cavitatory lesions in 19 zones on the 
iliac oblique film, but only 7 on the AP or lateral projections. This data confirms in a clinical setting what 
previous studies with computer simulations226 and simulated defects in a cadaveric pelvis270 have 
demonstrated regarding the value of oblique films of the pelvis for detection of osteolytic lesions. 
Hodgkinson32 has argued that acetabular radiolucent lines are predictive of acetabular component loosening. 
In this series radiolucent lines, although not osteolytic defects, around the acetabulum were seen significantly 
more commonly on the AP film. This finding is supported by a previous study Kawate & Yajima227 examining 
radiographic assessment of cement mantle thickness in the acetabulum. 
 
Adequate radiographic assessment of femoral component loosening requires assessment of radiolucent lines 
and osteolytic lesions33;34. The detection of these changes on plain AP radiographs is the commonly accepted 
practice223. In this study the AP view was significantly more sensitive for prosthesis-cement radiolucencies than 
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any other projection (p<0.001). The IO was the most sensitive view for cement-bone radiolucent lines 
(p<0.001). For the femoral component, the lateral view was statistically inferior to either the AP or IO views for 
all radiographic changes (p>0.05). 
 
In this study, the lateral projection was the least sensitive view for both radiolucent lines and osteolysis in the 
femur and acetabulum. In evaluation of loosening the lateral view did not offer any additional information 
over the IO or AP projections alone. The lateral however does provide an orthogonal plane for assessment of 
implant position. Implant position has been associated with longevity of the hip replacement273, and there may 
therefore be a role in a postoperative lateral film for prognostic value.  
 
It is well established that addition of further imaging modalities can be used to increase the detection rate of 
early prosthetic loosening. Imaging modalities such as subtraction arthrography272;274, nuclear 
arthrography272;275 and bone scintigraphy272;276 have all been used to increase the detection rate of early 
prosthetic loosening. Due to high dosage of radiation or the invasive nature of the procedure, these 
investigations are commonly used only when there is evidence of radiological change on plain x-ray.  
 
Whilst it is a limitation to this study that we did not compare plain radiography with these other imaging 
modalities, we did not aim to establish the overall sensitivity of plain radiographs, rather to establish in the 
follow-up and screening setting the most effective combination of plain films to demonstrate radiographic 
evidence of loosening. There are no similar clinical studies evaluating this and the data presented 
demonstrates the combination of AP and IO films to be significantly more sensitive than the commonly used 
combination of AP and lateral films. 
 
In plain radiographic surveillance of total hip arthroplasty substitution of the lateral film with a modified iliac 
oblique improves sensitivity for radiolucent lines and osteolysis. We would recommend this simple change to 
improve the sensitivity and therefore effectiveness of joint surveillance programmes for radiographic evidence 
of failure. 
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SECTION 6 : PATIENT OUTCOME MEASURES AND FAILURE 
 
6.1 Introduction 
The long term follow up of post hip arthroplasty patients represents a significant challenge to all developed 
health care systems. Whilst the failure patterns of arthroplasty and the failure rates for individual prosthesis 
are well described by the joint registries it is important to identify individual patients with failing arthroplasties 
prior to catastrophic failure and fracture. Early identification of a failing arthroplasty allows for simpler revision 
surgery prior to catastrophic failure such as advanced osteolysis, peri-prosthetic fracture or component 
fracture. 
 
In the early development of joint replacements it was appropriate for patients to be seen regularly by their 
operating surgeon however with an increasing proportion of the population having a joint replacement and 
ever increasing healthcare costs the follow up burden is immense.  Increasingly NHS trusts are turning to ‘joint 
review programmes’ to provide clinical follow up without the health economic burden of unnecessary clinic 
visits and radiographs. Whilst for the majority of elderly patients it is unlikely that they will require revision 
surgery, in last year’s British Joint Registry report revision surgery constituted 10% of all procedures 
performed. The most common mode of failure for total hip replacements reported on the registry was 
osteolysis, which is normally silent in the early stages. 
 
Joint review programmes vary in their structure, but have a common theme of structured, often nurse led, 
review. The patients are not seen in the usual manner in clinic, but reviewed either by a joint review 
practitioner (normally a nurse or physiotherapist) with additional information in the form of radiographs and 
postal questionnaires. Patient outcome scores are becoming an important component of such review. In some 
centres Patient Reported Outcome Scores (PROMS) in conjunction with radiographs are being increasingly 
relied upon to guide the decision to review the patient clinically. In some centres a PROM score is being used 
as the sole outcome and surveillance measure. 
 
Outcome scores in joint replacement vary in the structure, design, administration and validation. None of the 
commonly used outcome scores are validated for use as a surveillance tool for failing arthroplasties, and it is 
unclear if this is a valid use of measures designed for a different purpose. 
 
The benefit of this approach has not been established and the sensitivity of these scores has yet to be 
determined for osteolytic change in total hip replacement. Whilst some outcome scores have been validated 
to be sensitive for post operative function following primary arthroplasty, no score has been validated as a 
long term surveillance tool, and it is unclear if any score is specific or sensitive enough detect failing hip 
replacements that potentially require revision. The aim is to establish the value of a variety of commonly used 
PROMs and other outcome measures in detecting early osteolysis without formal clinical patient review. 
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6.2 Materials & Methods 
In order to establish the benefit of the ‘Joint Review Programme’ approach patients undergoing their 10 year 
post arthroplasty follow up were enrolled into this arm of the study. In addition to radiographic and clinical 
review patients completed one of a number of outcome questionnaires. Three cohorts of patients were 
evaluated, all being followed up with a different combination of questionnaires. The five questionnaires were 
the Harris Hip Score (HHS), Merle d’Aubigne Score (MDA), Oxford Hip Score (OHS), Hospital for Special Surgery 
Score (HSS) and a Visual Analogue Score for pain (VAS). 
 
The patient cohorts were identified using the arthroplasty registers in two hospitals (The Norfolk and Norwich 
University Hospital, and the West Suffolk Hospital). Three cohorts of patients were identified who were 
already undergoing annual clinical, radiographic and patient reported scoring as part of their surveillance 
programme. These cohorts were identified as all patients had a similar cemented metal on polyethylene THR, 
and the follow-up protocol was identical in each case, bar the use of a different patient outcome score. These 
were non-selected cohorts of patients, and the whole cohort was included in each case, although each was 
operated on by a different surgical team.  
 
Patients in these cohorts were reviewed clinically at 10 years prior to the start of this investigation, and the 
decision to revise their prosthesis or not had already been taken without access to the hip outcome scores. 
The patients were accordingly divided into a failed and surviving group based on the outcome of this 10 year 
review. Patients who were offered revision surgery were defined as failures. In all cases the indications for 
revision were similar; pain in the presence of radiographic evidence of loosening. Patients who were offered 
revision surgery, but declined, were also counted as failures for the purposes of this study. 
 
Individual scores collected as outcome measures at the time of the 10 year review were identified from the 
arthroplasty database at each hospital, and the outcome of the clinic attendance through examination of the 
patients notes. The scores were collected in these cases as outcome measures, and not as part of the hip 
surveillance programme. 
 
The mean scores in each group were calculated, and a two tailed Student’s T test used to assess for significant 
differences between the failed and surviving cohorts. An alpha error of 0.05 was defined as significant in all 
cases. Data were further analysed with ROC analysis as previously described (Chapter 3) to assess the 
sensitivity and specificity of each score for detecting failure and to compare the usefulness of each score as a 
screening tool. 
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6.3 Results & Discussion 
Four hundred and twelve patients were identified in two institutions who had been prospectively followed up 
for at least ten years, and had completed regular questionnaires. The patients were divided into four separate 
cohorts:  
 Sixty six patients with Biometric stem/universal cup were identified who had been followed up with 
the hospital for special surgery score (HSS). 
 Ninety two patients scored with the Oxford hip score (OHS) who underwent Elite Plus (DePuy, Warsaw 
Indina) total hip replacements were included at their 10 year follow up visit.  
 A cohort of 149 patients who underwent Exeter Universal total arthroplasties were followed up with 
the Merle d’Aubigne (MDA) for a total of ten years.  
 A further cohort of patients who received Exeter Total Hip replacements was included at their 12 year 
follow-up visit. These patients were scored with the Harris Hip score and also a visual analogue pain 
score (graded 0-10).  
 
6.3.1 Scores Divided by Patient Outcome 
The scores for each cohort are given (Table 6.3.1). There were statistically significant differences between the 
patients scored with the HSS (Surviving 55.7 vs Failed 50.6 p<0.005), Harris Hip Score (Surviving 78.0 vs Failed 
46.9 p <0.0001) and VAS (Surviving 9.0 vs 5.2) between the surviving and failure groups. There was no 
statistically significant difference between the groups scored with the Oxford score, although the surviving 
arthroplasties scored 4 points better than the failed group (Surviving 22.2 vs 26.1 p=0.1176). There was no 
difference in the mean values between the subgroups scored with the MDA score.  
 
Score Group Number Mean St Dev p= 
HSS Surviving 46 55.7 5.06  
 Failed 16 50.6 5.01 0.0005 
Oxford Surviving 40 22.2 11.15  
 Failed 52 26.1 11.92 0.1176 
MDA Surviving 142 15.0 2.12  
 Failed 6 15.0 2.08 0.96 
Harris Surviving 95 78.0 15.59  
 Failed 10 46.9 18.34 <0.0001 
Pain Surviving 95 9.0 8.86  
 Failed 11 5.2 10.09 <0.0001 
Table 6.3.1 : Mean Scores and Significance values 
 
6.3.2 Scores Distribution 
The distribution of each score is given (Figure 6.3.1). As can be seen the spread of data differs between 
subgroups in cohorts bar the MDA score. Interestingly the Harris score is associated with a large number of 
outliers in the surviving cohort, which is not seen with the other scores. This represents patients with a low 
score, who do not require revision surgery, a false positive result.  
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Score Distributions by Outcome
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Figure 6.3.1 : Box & Whisker Plot. Distributions of scores, means and 95% confidence intervals per subgroup 
 
6.3.3 ROC Analysis 
The ROC analysis tables are given in full in the appendix and ROC curves have been plotted from this analysis 
(Figure 6.3.2). The area under the curve (AUC) is given and is analogous to the predictive value of the scoring 
system for arthroplasty failure (Table 6.3.2). All three scores (HSS, HHS, VAS) that showed statistically 
significant differences between the failed and surviving groups were highly predictive of loosening with an 
AUC of >0.70. The calculated ROC curve was significantly different from chance in each case. 
 
Although all three scores were predictive of failure the HHS (AUC 0.89) and VAS (AUC 0.90) outperformed the 
HSS (VAS 0.77). Based on these results (see appendix for full results) screening patients with the HHS for 
loosening using a threshold value of <55.5 could be 80% (95% CI = 44.4 to 97.5 %) sensitive and 91% (95% CI = 
84.1 to 96.3%) specific for aseptic loosening. The VAS marginally outperforms this and using a threshold of VAS 
>2 would be 82% sensitive (95% CI = 48.2 to 97.7%) and 87% Specific (95% CI = 79.0 to 93.1). 
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Score AUC p= 
MDA 0.50 0.94 
OHS 0.60 0.095 
HSS 0.77 0.0009 
HHS 0.89 <0.0001 
VAS 0.90 <0.0001 
Table 6.3.2 ROC Analysis scores 
 
It appears likely that the discriminatory power of the Harris Hip Score is due to the large component of the 
total score that is derived from the pain score (50%) as is seen by the marginally improved scoring for the VAS. 
What is interesting is the wide disparity between accepted hip outcome scores as instruments to discriminate 
between failing and well performing hips at their follow up. While all the scores used have been validated as 
outcome measures for success of the arthroplasty it would appear that selection of score has a large bearing 
on the value of the score for hip arthroplasty surveillance. Encouragingly all scores showed some change 
between the two groups. 
 
It is difficult to explain the failure of any score to improve on the VAS score, this may be due to the high 
specificity of the score. It is well recognised that outcome measure including a functional component suffer 
from the inability to discriminate between pathology in the same limb and else where208. The response to a 
question on walking distance for example could be reflective of limits imposed on the patient by conditions as 
diverse as congestive cardiac failure, vascular insufficiency, spinal stenosis and cerebrovascular accident.  
Whilst pain may radiate and may come from other sites it is more sensitive and specific to ask the patient to 
complete a VAS than any other measure228. An alternative explanation is that the decision to revise the 
prosthesis may be bias towards a pain score. Patients in pain are more likely to request or agree to revision 
surgery than those with ‘silent’ failure. 
 
Although early revision may be desirable to prevent peri-prosthetic fracture it is often difficult to predict who 
will require surgery as most implant failures are painless in the initial stages. Annual clinical and radiological 
follow-up is the benchmark to detect early failure but is labour intensive and financially expensive. On this less 
resource intensive alternatives to follow-up are being implemented. There are many validated scoring systems 
in current use for the evaluation of hip replacement. However, all of these scores have been designed as a 
measure of clinical outcome and none are validated to monitor for failure. Whilst it seems to make sense that 
a failing hip replacement is likely to perform more poorly than a successful one and therefore have a lower 
score there is no previous data to assess the sensitivity or reliability of outcome measures in arthroplasty 
surveillance. 
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Whilst this study goes some way to attempting to validate the use of outcome measures for arthroplasty 
surveillance it is limited in that it does not evaluate serial measurements of the same patient. It is known that 
hip scores do change over time, and as such a single measurement may not be enough to answer the question 
“Is it loose?”, and differing threshold values may be required at different follow up periods.  
 
6.4 Methodology and Weaknesses 
This study is a retrospective study, and assesses patients in whom the outcome has already been determined 
through clinical review. Whilst this has the potential benefit that the patients score has not influenced the 
decision to revise, and therefore minimises the potential for observer bias, it does potentially introduce other 
forms of bias. 
 
The patients are all from different cohorts, and so as such there is no guarantee that there are the same 
selection of symptoms, or even that there outcomes are standardised. Whilst including patients who are being 
followed up in the same review programme reduces that potential for selection bias there is still that 
possibility. 
 
A better study methodology would be to administer all questionnaires to each patient, and then blind the 
clinician performing the follow-up review to the results of the outcome score and assess which scores most 
closely reflect the clinical decision made. This would however require a prospective study undertaken over a 
ten year follow up period, making it impractical within the time constraints of this study. 
 
Whilst this study is flawed in it’s design it does provide some measure of the sensitivity and specificity of 
various scores for detecting aseptic loosening around the hip, and is the first study to do so. The use of 
prospectively collected scores which have not been used in the clinical decision making process reduces the 
likelihood of observer bias.  
 
6.5 Conclusion 
This data demonstrates that there is value in the use of patient reported outcome measures in the follow up of 
hip arthroplasty. This study demonstrates that PROMs may be used with acceptable sensitivity and specificity 
as a screening tool for arthroplasty follow up, and justifies the use of these instruments as screening tools for 
aseptic loosening in hip replacement. 
 
Despite the methodological flaws this study adds valuable information on a previously unstudied field. The 
wildly differing findings in the sensitivity and specificity of these scores for hip surveillance should be 
considered when hospitals are designing their arthroplasty follow up protocols.  
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Use of the VAS for pain as a single follow up tool for hip arthroplasty compares favourably with the published 
results for radiographic review.  Using a threshold of VAS >2 would be 82% sensitive and 87% specific, 
comparing well with standard AP and lateral radiographs reported to have a sensitivity for component 
loosening of between 85-89%. 
 
The failure of any hip specific score to outperform a VAS for pain does raise some questions about the 
reliability of these measures. Are these scores failing on face validity – are we really measuring hip 
performance, or are they so influenced by co-morbidities that PROMs fail to add anything to the simple 
question “Does your hip hurt?” 
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Figure 6.3.2 : Receiver Operator Curve. Sensitivity vs specificity for failure by score.
  Page 122 
 
SECTION 7 : CONCLUSION 
 
The primary objective of this study was to evaluate if patient specific factors had any role to play in the process 
of periprosthetic osteolysis. The answer to this question is resoundingly “yes”. The study has demonstrated 
that patient specific factors both biologically and epidemiologically  have a key role to play in osteolysis. It has 
also established improved methods for radiographic and clinical follow up of patients with a total joint 
arthroplasty.  
 
Returning to the original study questions (Chapter 2) we are able to answer the majority of these to a greater 
or lesser degree, and have taken some steps towards unpicking the process of osteolysis, and how it varies 
from patient to patient. 
 
1. Does the osteolytic cascade vary from patient to patient? 
This question is difficult to answer has a whole, and as has been previously outlined is best answered as a 
series of smaller questions. 
 
a. Can we reliably measure gene expression in osteoarthritic human joints? 
Gene expression through both manual TaqMan and TLDA expression analysis was successfully 
performed on the majority of the tissue retrieved intra-operatively. Of the patients who were initially 
included in the study 67 had RNA extracted and reverse transcribed passing quality control  for RNA 
extraction, lack of contamination and stability of housekeeping gene expression. Further quality 
control steps with assessment of intra- and inter- observer error demonstrated the technique to be 
reproducible. Despite the fibrous nature of hip tissue it has been possible to quantify gene expression 
through RNA extraction in a reliable and reproducible manner.  
 
Some patients failed the quality control steps, which is a usual finding in this type of study and is 
explained by the exacting laboratory technique for PCR studies, with any technique errors being 
multiplied many thousands of times. The addition of quality control steps and intra- observer reliability 
testing makes the results of this study robust and believable.  It seems highly likely that the gene 
expression was reliably measured in the samples taken for this study. 
 
b. Does osteoarthritis differ in biological environment from patient to patient? 
Analysis of the gene expression ranges in the primary joint tissues tested demonstrated a mixture of 
variation in primary joint tissues. Coefficient of variation ranged between 3 and 202, showing some 
genes had uniform expression, whilst others had greatly varying expression. The results of this study 
were interpreted in light of this finding. 
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c. Is there any observed variation local or global within the joint? 
Variation of gene expression was measured both with the manual TaqMan method, and the with the 
TLDA method. Although limited samples were taken, with only two tissues being sampled there was 
highly consistent gene expression rates between these two tissues, and between different control 
samples from the same tissue (correlation coefficient range 0.77-0.98). 
 
This observation is interesting, and demonstrates a consistent intra-articular environment which is 
similar between tissues within the joint. This suggests that the disease process of osteoarthritis 
represent a global, rather than local change within the joint. Further study is required in this area to 
look at a more comprehensive set of tissue samples. 
 
d. Do joints with osteolytic change have a different gene expression pattern to native hip joints? 
In the majority of genes tested there were significant differences between the groups. This is likely a 
result of the selection of genes, which was based on a review of the literature and selection of genes 
previously implicated in animal models or human studies of osteolysis. Of the 68 genes eventually 
included in the analysis 35 reached statistically significant difference between the study groups and 
the primaries. 
 
There was a marked difference in gene expression in this study between the osteolytic group and 
primary arthroplasties. 
 
e. Are these changes due to the joint replacement in situ, or to loosening itself? 
This has been a more difficult question to conclusively answer, however sixteen genes were identified 
where expression levels were highly predictive of the presence of a loose arthroplasty, rather than 
simply an arthroplasty being present. 
 
This is the first study of this type to establish which of these factors are associated with an osteolytic 
response, rather than simply the response to a joint replacement in situ. It is possible that these 
factors could be used as tissue or serum markers for osteolytic change in the future. 
 
f. Are observed biological changes wear debris related or do they represent a tendency to loosen? 
It is impossible to conclusively answer this question with the current study design. Without following 
patients from the implantation of their arthroplasty through the failure of their joint replacement it is 
not possible to say if there is a biological tendency to loosen. 
 
However this study has established that there are differences in baseline expression of genes between 
patients, and that those same genes are implicated in the process of osteolysis rather than simply in 
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the response to wear debris. It certainly seems plausible based on these results that osteolytic change 
may be in part due to a patient “tendency” towards osteolysis. 
 
2. What are the patient characteristics most likely to predispose to joint loosening? 
There are a number of patient risk factors that have been identified as contributing to osteolytic change, 
and failure of THRs are predictable from pre-operatively observed patient factors. Over long term follow 
up patients under 65 years of age and with greater co-morbidities are at significantly higher risk of failure 
of their joint replacement. This study suggests that overweight patients and those who smoke should be 
followed up more carefully as there was a higher failure rate in these groups.  
 
3. What is the best radiographic evaluation of osteolysis? 
Diagnosis of osteolysis is key to preventing the excess morbidity and health economic complications of a 
periprosthetic fracture. Careful evaluation of commonly used radiographic views demonstrated clearly 
that the currently used combination of anteroposterior and lateral films is inferior to an anteroposterior 
and iliac-oblique film. 
 
4. Is it possible to use a patient administered outcome scores to identify osteolytic arthroplasties? 
Although in common use patient administered outcome scores have not been evaluated for their 
sensitivity and specificity. Unsurprisingly the questionnaires evaluated here all performed with different 
sensitivities and specificities. Surprisingly the best scores (visual analogue, and Harris) performed with 
similar specificity and sensitivity to traditional radiographs. 
 
During the course of the study several incidental findings have been of interest. It was possible to establish 
that some additional pathways are likely to be involved in osteolysis that have not been previously identified. 
We were also able to establish that each osteoarthritic joint had a different local environment, and that while 
that varied between joints it did not vary appreciably throughout the joint tissues studied. 
 
This study has made the first steps towards identifying which host pathways are responsible for variation 
between patients, and in addition opening up a new area for further research and understanding of the 
osteolytic pathway. We have also established some simple changes of practice that will benefit patients 
through earlier and more accurate diagnosis of their osteolytic joint. 
  
There are a number of unanswered questions raised by this work, and a number of areas where further 
investigation could yield some interesting and clinically relevant results. 
 
1. Peripheral Blood Expression. Having established that each primary OA joint is different, and that there 
are a number of traits that may be associated with eventual osteolytic loosening it would helpful to 
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establish if the tissue expression measured within the joint is reflected in the peripheral blood i.e. is 
the consistent biological environment found across the joint reflected in the peripheral blood. This 
could potentially allow identification of individuals at risk of loosening without the need for invasive 
tissue sampling. This study is currently being performed. 
 
2. In-situ Hybridisation and Histopathology . Although the aim of this study was not to establish the 
mechanism of aseptic loosening, but rather to establish which pathways may be involved in variation 
between individuals a number of the pathways investigated have for the first time been implicated in 
the process of osteolysis. Further investigation with in-situ immunofluorescence would allow 
localisation of these factors within the tissue and potentially explain where these observations fit into 
what is already known about osteolysis 
 
3.  Bilateral hip replacements. Many patients suffer from osteoarthritis of many joints, and hence 
undergo several primary arthroplasty procedures. An extremely valuable extension to this study would 
be to take samples from different joints of the same patient. These samples could be used to establish 
if the ‘biological’ environment found in this study was common to the whole patient, or was a factor of 
the individual joint at the time of tissue sample.  
 
This study has demonstrated that patient specific factors of a biological and epidemiological conclusively play a 
role in the process of osteolysis. On the basis of these results further research is justified in a number of areas.  
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         DEPARTMENT OF TRAUMA & ORTHOPAEDICS 
TELEPHONE:  01603 287850        NORFOLK & NORWICH UNIVERSITY HOSPITAL 
FAX:  01603 287498                                                   COLNEY 
                                                        NORWICH   NR4 7UY 
01603 286286 
 
PATIENT CONSENT FORM 
 
Osteolysis in total joint arthroplasty – are patient factors important? 
 
Investigators- Mr Ben Ollivere, Mr James Wimhurst, Miss Clare Darrah, 
Mr Simon Donell 
 
Patient Initials:  Date of Birth:  Hosp. No: 
             
          Initials 
 
1) I confirm that I have read and understood the attached information sheet            
and have had the opportunity to ask questions 
 
 
2) I understand that my participation is voluntary and I am free to                           
     withdraw at any time without giving any reason, without my medical care 
     or rights being affected 
 
 
3) I agree that my GP will be informed about my participation in the study            
 
4) I agree to take part in the above study                      
 
 
 
-------------------------  ---------------- --------------------------- 
Name of the patient               Date   Signature 
 
 
 
 
-----------------------------  --------------------- --------------------------------- 
Name of the investigator  Date   Signature 
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         DEPARTMENT OF TRAUMA & ORTHOPAEDICS 
TELEPHONE:  01603 287850        NORFOLK & NORWICH UNIVERSITY HOSPITAL 
FAX:  01603 287498                                                   COLNEY 
                                                        NORWICH   NR4 7UY 
01603 286286 
Patient Information Sheet 
 
Study Title : 
Osteolysis in total joint replacement – are patient factors important? 
 
Invitation : 
You are being invited to participate in this research project as you are about to undergo hip 
replacement or revision surgery. Before you decide if you wish to take part in the study it is important 
that you understand what the study is about and what it involves. Please take time to read the following 
and talk to others if you wish. 
 
You may wish to discuss this with a member of PALS, the patient advice and liason service, who can 
be contacted on 01603 286 286 (extension 5306). Your orthopaedic consultant will also be happy to 
discuss this with you. 
 
What is the purpose of the study? 
This study is being conducted to study the way in which hip replacements wear out. All hip 
replacements fail, but they last different lengths of time in different people. This study aims to see if 
differences in immune cells between different people have an effect of the longevity of a hip 
replacement. 
 
Why have I been approached? 
You have been approached as you are either having a primary (first) hip replacement or revision 
(second) hip replacement at the Norfolk & Norwich University Hospital. There is no specific reason 
you have been approached other than that you are undergoing joint replacement surgery and your 
consultant has consented for your involvement in the study. 
 
Do I have to take part? 
You do not have to take part in the study, and your treatment will not change in anyway if you decide 
to take part or not. If you decide to take part you will be asked to sign a consent form and given this 
information sheet to take away with you. 
 
What will happen if I take part? 
If you decide to take part you will be asked to give a second blood sample in addition to the samples 
you will need prior to the operation. You will not have an additional venepuncture (needle), just 
slightly more blood will be taken when you have your pre-operative blood tests. 
 
In addition some of the spare tissue from your hip that is normally incinerated after the operation will 
be kept, and tested for certain types of proteins that may give us a clue as to how people respond to hip 
replacements, and hence why they might fail. No additional tissue will be taken from you, and all 
tissue will be stored in a licensed tissue bank, anonymised by number. 
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What do I have to do? 
You will be asked to sign a consent form at pre-assessment, but there is nothing else specific you must 
do. The extra blood sample will be taken at the same time as your pre-operative bloods, and the 
samples of tissue are from tissue normally wasted during joint replacement surgery. 
What are the benefits of taking part? 
The main benefits of taking part are in contributing to our knowledge of how joint replacement 
operations are affected by the immune system of the patient. A more complete understanding of this 
may help us treat patients in the future, but will not directly impact on your care. 
 
Will my information be kept confidential? 
All information which is collected during the study will be kept confidential. Although the overall 
results will be published no individual results that could be traced back to you will be released. 
 
What will happen to the results of the research? 
The results of the various laboratory tests will be collected and analysed statiscally. It is hoped that by 
comparing various groups of patients it will be possible to identify factors that may results in early 
failure of prosthetic joints. The duration of the study will be approximately 2 years. The results of 
study are likely to be published as scientific papers, and also as part of a doctoral thesis. You may 
obtain copies of the results by contacting us after the estimated completion date of the project. 
 
Who is organising and funding the research? 
The research is being organised by a partnership between the Institute of Orthopaedics at the Norfolk 
& Norwich University Hospital, and the School of Biological Sciences at the University of East 
Anglia. The work is supported by the Gwen Fish Trust, and Action Arthritis. Two charitable bodies 
who support research into musclo-skeletal disease. 
The doctor undertaking the research is not being paid to do so, and you will not receive any payment 
for taking part in the research. 
 
Who has reviewed this study? 
Cambridge (3) REC have reviewed this study. 
 
Contact details 
For further information regarding the study please contact : 
 Mr B. Ollivere 
 C/O Clare Darrah 
 Research co-ordinator, Institute of Orthopaedics 
 Norfolk & Norwich University Hospital 
 Colney Lane 
 Norwich 
 NR4 7UY 
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APPENDIX 2 : LABORATORY PROTOCOLS 
 
Specimen Collection Protocol 
Osteolysis Study 
Ben Ollivere, Clare Darrah, Simon Donell 
 
This study aims to examine the differences between patients immune response and how this affects 
their body’s response to total hip replacement. We need to collect intra-operative samples from 
primary THR, revision THR and periprosthetic fracture patients. 
 
Primary Hip Replacement 
Surgeon’s Instructions 
 Please take samples of approximately 1cm x 1cm 
 They should be washed in saline if possible 
 They do not need to be taken with fresh instruments 
 They may be in two pieces so long as from a similar anatomical location 
Please take samples of tissue from : 
 Hip joint capsule 
 Ligamentum terres 
 A bone chip from the femoral head 
 
Scrub Nurse Instructions 
 Please inform Clare on 2551 when the patient is in the anaesthetic room, and when the samples 
are taken 
 Please place the sample in a sterile universal container (with a conical bottom), and label each 
pot with the origin of the tissue. 
 Please call Clare on 2551 when the sample is ready 
 Clare will cover the sample will be covered in RNAlater, and stored upright. 
 Samples are sent to the tissue bank labelled ‘FAO Ian Sherrifs Hip Tissue Study’ 
 
Revision Hip replacement 
The sample technique and storage are the same, but please take samples of : 
 Capsule 
 Acetabular membrane 
 Femoral membrane 
 Bone 
 
Periprosthetic fracture or revision for dislocation 
The sample technique and storage are the same, but please take samples of : 
 Capsule 
 Acetabular membrane 
 Femoral membrane 
 Bone 
 
Copies of the study protocol, patient information and consent forms are available from the Institute of 
Orthopaedics. 
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Osteolysis Study Protocol 
Tissue Extraction 
Suitable for : 
Capsule, ligamentum teres, femoral and acetabular membranes 
 
Tissue Extraction 
 
1. Thoroughly defrost tissue. Cut 1cm piece from tissue, and replace remainder in RNAlater and refreeze. 
Blot dry with sterile gauze and carefully slice on sterile petri dish to fine fragments 
2. Mix with 2mls Trizol (in fume cupboard) and use UltraTurrox to ‘blend’ tissue. NB not all tissue will 
blend, and residual is expected. Falcon (wide) tubes are best. 
3. Spin for 5 minutes. 
4. Take supernatant mix with 400 ml/ml Chloroform so 800  ml and vortex 
5. Spin down for 10 mins at 14,000. Take supernatant (top layer only no solid!) 
6. Mix 1:1 with pure ethanol. 
 
RNA Extraction Column 
For each run spin for 30 sec on desk centrifuge. Quagen RNeasy kits  
1. Run the sample 700 ml at a time through tube until all collected. Discard run off 
2. Run 700 ml RW1 through column. Discard excess 
3. Run 500 ml RPE through column. Discard excess. 
4. Repeat step 3. 
5. Swap collector to fresh ependorf. Run 30 ml water through tube 
6. Save sample and Nanodrop 
 
Nanodrop 
Use the RNA syringe, and the RNA nanodrop. 
1. Start the nanodrop software 
2. Select nucleic acid measurement 
3. Select RNA-40 from the coloured drop down box top right 
4. Place 1.5 ml analystical grade water and select ‘Blank’ 
5. Select ‘Record’ 
6. For each sample : 
a. Type sample ID into white box on right hand side 
b. Wipe clean with tissue 
c. Place 1.5 ml sample on spectrometer 
d. Click Measure 
7. Click ‘print report’ when done for summary tables. 
 
Interpreting results : 
 RNA levels above 100 ng/ml are ideal. Analysis is possible above 40 ng/ml 
 The 260/280 measurements are purity measures and should be between 1.9 and 2.1 
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APPENDIX 3: LABORATORY RESULTS 
 
Appendix 3.1 Candidate gene CT value summary 
  CT Value Range 
Gene 
Number 
Run Median St Dev Min Max 
ACP5 43 33.5661 2.622386 29.05378 40 
ADAMTS 14 12 40 1.918017 34.30355 40 
ADAMTS 2 39 34.87006 2.323608 31.85571 40 
ADAMTS 3 6 40 1.078802 36.68633 40 
B2M 45 29.73396 1.60453 26.19092 34.85827 
BAK1 0 40 0 40 40 
BCL2A1 20 40 2.971501 31.26563 40 
BMP4 24 37.00136 2.34139 33.51771 40 
CASP3 28 36.4507 2.659144 32.27854 40 
CCL18 44 32.7915 2.25033 29.44291 40 
CCL2 42 34.45749 2.315112 30.58138 40 
CCL3 37 34.90569 2.901999 30.38281 40 
CCR1 39 34.98052 2.146578 32.31565 40 
CD14 45 32.74352 1.37097 30.59909 37.00171 
CD2 23 37.41019 2.394313 32.92822 40 
CD28 26 36.44666 2.388612 33.34097 40 
CD36 40 34.02876 2.434159 31.33325 40 
CD58 40 34.94667 2.192413 31.84194 40 
CD80 7 40 1.450672 35.03566 40 
CD86 35 35.87174 2.423903 32.11194 40 
CHIT1 29 35.85667 4.983597 25.88196 40 
CILP1 35 34.30995 3.071921 30.4786 40 
COL1A1 45 29.83762 1.754838 26.1049 33.65847 
COL1A2 45 31.09769 1.8455 27.69495 36.5193 
COL3A1 45 30.78216 2.059671 26.89785 35.46236 
CSF1 43 34.39767 1.867974 30.95527 40 
CTLA4 3 40 0.798961 36.6002 40 
CTSG 29 36.12246 2.788424 28.78508 40 
CTSK 45 32.15099 1.666725 29.16348 36.81389 
CXCL10 13 40 2.159484 31.86969 40 
CXCL9 18 40 3.138086 29.88101 40 
DKK1 0 40 0 40 40 
DKK2 6 40 1.468108 33.15152 40 
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DKK4 0 40 0 40 40 
ERCC1 42 32.67963 2.868466 28.58408 40 
FASLG 2 40 0.646642 36.8782 40 
FGF18 18 40 2.207461 32.83255 40 
FRZB 15 40 2.308359 33.63761 40 
IFNg 1 40 0.446692 37.0035 40 
IGF1 37 34.81358 2.903377 29.7551 40 
IL10 18 40 2.118038 33.94907 40 
IL11 2 40 0.647567 36.77985 40 
IL12A 0 40 0 40 40 
IL12B 1 40 4.825464 7.629801 40 
IL13 0 40 0 40 40 
IL17A 0 40 0 40 40 
IL1A 1 40 0.604441 35.94529 40 
IL1B 5 40 1.735695 30.89952 40 
IL1RN 34 34.93176 3.060647 28.90755 40 
IL4 0 40 0 40 40 
IL6 16 40 2.451764 32.59131 40 
IL8 29 36.51638 3.35764 25.71296 40 
IRAK3 30 36.27755 2.715637 32.50203 40 
ITGAM 44 33.66364 1.748641 31.77 40 
ITGB2 45 32.56638 1.813996 29.5571 36.94416 
MARCO 41 33.23087 2.418824 31.12124 40 
MMP1 22 40 2.346803 33.16689 40 
MMP12 12 40 3.625256 17.61742 40 
MMP13 29 35.2654 3.350623 29.75378 40 
MMP9 44 28.73965 3.381699 23.25545 40 
NOS2 0 40 0 40 40 
PDGFA 35 35.62775 2.485594 31.75851 40 
PDGFB 34 35.37938 2.405701 33.10162 40 
PTGS2 11 40 2.037421 33.59637 40 
SERPINA3 29 36.28571 2.670849 32.22977 40 
SFRP1 29 35.64939 3.154021 30.50071 40 
SFRP2 35 33.03574 3.902975 28.03645 40 
SOST 1 40 1.153686 32.26084 40 
TGFB1 44 33.49304 1.525177 30.93756 40 
TGFB2 23 36.97233 2.509282 33.10568 40 
TGFB3 30 36.34644 2.502236 32.65017 40 
TIMP1 45 31.02616 1.298979 28.54503 33.46099 
TLR1 18 40 2.152633 33.72356 40 
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TLR2 24 36.91743 2.558957 32.78392 40 
TLR3 23 36.97402 2.966539 31.844 40 
TLR4 36 34.6432 2.49838 32.01769 40 
TLR5 32 35.51426 2.562497 32.50695 40 
TM7SF4 4 40 1.171767 34.5673 40 
TNF 14 40 2.079828 34.39137 40 
TNFRSF11A 24 36.89891 2.139238 34.22996 40 
TNFRSF11B 22 40 2.781231 32.58606 40 
TNFRSF1A 43 33.33953 1.979438 30.70426 40 
TNFRSF1B 14 40 1.988424 33.71542 40 
TNFSF10 35 34.75537 2.746066 31.56017 40 
TNFSF11 5 40 1.042711 35.9604 40 
TP53 40 35.20268 1.902355 32.92422 40 
VDR 33 36.07936 2.301988 33.21905 40 
VEGFA 36 35.46609 2.311461 32.23267 40 
VEGFB 45 31.92552 1.764105 29.3199 35.97604 
WNT10B 1 40 0.456815 36.93559 40 
WNT5A 9 40 1.685198 35.08881 40 
WNT7B 3 40 0.819798 36.46114 40 
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Appendix 3.2: ROC Tables 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.2870 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.2942 28.57 3.669% to 70.96% 100.0 79.41% to 100.0%   
< 0.3281 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.4047 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.5165 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.6013 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.7065 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.8022 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.8158 42.86 9.899% to 81.59% 62.50 35.43% to 84.80% 1.14 
< 0.9458 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 1.085 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 1.294 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 1.690 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 1.931 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 2.288 100.0 59.04% to 100.0% 50.00 24.65% to 75.35% 2.00 
< 2.627 100.0 59.04% to 100.0% 43.75 19.75% to 70.12% 1.78 
< 3.144 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 3.713 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 4.116 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 4.872 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 6.463 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 8.186 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
VEGF  ROC Table 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.004457 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.007327 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
< 0.007763 0.0 0.0% to 40.96% 81.25 54.35% to 95.95% 0.00 
< 0.008743 14.29 0.3610% to 57.87% 81.25 54.35% to 95.95% 0.76 
< 0.01616 14.29 0.3610% to 57.87% 75.00 47.62% to 92.73% 0.57 
< 0.02376 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
< 0.02514 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.03392 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.04373 42.86 9.899% to 81.59% 62.50 35.43% to 84.80% 1.14 
< 0.05435 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 0.06777 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 0.08575 57.14 18.41% to 90.10% 50.00 24.65% to 75.35% 1.14 
< 0.1023 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 0.1106 71.43 29.04% to 96.33% 43.75 19.75% to 70.12% 1.27 
< 0.1181 71.43 29.04% to 96.33% 37.50 15.20% to 64.57% 1.14 
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< 0.1221 71.43 29.04% to 96.33% 31.25 11.02% to 58.66% 1.04 
< 0.1470 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.1713 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.1994 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.3412 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 0.4672 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 0.7909 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
VEGF  ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0005275 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.0006589 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.0008929 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.001049 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.001211 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
< 0.001578 57.14 18.41% to 90.10% 87.50 61.65% to 98.45% 4.57 
< 0.002033 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
< 0.002529 71.43 29.04% to 96.33% 81.25 54.35% to 95.95% 3.81 
< 0.002827 71.43 29.04% to 96.33% 75.00 47.62% to 92.73% 2.86 
< 0.003304 85.71 42.13% to 99.64% 75.00 47.62% to 92.73% 3.43 
< 0.004422 85.71 42.13% to 99.64% 68.75 41.34% to 88.98% 2.74 
< 0.005418 100.0 59.04% to 100.0% 68.75 41.34% to 88.98% 3.20 
< 0.006026 100.0 59.04% to 100.0% 62.50 35.43% to 84.80% 2.67 
< 0.006553 100.0 59.04% to 100.0% 56.25 29.88% to 80.25% 2.29 
< 0.006952 100.0 59.04% to 100.0% 50.00 24.65% to 75.35% 2.00 
< 0.007252 100.0 59.04% to 100.0% 43.75 19.75% to 70.12% 1.78 
< 0.007497 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 0.01017 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.01437 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.01700 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.02439 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.07351 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
IGF 18 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.001309 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.002331 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
< 0.003837 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.005563 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.006927 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.008575 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
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< 0.009935 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.01194 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.01560 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.01783 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
< 0.03074 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.04626 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.05109 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.05435 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.05956 100.0 59.04% to 100.0% 50.00 24.65% to 75.35% 2.00 
< 0.06570 100.0 59.04% to 100.0% 43.75 19.75% to 70.12% 1.78 
< 0.07394 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 0.08027 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.09672 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.1146 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.1238 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.1536 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
IGF 1 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.04270 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.08088 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.1081 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.1292 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.1576 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.1790 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.1920 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.2986 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.4075 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.4240 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 0.4605 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.5748 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.7849 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 1.395 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 1.989 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 2.401 100.0 59.04% to 100.0% 43.75 19.75% to 70.12% 1.78 
< 2.966 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 3.240 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 4.498 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 5.933 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 6.220 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 8.554 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
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CCL 18 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.006838 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.01476 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
< 0.02510 0.0 0.0% to 40.96% 81.25 54.35% to 95.95% 0.00 
< 0.04309 0.0 0.0% to 40.96% 75.00 47.62% to 92.73% 0.00 
< 0.05880 14.29 0.3610% to 57.87% 75.00 47.62% to 92.73% 0.57 
< 0.07665 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
< 0.1051 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.1190 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.1283 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.1468 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 0.2205 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.3037 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.4389 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 0.7673 71.43 29.04% to 96.33% 43.75 19.75% to 70.12% 1.27 
< 1.138 71.43 29.04% to 96.33% 37.50 15.20% to 64.57% 1.14 
< 1.476 71.43 29.04% to 96.33% 31.25 11.02% to 58.66% 1.04 
< 1.658 71.43 29.04% to 96.33% 25.00 7.266% to 52.38% 0.95 
< 1.722 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 1.804 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 2.183 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 2.705 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 3.423 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
CCL 3 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.005177 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.01553 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
< 0.03027 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.03945 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.04159 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.04479 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
< 0.05374 28.57 3.669% to 70.96% 68.75 41.34% to 88.98% 0.91 
< 0.06889 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.08003 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.09740 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
< 0.1188 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.1368 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.1543 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
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< 0.1825 71.43 29.04% to 96.33% 43.75 19.75% to 70.12% 1.27 
< 0.2165 71.43 29.04% to 96.33% 37.50 15.20% to 64.57% 1.14 
< 0.2519 71.43 29.04% to 96.33% 31.25 11.02% to 58.66% 1.04 
< 0.2763 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.3008 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.3944 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.6185 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.8703 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 1.002 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
CCR1 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0004031 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.0008152 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
< 0.001211 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.002074 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.002827 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.003304 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.004422 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.006074 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.007327 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.01119 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 0.01539 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.01700 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.06156 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 0.1107 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.1193 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.1285 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.1730 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.2740 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.4522 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.7901 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 1.029 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 1.079 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
CXCL9 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0004031 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.0009279 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
< 0.001578 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.002033 14.29 0.3610% to 57.87% 81.25 54.35% to 95.95% 0.76 
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< 0.002529 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.002827 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
< 0.003304 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.004422 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.006074 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.007327 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 0.008552 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 0.01117 57.14 18.41% to 90.10% 50.00 24.65% to 75.35% 1.14 
< 0.01376 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 0.01534 71.43 29.04% to 96.33% 43.75 19.75% to 70.12% 1.27 
< 0.01700 71.43 29.04% to 96.33% 37.50 15.20% to 64.57% 1.14 
< 0.02328 71.43 29.04% to 96.33% 31.25 11.02% to 58.66% 1.04 
< 0.04281 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.06547 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.07425 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.09545 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 0.1840 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 0.2660 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
CXCL10 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
> 0.0003990 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
> 0.0005275 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
> 0.0006589 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
> 0.0009425 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
> 0.001211 71.43 29.04% to 96.33% 18.75 4.047% to 45.65% 0.88 
> 0.001578 57.14 18.41% to 90.10% 18.75 4.047% to 45.65% 0.70 
> 0.002329 57.14 18.41% to 90.10% 25.00 7.266% to 52.38% 0.76 
> 0.003301 57.14 18.41% to 90.10% 31.25 11.02% to 58.66% 0.83 
> 0.003810 57.14 18.41% to 90.10% 37.50 15.20% to 64.57% 0.91 
> 0.004806 57.14 18.41% to 90.10% 43.75 19.75% to 70.12% 1.02 
> 0.006026 57.14 18.41% to 90.10% 50.00 24.65% to 75.35% 1.14 
> 0.006682 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
> 0.007252 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
> 0.007497 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
> 0.01177 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
> 0.01700 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
> 0.02803 57.14 18.41% to 90.10% 87.50 61.65% to 98.45% 4.57 
> 0.03881 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
> 0.04222 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
> 0.04925 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
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> 0.08267 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
> 0.1140 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
TNF  ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0006371 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.001049 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.001192 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.001559 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.002033 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.002529 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.002827 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.004300 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.006169 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.006825 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
< 0.007252 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.007497 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.008160 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 0.01111 71.43 29.04% to 96.33% 43.75 19.75% to 70.12% 1.27 
< 0.01427 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.01552 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.01700 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.04593 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.08327 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.09933 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 0.1111 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 0.2556 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
CD120  ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0006548 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.0008929 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.001049 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.001211 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
< 0.001578 57.14 18.41% to 90.10% 93.75 69.77% to 99.84% 9.14 
< 0.002033 57.14 18.41% to 90.10% 87.50 61.65% to 98.45% 4.57 
< 0.002529 71.43 29.04% to 96.33% 87.50 61.65% to 98.45% 5.71 
< 0.002827 71.43 29.04% to 96.33% 81.25 54.35% to 95.95% 3.81 
< 0.003304 85.71 42.13% to 99.64% 81.25 54.35% to 95.95% 4.57 
< 0.003810 85.71 42.13% to 99.64% 75.00 47.62% to 92.73% 3.43 
< 0.004454 85.71 42.13% to 99.64% 68.75 41.34% to 88.98% 2.74 
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< 0.005418 100.0 59.04% to 100.0% 68.75 41.34% to 88.98% 3.20 
< 0.006026 100.0 59.04% to 100.0% 62.50 35.43% to 84.80% 2.67 
< 0.006682 100.0 59.04% to 100.0% 56.25 29.88% to 80.25% 2.29 
< 0.007252 100.0 59.04% to 100.0% 50.00 24.65% to 75.35% 2.00 
< 0.007497 100.0 59.04% to 100.0% 43.75 19.75% to 70.12% 1.78 
< 0.008541 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 0.01025 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.01167 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.01416 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.01700 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.06714 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
OPG ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.001142 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.001559 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.002331 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.003336 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.004327 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.005463 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
< 0.006198 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.006852 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.007497 42.86 9.899% to 81.59% 62.50 35.43% to 84.80% 1.14 
< 0.008963 42.86 9.899% to 81.59% 56.25 29.88% to 80.25% 0.98 
< 0.01267 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 0.01651 57.14 18.41% to 90.10% 50.00 24.65% to 75.35% 1.14 
< 0.02007 57.14 18.41% to 90.10% 43.75 19.75% to 70.12% 1.02 
< 0.02726 57.14 18.41% to 90.10% 37.50 15.20% to 64.57% 0.91 
< 0.03576 57.14 18.41% to 90.10% 31.25 11.02% to 58.66% 0.83 
< 0.04167 71.43 29.04% to 96.33% 31.25 11.02% to 58.66% 1.04 
< 0.04815 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.06603 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.09813 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.1164 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.1277 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.1651 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
RANK ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0006589 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.0008929 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
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< 0.001049 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.001211 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.001578 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
< 0.002033 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.002529 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
< 0.002827 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.003336 71.43 29.04% to 96.33% 75.00 47.62% to 92.73% 2.86 
< 0.004010 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
< 0.004622 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.005675 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.006682 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.007327 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.009017 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.01322 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.01700 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.01949 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.02784 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.04973 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.06887 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.09464 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
TLR 3 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.001049 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.001211 28.57 3.669% to 70.96% 100.0 79.41% to 100.0%   
< 0.001578 42.86 9.899% to 81.59% 100.0 79.41% to 100.0%   
< 0.002805 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
< 0.005430 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
< 0.01125 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.01783 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.02816 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.03812 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.04731 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
< 0.06379 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.08476 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.1063 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.1166 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.1535 100.0 59.04% to 100.0% 50.00 24.65% to 75.35% 2.00 
< 0.2041 100.0 59.04% to 100.0% 43.75 19.75% to 70.12% 1.78 
< 0.3292 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 0.4462 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
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< 0.4621 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.7557 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 1.082 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 1.126 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
TLR 5 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0007656 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.001049 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.001192 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.001304 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.001578 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
< 0.002033 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.002529 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
< 0.002827 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.003948 71.43 29.04% to 96.33% 75.00 47.62% to 92.73% 2.86 
< 0.005418 85.71 42.13% to 99.64% 75.00 47.62% to 92.73% 3.43 
< 0.006426 85.71 42.13% to 99.64% 68.75 41.34% to 88.98% 2.74 
< 0.007327 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.01177 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.01700 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.01879 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.01986 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.02138 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 0.03479 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.06542 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.1001 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.1256 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.1630 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
FRZB ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0008929 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.001049 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.001466 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.002033 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.002529 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
< 0.002827 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.003304 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
< 0.004422 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.005418 71.43 29.04% to 96.33% 75.00 47.62% to 92.73% 2.86 
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< 0.006426 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
< 0.007327 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.009214 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.01341 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.01700 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.01941 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.02332 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.02614 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 0.03031 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.04817 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.08920 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.1221 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.1311 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
SFRP ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.002033 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.003650 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.005103 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.005455 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
< 0.006026 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
< 0.006322 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.006967 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.01177 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.01700 42.86 9.899% to 81.59% 62.50 35.43% to 84.80% 1.14 
< 0.02195 42.86 9.899% to 81.59% 56.25 29.88% to 80.25% 0.98 
< 0.02977 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 0.03653 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
< 0.05191 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.08074 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.1055 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.1151 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.1213 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.1274 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.1721 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.2196 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 0.2644 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 0.6377 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
SFRP2 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
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> 0.0007097 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
> 0.0009897 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
> 0.001047 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
> 0.001070 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
> 0.001141 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
> 0.001219 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
> 0.001817 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
> 0.002516 71.43 29.04% to 96.33% 37.50 15.20% to 64.57% 1.14 
> 0.002740 71.43 29.04% to 96.33% 43.75 19.75% to 70.12% 1.27 
> 0.009209 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
> 0.03280 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
> 0.05024 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
> 0.05377 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
> 0.05773 42.86 9.899% to 81.59% 62.50 35.43% to 84.80% 1.14 
> 0.05855 28.57 3.669% to 70.96% 62.50 35.43% to 84.80% 0.76 
> 0.06125 28.57 3.669% to 70.96% 68.75 41.34% to 88.98% 0.91 
> 0.06605 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
> 0.1024 14.29 0.3610% to 57.87% 75.00 47.62% to 92.73% 0.57 
> 0.1457 14.29 0.3610% to 57.87% 81.25 54.35% to 95.95% 0.76 
> 0.1629 0.0 0.0% to 40.96% 81.25 54.35% to 95.95% 0.00 
> 0.4147 0.0 0.0% to 40.96% 87.50 61.65% to 98.45% 0.00 
> 0.8605 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
MMP13 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
> 0.0002140 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
> 0.0002673 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
> 0.0003691 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
> 0.0006958 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
> 0.0009403 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
> 0.0009897 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
> 0.001047 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
> 0.001149 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
> 0.001485 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
> 0.002183 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
> 0.003558 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
> 0.005986 85.71 42.13% to 99.64% 68.75 41.34% to 88.98% 2.74 
> 0.008804 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
> 0.01023 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
> 0.01100 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
> 0.01251 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
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> 0.01467 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
> 0.01626 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
> 0.02063 14.29 0.3610% to 57.87% 81.25 54.35% to 95.95% 0.76 
> 0.02598 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
> 0.03207 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
> 0.07276 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
MMP1 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0007656 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.001049 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.001211 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.001326 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
< 0.001580 57.14 18.41% to 90.10% 93.75 69.77% to 99.84% 9.14 
< 0.002329 57.14 18.41% to 90.10% 87.50 61.65% to 98.45% 4.57 
< 0.002827 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
< 0.003304 71.43 29.04% to 96.33% 81.25 54.35% to 95.95% 3.81 
< 0.004422 71.43 29.04% to 96.33% 75.00 47.62% to 92.73% 2.86 
< 0.005675 85.71 42.13% to 99.64% 75.00 47.62% to 92.73% 3.43 
< 0.006682 85.71 42.13% to 99.64% 68.75 41.34% to 88.98% 2.74 
< 0.007327 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.008941 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.01166 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.01450 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.01700 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.02854 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.04259 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.04691 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.06168 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.07701 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.09731 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
BMP4 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
> 0.003407 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
> 0.006364 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
> 0.006764 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
> 0.01037 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
> 0.01946 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
> 0.02737 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
> 0.03078 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
  Page 167 
 
> 0.05114 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
> 0.07164 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
> 0.07548 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
> 0.08606 71.43 29.04% to 96.33% 56.25 29.88% to 80.25% 1.63 
> 0.1052 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
> 0.1477 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
> 0.1888 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
> 0.2014 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
> 0.2124 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
> 0.2741 57.14 18.41% to 90.10% 87.50 61.65% to 98.45% 4.57 
> 0.3803 57.14 18.41% to 90.10% 93.75 69.77% to 99.84% 9.14 
> 0.4737 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
> 0.6015 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
> 0.7242 28.57 3.669% to 70.96% 100.0 79.41% to 100.0%   
> 51.02 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
IL8 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0007615 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.001162 28.57 3.669% to 70.96% 100.0 79.41% to 100.0%   
< 0.001578 42.86 9.899% to 81.59% 100.0 79.41% to 100.0%   
< 0.002033 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
< 0.002532 57.14 18.41% to 90.10% 93.75 69.77% to 99.84% 9.14 
< 0.003063 71.43 29.04% to 96.33% 93.75 69.77% to 99.84% 11.43 
< 0.005359 71.43 29.04% to 96.33% 87.50 61.65% to 98.45% 5.71 
< 0.008304 71.43 29.04% to 96.33% 81.25 54.35% to 95.95% 3.81 
< 0.009781 85.71 42.13% to 99.64% 81.25 54.35% to 95.95% 4.57 
< 0.01080 85.71 42.13% to 99.64% 75.00 47.62% to 92.73% 3.43 
< 0.01360 85.71 42.13% to 99.64% 68.75 41.34% to 88.98% 2.74 
< 0.02030 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.02806 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.03232 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.04287 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.08010 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.1094 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.1137 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.1232 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.1507 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 0.1739 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 0.2001 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
IRAK3 ROC Table 
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Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.01569 12.50 0.3160% to 52.65% 100.0 78.20% to 100.0%   
< 0.04074 12.50 0.3160% to 52.65% 93.33 68.05% to 99.83% 1.88 
< 0.1345 25.00 3.185% to 65.09% 93.33 68.05% to 99.83% 3.75 
< 0.2210 25.00 3.185% to 65.09% 86.67 59.54% to 98.34% 1.88 
< 0.2478 25.00 3.185% to 65.09% 80.00 51.91% to 95.67% 1.25 
< 0.2818 25.00 3.185% to 65.09% 73.33 44.90% to 92.21% 0.94 
< 0.3934 25.00 3.185% to 65.09% 66.67 38.38% to 88.18% 0.75 
< 0.4978 25.00 3.185% to 65.09% 60.00 32.29% to 83.66% 0.63 
< 0.6129 37.50 8.523% to 75.51% 60.00 32.29% to 83.66% 0.94 
< 0.7416 50.00 15.70% to 84.30% 60.00 32.29% to 83.66% 1.25 
< 0.8265 50.00 15.70% to 84.30% 53.33 26.59% to 78.73% 1.07 
< 1.316 62.50 24.49% to 91.48% 53.33 26.59% to 78.73% 1.34 
< 1.777 75.00 34.91% to 96.81% 53.33 26.59% to 78.73% 1.61 
< 2.248 75.00 34.91% to 96.81% 46.67 21.27% to 73.41% 1.41 
< 2.873 87.50 47.35% to 99.68% 46.67 21.27% to 73.41% 1.64 
< 3.983 87.50 47.35% to 99.68% 40.00 16.34% to 67.71% 1.46 
< 5.238 87.50 47.35% to 99.68% 33.33 11.82% to 61.62% 1.31 
< 5.819 87.50 47.35% to 99.68% 26.67 7.787% to 55.10% 1.19 
< 7.323 100.0 63.06% to 100.0% 26.67 7.787% to 55.10% 1.36 
< 9.032 100.0 63.06% to 100.0% 20.00 4.331% to 48.09% 1.25 
< 9.702 100.0 63.06% to 100.0% 13.33 1.658% to 40.46% 1.15 
< 10.14 100.0 63.06% to 100.0% 6.667 0.1686% to 31.95% 1.07 
APC 5 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0006867 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.001211 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.003803 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.006852 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.01064 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.01462 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.02304 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.03736 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.06968 42.86 9.899% to 81.59% 62.50 35.43% to 84.80% 1.14 
< 0.1058 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 0.1225 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 0.1322 57.14 18.41% to 90.10% 50.00 24.65% to 75.35% 1.14 
< 0.1531 57.14 18.41% to 90.10% 43.75 19.75% to 70.12% 1.02 
< 0.1781 57.14 18.41% to 90.10% 37.50 15.20% to 64.57% 0.91 
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< 0.2095 71.43 29.04% to 96.33% 37.50 15.20% to 64.57% 1.14 
< 0.2420 71.43 29.04% to 96.33% 31.25 11.02% to 58.66% 1.04 
< 0.2523 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.2803 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.3144 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.3755 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 1.293 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 2.196 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
BCL2A1 RIC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.03469 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.04467 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.05805 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.1106 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.2147 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.3565 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.4529 57.14 18.41% to 90.10% 81.25 54.35% to 95.95% 3.05 
< 0.4875 57.14 18.41% to 90.10% 75.00 47.62% to 92.73% 2.29 
< 0.7157 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.9420 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 1.153 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 1.590 57.14 18.41% to 90.10% 50.00 24.65% to 75.35% 1.14 
< 2.610 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 9.706 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 16.79 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 18.02 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 19.33 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 22.44 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 30.24 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 36.31 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 52.73 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 85.61 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
CHIT1 ROC Table 
 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.04555 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.06813 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.1263 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
  Page 170 
 
< 0.1657 28.57 3.669% to 70.96% 87.50 61.65% to 98.45% 2.29 
< 0.2046 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.2500 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
< 0.3593 28.57 3.669% to 70.96% 68.75 41.34% to 88.98% 0.91 
< 0.4623 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.5332 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.6311 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
< 0.6983 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.7352 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.7358 100.0 59.04% to 100.0% 62.50 35.43% to 84.80% 2.67 
< 1.175 100.0 59.04% to 100.0% 56.25 29.88% to 80.25% 2.29 
< 1.663 100.0 59.04% to 100.0% 50.00 24.65% to 75.35% 2.00 
< 1.749 100.0 59.04% to 100.0% 43.75 19.75% to 70.12% 1.78 
< 1.962 100.0 59.04% to 100.0% 37.50 15.20% to 64.57% 1.60 
< 2.633 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 3.339 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 3.772 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 4.580 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 7.605 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
CTSK ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.01171 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.02325 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.03760 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.06481 14.29 0.3610% to 57.87% 81.25 54.35% to 95.95% 0.76 
< 0.09347 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.1044 28.57 3.669% to 70.96% 75.00 47.62% to 92.73% 1.14 
< 0.1328 28.57 3.669% to 70.96% 68.75 41.34% to 88.98% 0.91 
< 0.1606 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.1824 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.2099 57.14 18.41% to 90.10% 62.50 35.43% to 84.80% 1.52 
< 0.2261 57.14 18.41% to 90.10% 56.25 29.88% to 80.25% 1.31 
< 0.2798 57.14 18.41% to 90.10% 50.00 24.65% to 75.35% 1.14 
< 0.3840 71.43 29.04% to 96.33% 50.00 24.65% to 75.35% 1.43 
< 0.4505 71.43 29.04% to 96.33% 43.75 19.75% to 70.12% 1.27 
< 0.4981 71.43 29.04% to 96.33% 37.50 15.20% to 64.57% 1.14 
< 0.5506 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.7960 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 1.041 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 1.091 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
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< 1.316 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 1.561 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 1.676 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
ITGAM ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.0003990 0.0 0.0% to 40.96% 93.75 69.77% to 99.84% 0.00 
< 0.0007615 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.001049 28.57 3.669% to 70.96% 93.75 69.77% to 99.84% 4.57 
< 0.001192 42.86 9.899% to 81.59% 93.75 69.77% to 99.84% 6.86 
< 0.001304 42.86 9.899% to 81.59% 87.50 61.65% to 98.45% 3.43 
< 0.001779 57.14 18.41% to 90.10% 87.50 61.65% to 98.45% 4.57 
< 0.002529 71.43 29.04% to 96.33% 87.50 61.65% to 98.45% 5.71 
< 0.002827 71.43 29.04% to 96.33% 81.25 54.35% to 95.95% 3.81 
< 0.003304 85.71 42.13% to 99.64% 81.25 54.35% to 95.95% 4.57 
< 0.003810 85.71 42.13% to 99.64% 75.00 47.62% to 92.73% 3.43 
< 0.004729 85.71 42.13% to 99.64% 68.75 41.34% to 88.98% 2.74 
< 0.005949 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.006682 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.007245 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.007416 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.007497 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.01177 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.01700 85.71 42.13% to 99.64% 25.00 7.266% to 52.38% 1.14 
< 0.01900 85.71 42.13% to 99.64% 18.75 4.047% to 45.65% 1.05 
< 0.04337 85.71 42.13% to 99.64% 12.50 1.551% to 38.35% 0.98 
< 0.09152 85.71 42.13% to 99.64% 6.250 0.1581% to 30.23% 0.91 
< 0.2432 85.71 42.13% to 99.64% 0.0 0.0% to 20.59% 0.86 
PTGS2 ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 0.008882 14.29 0.3610% to 57.87% 100.0 79.41% to 100.0%   
< 0.01509 14.29 0.3610% to 57.87% 93.75 69.77% to 99.84% 2.29 
< 0.01848 14.29 0.3610% to 57.87% 87.50 61.65% to 98.45% 1.14 
< 0.02128 14.29 0.3610% to 57.87% 81.25 54.35% to 95.95% 0.76 
< 0.02387 28.57 3.669% to 70.96% 81.25 54.35% to 95.95% 1.52 
< 0.02915 42.86 9.899% to 81.59% 81.25 54.35% to 95.95% 2.29 
< 0.03413 42.86 9.899% to 81.59% 75.00 47.62% to 92.73% 1.71 
< 0.04109 42.86 9.899% to 81.59% 68.75 41.34% to 88.98% 1.37 
< 0.05145 57.14 18.41% to 90.10% 68.75 41.34% to 88.98% 1.83 
< 0.06693 71.43 29.04% to 96.33% 68.75 41.34% to 88.98% 2.29 
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< 0.07955 71.43 29.04% to 96.33% 62.50 35.43% to 84.80% 1.90 
< 0.08237 85.71 42.13% to 99.64% 62.50 35.43% to 84.80% 2.29 
< 0.09195 85.71 42.13% to 99.64% 56.25 29.88% to 80.25% 1.96 
< 0.1053 85.71 42.13% to 99.64% 50.00 24.65% to 75.35% 1.71 
< 0.1135 85.71 42.13% to 99.64% 43.75 19.75% to 70.12% 1.52 
< 0.1217 85.71 42.13% to 99.64% 37.50 15.20% to 64.57% 1.37 
< 0.1373 85.71 42.13% to 99.64% 31.25 11.02% to 58.66% 1.25 
< 0.1825 100.0 59.04% to 100.0% 31.25 11.02% to 58.66% 1.45 
< 0.2175 100.0 59.04% to 100.0% 25.00 7.266% to 52.38% 1.33 
< 0.2222 100.0 59.04% to 100.0% 18.75 4.047% to 45.65% 1.23 
< 0.3100 100.0 59.04% to 100.0% 12.50 1.551% to 38.35% 1.14 
< 0.4327 100.0 59.04% to 100.0% 6.250 0.1581% to 30.23% 1.07 
TP53 ROC Table 
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Appendix F – ROC Tables for PROMS 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 42.50 5.556 0.1406% to 27.29% 100.0 92.29% to 100.0%   
< 43.50 11.11 1.375% to 34.71% 100.0 92.29% to 100.0%   
< 44.50 16.67 3.578% to 41.42% 100.0 92.29% to 100.0%   
< 45.50 16.67 3.578% to 41.42% 95.65 85.16% to 99.47% 3.83 
< 46.50 16.67 3.578% to 41.42% 93.48 82.10% to 98.63% 2.56 
< 47.50 38.89 17.30% to 64.25% 93.48 82.10% to 98.63% 5.96 
< 48.50 38.89 17.30% to 64.25% 89.13 76.43% to 96.38% 3.58 
< 49.50 38.89 17.30% to 64.25% 86.96 73.74% to 95.06% 2.98 
< 50.50 44.44 21.53% to 69.24% 80.43 66.09% to 90.64% 2.27 
< 51.50 50.00 26.02% to 73.98% 76.09 61.23% to 87.41% 2.09 
< 52.50 61.11 35.75% to 82.70% 71.74 56.54% to 84.01% 2.16 
< 53.50 66.67 40.99% to 86.66% 71.74 56.54% to 84.01% 2.36 
< 54.50 83.33 58.58% to 96.42% 67.39 51.98% to 80.47% 2.56 
< 55.50 83.33 58.58% to 96.42% 56.52 41.11% to 71.07% 1.92 
< 56.50 88.89 65.29% to 98.62% 50.00 34.90% to 65.10% 1.78 
< 57.50 88.89 65.29% to 98.62% 45.65 30.90% to 60.99% 1.64 
< 58.50 94.44 72.71% to 99.86% 32.61 19.53% to 48.02% 1.40 
< 59.50 100.0 81.47% to 100.0% 21.74 10.95% to 36.36% 1.28 
< 60.50 100.0 81.47% to 100.0% 19.57 9.358% to 33.91% 1.24 
< 61.50 100.0 81.47% to 100.0% 6.522 1.366% to 17.90% 1.07 
< 63.50 100.0 81.47% to 100.0% 4.348 0.5309% to 14.84% 1.05 
HSS Score ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
> 12.50 90.38 78.97% to 96.80% 20.00 9.052% to 35.65% 1.13 
> 13.50 86.54 74.21% to 94.41% 27.50 14.60% to 43.89% 1.19 
> 14.50 76.92 63.16% to 87.47% 35.00 20.63% to 51.68% 1.18 
> 15.50 71.15 56.92% to 82.87% 37.50 22.73% to 54.20% 1.14 
> 16.50 71.15 56.92% to 82.87% 40.00 24.86% to 56.67% 1.19 
> 17.50 65.38 50.91% to 78.03% 45.00 29.26% to 61.51% 1.19 
> 18.50 59.62 45.10% to 72.99% 47.50 31.51% to 63.87% 1.14 
> 19.50 55.77 41.33% to 69.53% 50.00 33.80% to 66.20% 1.12 
> 20.50 53.85 39.47% to 67.77% 57.50 40.89% to 72.96% 1.27 
> 22.00 51.92 37.63% to 65.99% 65.00 48.32% to 79.37% 1.48 
> 23.50 51.92 37.63% to 65.99% 70.00 53.47% to 83.44% 1.73 
> 24.50 50.00 35.81% to 64.19% 70.00 53.47% to 83.44% 1.67 
> 25.50 50.00 35.81% to 64.19% 72.50 56.11% to 85.40% 1.82 
> 27.00 42.31 28.73% to 56.80% 77.50 61.55% to 89.16% 1.88 
> 28.50 40.38 27.01% to 54.90% 80.00 64.35% to 90.95% 2.02 
> 31.00 32.69 20.33% to 47.10% 80.00 64.35% to 90.95% 1.63 
> 34.00 30.77 18.72% to 45.10% 80.00 64.35% to 90.95% 1.54 
> 36.00 28.85 17.13% to 43.08% 80.00 64.35% to 90.95% 1.44 
> 37.50 25.00 14.03% to 38.95% 80.00 64.35% to 90.95% 1.25 
> 38.50 23.08 12.53% to 36.84% 82.50 67.22% to 92.66% 1.32 
> 39.50 19.23 9.627% to 32.53% 87.50 73.20% to 95.81% 1.54 
> 40.50 15.38 6.884% to 28.08% 90.00 76.34% to 97.21% 1.54 
> 41.50 13.46 5.588% to 25.79% 92.50 79.61% to 98.43% 1.79 
> 43.00 13.46 5.588% to 25.79% 95.00 83.08% to 99.39% 2.69 
> 44.50 9.615 3.196% to 21.03% 97.50 86.84% to 99.94% 3.85 
> 45.50 7.692 2.136% to 18.54% 97.50 86.84% to 99.94% 3.08 
> 46.50 3.846 0.4692% to 13.21% 97.50 86.84% to 99.94% 1.54 
> 47.50 1.923 0.04868% to 10.26% 97.50 86.84% to 99.94% 0.77 
> 50.50 0.0 0.0% to 6.848% 97.50 86.84% to 99.94% 0.00 
Oxford Score ROC Table 
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Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 9.500 0.0 0.0% to 40.96% 99.30 96.14% to 99.98% 0.00 
< 10.50 0.0 0.0% to 40.96% 97.18 92.94% to 99.23% 0.00 
< 11.50 0.0 0.0% to 40.96% 92.96 87.43% to 96.57% 0.00 
< 12.50 14.29 0.3610% to 57.87% 84.51 77.49% to 90.03% 0.92 
< 13.50 28.57 3.669% to 70.96% 77.46 69.70% to 84.05% 1.27 
< 14.50 42.86 9.899% to 81.59% 64.08 55.61% to 71.96% 1.19 
< 15.50 57.14 18.41% to 90.10% 49.30 40.81% to 57.81% 1.13 
< 16.50 57.14 18.41% to 90.10% 32.39 24.79% to 40.75% 0.85 
< 17.50 100.0 59.04% to 100.0% 7.042 3.429% to 12.57% 1.08 
MDA Score ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
< 20.00 0.0 0.0% to 30.85% 98.95 94.27% to 99.97% 0.00 
< 26.50 10.00 0.2529% to 44.50% 97.89 92.60% to 99.74% 4.75 
< 32.00 20.00 2.521% to 55.61% 97.89 92.60% to 99.74% 9.50 
< 33.50 30.00 6.674% to 65.25% 97.89 92.60% to 99.74% 14.25 
< 36.00 40.00 12.16% to 73.76% 97.89 92.60% to 99.74% 19.00 
< 38.50 40.00 12.16% to 73.76% 96.84 91.05% to 99.34% 12.67 
< 40.00 40.00 12.16% to 73.76% 95.79 89.57% to 98.84% 9.50 
< 42.00 40.00 12.16% to 73.76% 94.74 88.14% to 98.27% 7.60 
< 44.50 40.00 12.16% to 73.76% 93.68 86.76% to 97.65% 6.33 
< 48.00 50.00 18.71% to 81.29% 93.68 86.76% to 97.65% 7.92 
< 50.50 70.00 34.75% to 93.33% 93.68 86.76% to 97.65% 11.08 
< 51.50 70.00 34.75% to 93.33% 92.63 85.41% to 96.99% 9.50 
< 55.50 80.00 44.39% to 97.48% 91.58 84.08% to 96.29% 9.50 
< 59.50 80.00 44.39% to 97.48% 90.53 82.78% to 95.58% 8.44 
< 61.00 80.00 44.39% to 97.48% 88.42 80.23% to 94.08% 6.91 
< 62.50 80.00 44.39% to 97.48% 87.37 78.97% to 93.30% 6.33 
< 63.50 80.00 44.39% to 97.48% 86.32 77.74% to 92.51% 5.85 
< 64.50 80.00 44.39% to 97.48% 84.21 75.30% to 90.88% 5.07 
< 65.50 80.00 44.39% to 97.48% 82.11 72.90% to 89.22% 4.47 
< 67.00 80.00 44.39% to 97.48% 81.05 71.72% to 88.37% 4.22 
< 68.50 90.00 55.50% to 99.75% 77.89 68.22% to 85.77% 4.07 
< 69.50 90.00 55.50% to 99.75% 76.84 67.06% to 84.88% 3.89 
< 70.50 90.00 55.50% to 99.75% 74.74 64.78% to 83.09% 3.56 
< 71.50 90.00 55.50% to 99.75% 72.63 62.52% to 81.28% 3.29 
< 72.50 90.00 55.50% to 99.75% 71.58 61.40% to 80.36% 3.17 
< 74.50 90.00 55.50% to 99.75% 70.53 60.29% to 79.44% 3.05 
< 76.50 90.00 55.50% to 99.75% 69.47 59.18% to 78.51% 2.95 
< 77.50 90.00 55.50% to 99.75% 67.37 56.98% to 76.64% 2.76 
< 78.50 90.00 55.50% to 99.75% 64.21 53.72% to 73.79% 2.51 
< 79.50 90.00 55.50% to 99.75% 63.16 52.64% to 72.83% 2.44 
< 80.50 90.00 55.50% to 99.75% 61.05 50.50% to 70.89% 2.31 
< 81.50 90.00 55.50% to 99.75% 58.95 48.38% to 68.94% 2.19 
< 82.50 90.00 55.50% to 99.75% 56.84 46.28% to 66.97% 2.09 
< 83.50 100.0 69.15% to 100.0% 51.58 41.10% to 61.96% 2.07 
< 84.50 100.0 69.15% to 100.0% 47.37 37.03% to 57.88% 1.90 
< 85.50 100.0 69.15% to 100.0% 40.00 30.08% to 50.56% 1.67 
< 86.50 100.0 69.15% to 100.0% 37.89 28.14% to 48.43% 1.61 
< 87.50 100.0 69.15% to 100.0% 32.63 23.36% to 43.02% 1.48 
< 88.50 100.0 69.15% to 100.0% 31.58 22.42% to 41.92% 1.46 
< 90.00 100.0 69.15% to 100.0% 22.11 14.23% to 31.78% 1.28 
Harris Score ROC Table 
 
Cutoff Sensitivity% 95% CI Specificity% 95% CI Likelihood ratio 
> 8.00 0.0 0.0% to 28.49% 98.95 94.27% to 99.97% 0.00 
> 6.00 18.18 2.283% to 51.78% 97.89 92.60% to 99.74% 8.64 
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> 4.00 72.73 39.03% to 93.98% 87.37 78.97% to 93.30% 5.76 
> 2.00 81.82 48.22% to 97.72% 87.37 78.97% to 93.30% 6.48 
> 0.00 100.0 71.51% to 100.0% 58.95 48.38% to 68.94% 2.44 
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APPENDIX 4 : GLOSSARY 
AP  Anteroposterior. A radiographic projection showing the patient from the front on the 
radiograph 
APC  Antigen Presenting Cell. A cell that initiates an immune response by presenting antigens on 
it’s surface usually a macrophage or dendritic cell.  
AUC  Area Under Curve. An indicator of the over all strength of association in ROC analysis. 
AVN  Avascular Necrosis. Death of a bone and subsequent collapse. Usually due to a loss of blood 
supply. 
BMP  Bone Morphogenic Protein. A family of proteins that act as signal molecules to promote 
and control bone healing and repair. 
BMI  Body Mass Index. A measure of patient weight. Given in kg/m2. 
CD  Cluster of differentiation. 
CT  Cycles to Threshold. The number of PCR cycles undergone until the RNA expression is 
measurable 
cDNA  Chimeric DNA. A DNA library normally produced by reverse transcription. 
CTSG  Cathepsin G. An intracellular signal molecule. 
CTSK  Cathepsin K. An intracellular signal molecule. 
COL  One of the family of Collagen genes. 
DKK  Dickkopf family of proteins inhibit the WNT pathway. 
FRZB  Frizzled Related Protein. An extracellular antagonist of the WNT signalling pathway. 
FGF  Fibroblast Growth Factor. Promotes differentiation of osteoblasts.  
HHS  Harris Hip Score. A surgeon reported outcome measure 
Housekeeping gene – A gene which is known to be linearly expressed in the tissue of interest and so 
may be used to correct for error in laboratory technique. 
HSS  Hospital for Special Surgery score. A surgeon reported outcome measure. 
IB  Iliac Oblique. A radiographic projection most usually used to visualise the acetabulum. 
IGF  Insulin like Growth Factor. A secreted local growth factor. 
MDA  Merle d’Aubigne. A surgeon reported outcome score. 
MMP  Matrix Metalloprotein. A proteinase capable of breaking down extra-cellular matrix. 
Osteolysis The process of bone loss in response to wear debris or other stimulus.  
OPG  Osteoprotegerin. A secreted decoy receptor which binds the RANK Ligand. 
OHS  Oxford Hip Score. A patient reported outcome measure. 
PCR  Polymerase Chain Reaction. A method for replicating DNA sequences of interest.  
RA  Rheumatoid Arthritis 
RANK  Receptor Activator of Nuclear Factor κ B (RANK). The receptor for the RANK pathway which 
activates osteoclastic activity. 
ROC  Receiver Operator Characteristic. A statistical method for quantifying strength of 
association. 
TaqMan An method utilising the Taq Polymerase to perform quantitative PCR. 
TNF  Tumour Necrosis Factor. A group of extra-cellular signal molecules involved in modulation 
of the inflammatory response.  
TLDA  TaqMan Low Density Array. An automated method for undertaking TaqMan analysis. 
TLR   Toll Like Receptor. A family of receptors similar in structure to Toll. 
TRAP   Tartrate Resistant Acid Phosphatase. The enzyme that metabolises bone matric TRAP is 
therefore a marker of bone breakdown by osteoclasts.  
THR  Total Hip Replacement 
NJR  National Joint Registry 
NSAID  Non-steroidal Anti Inflammatory Drug. A family of drugs that inhibit the action of cyclo-
oxygenase and have been shown to inhibit bone healing and remodelling 
NICE  National Institute for Clinical Excellence 
VEGF  Vascular Endothelial Growth Factor. A secreted local growth factor associated with 
neovascularisation. 
WNT  Wingless. A family intracellular signalling molecules that are related to the Wingless protein 
in Drosophila   
